

16-  
66-

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.



GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:10:34 : Search time 1444.83 Seconds  
(without alignments)  
224.186 Million cell updates/sec

Title: us-09-719-737-2

Perfect score: 20

Sequence: 1 gtccacagactgcacact 20

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 16154066 segs, 8097743376 residues

Total number of hits satisfying chosen parameters: 102860

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : EST:  
1: em\_estba:\*  
2: em\_esthum:\*  
3: em\_estlu:\*  
4: em\_estlu:\*  
5: em\_estov:\*  
6: em\_estpl:\*  
7: em\_estro:\*  
8: em\_hlc:\*  
9: gb\_est1:\*  
10: gb\_est2:\*  
11: gb\_hlc:\*  
12: gb\_est3:\*  
13: gb\_est4:\*  
14: gb\_est5:\*  
15: em\_estfun:\*  
16: em\_estom:\*  
17: gb\_gss:\*  
18: em\_gss\_hum:\*  
19: em\_gss\_inv:\*  
20: em\_gss\_pln:\*  
21: em\_gss\_vrt:\*  
22: em\_gss\_fun:\*  
23: em\_gss\_mam:\*  
24: em\_gss\_mus:\*  
25: em\_gss\_other:\*  
26: em\_gss\_pro:\*  
27: em\_gss\_rtdi:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
c 1	13.6	66.0	36	17	AL752038 Arabidops
c 2	13.6	66.0	43	17	BH811442 SALK_0586
c 3	12.6	63.0	46	12	BF983620 602304738
c 4	12.4	62.0	40	12	BF784339 602110114
c 5	12.2	61.0	31	17	AZ435998 1M0223M19
c 6	12.2	61.0	40	9	AT708971 as61d12.x

Result No.	Score	Query Match	Length	ID	Description
c 7	12.2	61.0	46	9	AA576353 nh10q03.s
c 8	12	60.0	50	9	AU103972
c 9	12	60.0	50	9	AU106874
c 10	12	60.0	50	9	AU106878
c 11	11.8	59.0	21	17	A2647787
c 12	11.8	59.0	44	14	H44436
c 13	11.6	58.0	27	17	A2387826
c 14	11.6	58.0	29	17	A2310013
c 15	11.6	58.0	37	17	A2338635
c 16	11.6	58.0	44	17	A2502054
c 17	11.6	58.0	45	17	A2760255
c 18	11.6	58.0	50	9	AU103964
c 19	11.6	58.0	50	9	AU103967
c 20	11.6	58.0	50	9	AU105804
c 21	11.6	58.0	50	9	AU107143
c 22	11.6	58.0	50	9	AU107145
c 23	11.6	58.0	50	9	AU107146
c 24	11.4	57.0	46	17	A2768227
c 25	11.4	57.0	50	9	AU102274
c 26	11.4	57.0	50	9	AU102275
c 27	11.2	56.0	27	17	A2655087
c 28	11.2	56.0	36	13	BG973952
c 29	11.2	56.0	37	9	A1647510
c 30	11.2	56.0	39	13	B1078535
c 31	11.2	56.0	40	17	A2378558
c 32	11.2	56.0	42	14	H14364
c 33	11.2	56.0	42	17	BH626517
c 34	11.2	56.0	43	9	AA994992
c 35	11.2	56.0	43	14	R79446
c 36	11.2	56.0	44	10	AV844185
c 37	11.2	56.0	45	12	BF533864
c 38	11.2	56.0	48	12	BF232745
c 39	11.2	56.0	48	12	BF235094
c 40	11.2	56.0	48	17	BF235094
c 41	11.2	56.0	49	9	A2800533
c 42	11.2	56.0	49	9	A1560790
c 43	11.2	56.0	49	9	AA572078
c 44	11.2	56.0	50	9	AU102678
c 45	11.2	56.0	50	9	AU104734
c 46	11.2	56.0	50	9	AU105732

#### ALIGNMENTS

RESULT 1  
AL752038/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL

AL752038 36 bp DNA linear GSS 17-JUN-2002  
Arabidopsis thaliana T-DNA flanking sequence GK-010E07-014869,  
genomic survey sequence.  
AL752038  
AL752038.1 GI:21484536  
GSS.  
thale cress.  
Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
1  
Strizhov,N., Li,Y., Rosso,M., Viehoever,P., Dekker,K., Seadler,H.  
and Weissshaar,B.  
A pipeline for automated high-throughput generation of PSTs  
(flanking sequence tags) from Arabidopsis thaliana T-DNA  
transformed lines  
Unpublished  
2  
Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weissshaar,B.  
A new Arabidopsis thaliana T-DNA mutagenesis population (GABI-Kat)  
for flanking sequence tag based reverse genetics  
Unpublished  
3 (bases 1 to 36)  
Rosso,M., Li,Y., Strizhov,N. and Weissshaar,B.  
Direct Submission  
Submitted (17-JUN-2002) Weissshaar B., Max-Planck-Institut fuer

## COMMENT

Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany  
This sequence is recovered from the left border of the T-DNA. It  
indicates an insertion within the locus defined by clone tsm2. The  
sequences are generated at the MPI for Plant Breeding Research in  
the context of the GABI-Kat project. GABI-Kat is part of the German  
plant genomics program designated 'GABI'. Information on line  
availability can be found at:  
<http://www.mpiz-koeln.mpg.de/GABI-Kat/>.

## FEATURES

## source

Location/Qualifiers

1..36

/organism="Arabidopsis thaliana"

/strain="Columbia 0"

/db\_xref="taxon:3702"

/clone="GK-010E07-014869"

/note="PCR was performed on DNA from Arabidopsis thaliana"

plants (T1) which were transformed with the T-DNA from

vector PAC106. The lines contain one or more T-DNA

insertions. The DNA fragment(s) resulting from the PCR

were directly sequenced to determine the genomic sequence

flanking the insertion. Sequences displaying significant

similarity to the A. thaliana nuclear genome sequence were

processed for submission. T-DNA derived sequences were

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

removed"

## BASE COUNT

7 a 8 c 11 g 10 t

## ORIGIN

## Query Match

Best Local Similarity 68.0%; Score 13.6; DB 17; Length 36;  
Pred. No. 1.9e+04;

Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 GTTCCACAGCTTGCACCT 20

Db 34 GATCCCATAGCTGCCACCT 15

## RESULT 2

## LOCUS

BH811442 43 bp DNA linear GSS 02-MAY-2002

DEFINITION SALK\_058616 Arabidopsis thaliana T-DNA insertion lines Arabidopsis

thaliana genomic clone SALK\_058616, DNA sequence.

## ACCESSION

BH811442

VERSION BH811442.1 GI:20389897

## KEYWORDS

## SOURCE

## ORGANISM

## thale cress.

Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

1 (bases 1 to 43)

Alonso,J.M., Leisner,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab

,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.

, Zimmerman,J., and Ecker,J.R.

A Sequence-indexed Library of Insertion Mutations in the

Arabidopsis genome

Unpublished (2001)

Contact: Joseph R. Ecker

Salk Institute Genomic Analysis Laboratory (SIGNAL)

The Salk Institute for Biological Studies

10010 N. Torrey Pines Road, La Jolla, CA 92037, USA

Tel: 858 453 4100 x1752

Fax: 858 558 6379

Email: eckersalk.edu

This is single pass sequence recovered from the left border of

T-DNA.

Class: T-DNA tagged.

Location/Qualifiers

1..43

/organism="Arabidopsis thaliana"

/strain="Columbia 0"

/db\_xref="taxon:3702"

/clone="SALK\_058616"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

## BASE COUNT

8 a 13 c 7 g 15 t

## ORIGIN

## Query Match

Best Local Similarity 68.0%; Score 13.6; DB 17; Length 43;  
Pred. No. 2.1e+04;

Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 GTTCCACAGCTTGCACCT 20

Db 14 GTTCCACAGCTTGCACCT 33

## RESULT 3

## LOCUS

BF983620/c 46 bp mRNA linear EST 23-JAN-2001

DEFINITION 602304738F1 NIH\_MGC\_88 Homo sapiens cDNA clone IMAGE:4396185 5',

mRNA sequence.

BF983620

VERSION BF983620.1 GI:12386432

## KEYWORDS

## SOURCE

## human.

## ORGANISM

## Homo sapiens

## Eukaryota;

## Metazoa;

## Chordata;

## Craniata;

## Vertebrata;

## Euteleostomi;

## Mammalia;

## Eutheria;

## Primates;

## Cathartini;

## Homini;

## Homo.

## 1 (bases 1 to 46)

## NIH-MGC

## http://mgc.nci.nih.gov/

## National Institutes of Health, Mammalian Gene Collection (MGC)

## Unpublished (1999)

## Contact: Robert Strausberg, Ph.D.

## Email: cga@bbs.fda.nih.gov

## Tissue Procurement: ATCC

## cDNA Library Preparation: Life Technologies, Inc.

## DNA Sequencing Arrayed by: The I.M.A.G.E. Consortium (LMML)

## Clone distribution: MGC clone distribution information can be

## found through the I.M.A.G.E. Consortium/LMML at:

## http://image.llnl.gov

## Plate: LLM1094 row: 1 column: 10

## High quality sequence stop: 46.

## Location/Qualifiers

## 1..46

## /organism="Homo sapiens"

## /db\_xref="taxon:9606"

## /clone="IMAGE:4396185"

## /clone\_lib="NIH\_MGC\_88"

## /tissue\_type="duodenal adenocarcinoma, cell line"

## /lab\_host="DH10B (phage-resistant)"

## /note="Organ: small intestine; Vector: pCMV-SPORT6;

## site\_1: NotI; site\_2: SalI; Cloned unidirectionally;

## oligo-dr primed. Average insert size 1.767 kb. Library

## enriched for full-length clones and constructed by Life

## Technologies. Note: this is a NIH\_MGC Library."

## BASE COUNT

7 a 16 c 15 g 8 t

## ORIGIN

## Query Match

Best Local Similarity 63.0%; Score 12.6; DB 12; Length 46;  
Pred. No. 6.1e+04;

Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 GTTCCACAGCTTGCACAC 19

Db 38 GTTCCACAGCTTGCACCC 20

## RESULT 4

## LOCUS

BF784339/c 40 bp mRNA linear EST 12-JAN-2001

BF784339

VERSION BF784339.1 GI:12386432

## KEYWORDS

## SOURCE

## human.

## ORGANISM

## Homo sapiens

## Eukaryota;

## Metazoa;

## Chordata;

## Craniata;

## Vertebrata;

## Euteleostomi;

## Mammalia;

## Eutheria;

DEFINITION 602110114F1 NCI\_CGAP\_Ki014 Mus musculus cDNA clone IMAGE:4238354  
5', mRNA sequence.  
ACCESSION BF784339  
VERSION BF784339.1 GI:12089375  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 40)  
NIH-MGC <http://mgc.nci.nih.gov/>.  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: [cgapb-remail.nih.gov](mailto:cgapb-remail.nih.gov)  
Tissue Procurement: Jeffrey E. Green, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
<http://image.llnl.gov>  
Plate: L1AM9849 row: 1 column: 03  
High quality sequence stop: 39.  
Location/Qualifiers  
1..40  
/organism="Mus musculus"  
/strain="FVB/N"  
/db\_xref="taxon:10090"  
/clone="IMAGE:4238354"  
/clone\_1lb="NCI\_CGAP\_Ki014"  
/lab\_host="DH10B (T1 phage-resistant)"  
/note="Organ: kidney; Vector: pCMV-SPORT6; Site: 1; NCI;  
Site: 2; Salt: Cloned unidirectionally. Primer: Oligo dt.  
Average insert size 1.75 kb. Constructed by Life  
Technologies. Note: this is a NCI\_CGAP Library. 1"  
BASE COUNT 2 a 11 c 17 g 10 t  
ORIGIN  
Query Match 62.0%; Score 12.4; DB 12; Length 40;  
Best Local Similarity 92.9%; Pred. No. 7; le+04;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 6 CACAGCTTGCACCC 19  
|||||  
Db 24 CACAGCTTGCACCC 11  
RESULT 5  
A2435998 31 bp DNA linear GSS 03-OCT-2000  
LOCUS 1M0223N19F Mouse 10kb plasmid UGCCIM library Mus musculus genomic  
DEFINITION clone UGCCIM0223N19 F, DNA sequence.  
ACCESSION A2435998  
VERSION A2435998.1 GI:10560011  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 31)  
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,  
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Relly,  
M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.  
and Wright, D., Weiss, R.  
Mouse whole genome scaffolding with paired end reads from 10kb  
plasmid inserts  
Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
84112, USA

Tel: 801 585 5606  
Fax: 801 585 7177  
Email: [ddunn@genetics.utah.edu](mailto:ddunn@genetics.utah.edu)  
Insert Length: 10000 Std Error: 0.00  
Plate: 0223 row: N column: 19  
Seq primer: CGTTCTAAAACGACGCCACGT  
Class: plasmid ends  
High quality sequence stop: 31.  
Location/Qualifiers  
1..31  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UGCCIM0223N19"  
/clone\_1lb="Mouse 10kb plasmid UGCCIM library"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: PMD42ny. Purified genomic DNA from M.  
musculus C57BL/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(<http://www.jax.org/resources/documents/dnares/>). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adapted DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of PMD42 (g11473211419b/AF12072.1), a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adapted mouse DNA was annealed to  
adapted vector DNA, and transformed into  
chemically-competent E. coli XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."  
BASE COUNT 5 a 12 c 6 g 8 t  
ORIGIN  
Query Match 61.0%; Score 12.2; DB 17; Length 31;  
Best Local Similarity 82.4%; Pred. No. 8e+04;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
OY 4 CCCGAGCTTGCACCT 20  
|||  
Db 2 CCCGAGCTTGCACCT 18  
RESULT 6  
A1708971 40 bp mRNA linear EST 04-JUN-1999  
LOCUS as61d12.x1 Barstead colon HPLR87 Homo sapiens cDNA clone  
DEFINITION IMAGE:2333207.3, similar to SW:RL10\_HUMAN P27635 60S RIBOSOMAL  
PROTEIN L10 ;, mRNA sequence.  
ACCESSION A1708971  
VERSION A1708971.1 GI:4998747  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1 (bases 1 to 40)  
Hillier, L., Allen, M., Bowles, L., Dubuque, T., Gaisel, G., Jost, S.,  
Kritzman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Maiti, M., Martin,  
J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theisling, B.,  
White, Y., Wylie, T., Waterston, R. and Wilson, R.  
WashU-NCI human EST Project  
Unpublished (1997)  
Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810



ACCESSION	AU106874
VERSION	AU106874.1
KEYWORDS	GI:13556395
SOURCE	EST.
ORGANISM	human.
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE	1 (bases 1 to 50)
JOURNAL MEDLINE COMMENT	Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hataa ,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki ,Y., Nakamura,Y., Suyama,A. and Sugano,S. Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites EMBO Rep. 2 (5), 388-393 (2001) 21270072
FEATURES	Contact: Yutaka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan Email: yusuzuki@ims.u-tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).
SOURCE	Location/Qualifiers
BASE COUNT	1..50
ORIGIN	/organism="Homo sapiens" /db_xref="taxon:9606" /clone="KAT01514" /clone_id="Sugano Homo sapiens cDNA library" /note="differential display comparison of untreated and dimethylflumarate treated U937 cells"
Query Match	Best Local Similarity 60.0%; Score 12; DB 9; Length 50;
Matches	15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
DQ	1 GTTCCAGACTGTGCCACCCT 20                     Db 30 GTGCCCGACGTTGCCCT 49
RESULT 10	
LOCUS	AU106878 50 bp mRNA linear EST 30-AUG-2001
DEFINITION	AU106878 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone KAT09217, mRNA sequence.
ACCESSION	AU106878
VERSION	AU106878.1
KEYWORDS	GI:13556399
SOURCE	EST.
ORGANISM	human.
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE	1 (bases 1 to 50)
JOURNAL MEDLINE COMMENT	Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hataa ,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki ,Y., Nakamura,Y., Suyama,A. and Sugano,S. Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites EMBO Rep. 2 (5), 388-393 (2001) 21270072
FEATURES	Contact: Yutaka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan Email: yusuzuki@ims.u-tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).
SOURCE	Location/Qualifiers
BASE COUNT	1..50

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="KAT9217"
/clone_lib="Sugano Homo sapiens cDNA library"
/note="Differential display comparison of untreated and
dimethylfluminate treated U937 cells"

BASE COUNT      4 a      16 c      21 g      9 t

ORIGIN

Query Match      60.0% Score 12; DB 9; Length 50;
Best Local Similarity 75.0% Pred. No. 1,2e+05;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

OY      1 GTTCCAGAGCTTGCCACCT 20
      11111111111111111111
Db      29 GTGCCCGACCTTGCCCCCT 48

RESULT 11
A2647787/c      21 bp      DNA      linear      GSS 14-DEC-2000
LOCUS      JM0514P24F Mouse 10kb plasmid UUCG1M library Mus musculus genomic
DEFINITION      clone UUCG1M0514P24 F, DNA sequence.
ACCESSION      A2647787
VERSION      A2647787.1 GI:11779601
KEYWORDS      GSS.
SOURCE      house mouse.
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murine; Mus.
REFERENCE      1 (bases 1 to 21)
AUTHORS      Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rogere,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
CONTACT      Robert B. Weiss
UNIVERSITY      University of Utah Genome Center
LOCATION      University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
TEL: 801 585 5606
FAX: 801 585 7177
EMAIL      ddunn@genetics.utah.edu
INSERT LENGTH      10000 Std Error: 0.00
PLATE      0514 row: P column: 24
SEQ PRIMER      CGTTGTAAACGACGGCCAGT
CLASS      plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1. 21
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG1M0514P24"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (g11473211419b1A129072.1), a copy-number

```





```

BASE COUNT      6 a      9 c      3 g      9 t
ORIGIN

Query Match      58.0%; Score 11.6; DB 17; Length 27;
Best Local Similarity 77.8%; Pred. No. 1.4e+05;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY      2 TTCCACGACGTTGCCACC 19
        ||||| 11 1 |||||
Db      1 TTCCATGAGGCTCCACC 18

RESULT 14
LOCUS      A2310013      29 bp      DNA      linear      GSS 29-SEP-2000
DEFINITION      JM001B12R Mouse 10kb plasmid UUCG1M library Mus musculus genomic
ACCESSION      A2310013
VERSION      A2310013.1 GI:10351576
KEYWORDS      GSS.
SOURCE      house mouse.
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 29)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly
, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0018 row: B column: 12
Seq primer: CACACGCAACACCTATGACC
Class: plasmid ends
High quality sequence stop: 29.
Location/Qualifiers
1..29
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG1M0018B12"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrolytically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (g11473211419b)AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells

```

BASE COUNT	0 a	14 c	6 g	9 t
ORIGIN				
Query Match	58.0%; Score 11.6; DB 17; Length 29;			
Best Local Similarity	77.8%; Pred. No. 1.5e+05;			
Matches	14; Conservative	0; Mismatches	4; Indels	0; Gaps
QY	3	TCCGAGAGCTTGCCACCT	20	
Db	4	TCCCGGTGCTGGCTGCT	21	
RESULT 15				
LOCUS	AZ338635	37 bp	DNA	linear
DEFINITION	1M006911R Mouse 10kb plasmid U00C1M library Mus musculus genomic			
ACCESSION	AZ338635			
VERSION	AZ338635.1	GI:10412103		
KEYWORDS	GSS.			
SOURCE	house mouse.			
ORGANISM	Mus musculus			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 37)			
AUTHORS	Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamll, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.			
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts			
JOURNAL	Unpublished (2000)			
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunne@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0069 Row: 1 Column: 15 Seq primer: CACACAGGAAACAGCTTACGACC Class: plasmid ends High quality sequence stop: 37. Location/Qualifiers 1. 37 /organism="Mus musculus" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="U00C1M006911S" /clone_lib="Mouse 10kb plasmid U00C1M library" /sex="Male" /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g14732141g14729072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells			

BASE COUNT	14 a	11 c	7 g	5 t
ORIGIN	and selected for ampicillin resistance."			

ORIGIN

Query Match

```
58.08; score 11.6; DB 17; length 37;
77.88; Pred, No. 1.6e+05;
```

Best Local Similarity 77.8%; Pred. No. 1.6e+05;  
Matches 14; Conservative 0; Mismatches 4

Matches 14; Conservative 0; Mismatches 4; Indels 0; Caps 0;

QY 1 GTCCGACGCTGCCAC 18

[illegible]

Search completed: November 28, 2002, 19:30:41  
Job time : 1447.83 secs

Job time : 1447.83 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:15:39 : Search time 42.069 Seconds

(without alignments)  
183,088 Million cell updates/sec

Title: US-09-719-737-2

Perfect score: 1 gttccagagctgcacct 20

Sequence: 1 gttccagagctgcacct 20

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 341543 seqs, 192557720 residues

Total number of hits satisfying chosen parameters: 177872

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 08  
Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications\_NA:\*

- 1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*
- 2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq:\*
- 3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*
- 4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*
- 5: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*
- 6: /cgn2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq:\*
- 7: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*
- 8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*
- 9: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*
- 10: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*
- 11: /cgn2\_6/ptodata/1/pubpna/US10\_NEW\_PUB.seq:\*
- 12: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 13: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*
- 14: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	14.4	72.0	20	10	US-09-752-639-36
2	14.4	72.0	20	10	US-09-984-198-36
3	13.6	68.0	25	10	US-09-815-153-9
4	13.2	66.0	31	10	US-09-801-274-992
5	12.6	63.0	20	10	US-09-841-366A-33
6	12.4	62.0	19	10	US-09-216-393-289
7	12.2	61.0	20	9	US-09-944-413-99
8	12.2	61.0	20	9	US-09-944-403-99
9	12.2	61.0	20	9	US-09-944-896-99
10	12.2	61.0	20	9	US-09-944-944-99
11	12.2	61.0	20	10	US-09-866-028-99
12	12.2	61.0	20	10	US-09-944-449-99
13	12.2	61.0	20	10	US-09-944-457-99
14	12.2	61.0	20	10	US-09-945-587-99
15	12.2	61.0	20	10	US-09-945-015-99
16	12.2	61.0	20	10	US-09-944-396-99
17	12.2	61.0	20	10	US-09-944-097-99
18	12.2	61.0	20	10	US-09-944-433-99
19	12.2	61.0	20	10	US-09-943-762-99

C 20	12.2	61.0	20	10	US-09-944-654-99	Sequence 99, Appl
C 21	12.2	61.0	20	10	US-09-943-851A-99	Sequence 99, Appl
C 22	12.2	61.0	28	10	US-09-835-381-11	Sequence 11, Appl
C 23	12.2	60.0	26	9	US-09-089-818B-5	Sequence 5, Appl
C 24	11.8	59.0	20	10	US-09-454-394-61	Sequence 61, Appl
C 25	11.8	59.0	20	10	US-09-454-394-64	Sequence 64, Appl
C 26	11.8	59.0	20	10	US-09-791-406-75	Sequence 75, Appl
C 27	11.8	59.0	35	10	US-09-867-565-5	Sequence 5, Appl
C 28	11.8	59.0	49	10	US-09-781-902-28	Sequence 28, Appl
C 29	11.6	58.0	34	9	US-09-764-868-1247	Sequence 1247, Ap
C 30	11.4	57.0	16	10	US-09-781-902-52	Sequence 52, Appl
C 31	11.4	57.0	31	10	US-09-801-274-352	Sequence 352, App
C 32	11.4	57.0	36	9	US-10-127-391-27	Sequence 27, Appl
C 33	11.4	57.0	39	9	US-09-252-150-59	Sequence 59, Appl
C 34	11.4	57.0	46	10	US-09-320-337-38	Sequence 38, Appl
C 35	11.2	56.0	20	10	US-09-733-294A-38	Sequence 39, Appl
C 36	11.2	56.0	20	10	US-09-733-294A-39	Sequence 376, App
C 37	11.2	56.0	25	9	US-09-978-295A-376	Sequence 376, App
C 38	11.2	56.0	25	9	US-09-978-697-376	Sequence 8, Appl
C 39	11.2	56.0	30	10	US-09-844-684-8	Sequence 65, Appl
C 40	11.2	55.0	20	10	US-09-733-294A-65	Sequence 68, Appl
C 41	11.2	55.0	22	10	US-09-755-665-68	Sequence 3303, Ap
C 42	11.2	55.0	25	10	US-09-866-108-3303	Sequence 3304, Ap
C 43	11.2	55.0	25	10	US-09-866-108-3304	Sequence 3305, Ap
C 44	11.2	55.0	25	10	US-09-866-108-3305	Sequence 3306, Ap
C 45	11.2	55.0	25	10	US-09-866-108-3306	Sequence 3306, Ap

#### ALIGNMENTS

RESULT 1  
US-09-752-639-36  
Sequence 36, Application US/09752639  
Patient No. US20020091243A1  
GENERAL INFORMATION:  
APPLICANT: Galanaga, T.  
APPLICANT: Granger, G.A.  
TITLE OF INVENTION: Factors Altering Tumor Necrosis  
TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods  
NUMBER OF SEQUENCES: 154  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORRISON & FOERSTER  
STREET: 755 PAGE MILL ROAD  
CITY: Palo Alto  
STATE: CA  
COUNTRY: USA  
ZIP: 94304-1018  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows  
SOFTWARE: FASTSEQ for Windows Version 2.0b  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/752, 639  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/US99/10793  
FILING DATE:  
APPLICATION NUMBER: 09/081,385  
FILING DATE:  
APPLICATION NUMBER: 08/964,747  
FILING DATE: 06-NOV-1997  
APPLICATION NUMBER: 60/030,761  
ATTORNEY/AGENT INFORMATION:  
NAME: Wu, Frank  
REGISTRATION NUMBER: 41,386  
REFERENCE/DOCKET NUMBER: 22000-20577.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-813-5600

TELEFAX: 650-494-0792  
TELEX: 706141  
INFORMATION FOR SEQ ID NO: 36:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-752-639-36

Query Match 72.0%; Score 14.4; DB 10; Length 20;  
Best local Similarity 93.8%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GTTCCGAGCTGGCC 16  
DB 1 GTTCCGAGCTGGTC 16

RESULT 2  
US-09-984-198-36  
Sequence 36, Application US/09984198  
Patent No. US20020106679A1  
GENERAL INFORMATION:  
APPLICANT: Galanaga, T.  
APPLICANT: Granger, G.A.  
TITLE OF INVENTION: Factors Altering Tumor Necrosis  
TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods  
NUMBER OF SEQUENCES: 154  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORRISON & FORSTER  
STREET: 755 PAGE MILL ROAD  
CITY: Palo Alto  
STATE: CA  
COUNTRY: USA  
ZIP: 94304-1018  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM compatible  
OPERATING SYSTEM: Windows  
SOFTWARE: FastSeq for Windows Version 2.0b  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/984,198  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/US99/10793  
FILING DATE:  
APPLICATION NUMBER: 09/081,385  
FILING DATE:  
APPLICATION NUMBER: 08/964,747  
FILING DATE: 05-NOV-1997  
APPLICATION NUMBER: 60/030,761  
FILING DATE: 06-NOV-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Wu, Frank  
REGISTRATION NUMBER: 41,386  
REFERENCE/DOCKET NUMBER: 22000-20577.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-813-5600  
TELEFAX: 650-494-0792  
TELEX: 706141  
INFORMATION FOR SEQ ID NO: 36:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-984-198-36  
Query Match 72.0%; Score 14.4; DB 10; Length 20;  
Best local Similarity 93.8%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1 GTTCCGAGCTGGCC 16  
DB 1 GTTCCGAGCTGGTC 16

RESULT 3  
US-09-815-153-9  
Sequence 9, Application US/09815153  
Patent No. US20020132978A1  
GENERAL INFORMATION:  
APPLICANT: RASTELLI, LUCA R.  
APPLICANT: GERBER, HANS-PETER  
TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM  
FILE REFERENCE: 10716/34  
CURRENT APPLICATION NUMBER: US/09/815,153  
CURRENT FILING DATE: 2001-03-21  
PRIOR APPLICATION NUMBER: 60/191,201  
PRIOR FILING DATE: 2000-03-21  
NUMBER OF SEQ ID NOS: 47  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 9  
LENGTH: 25  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-09-815-153-9

Query Match 68.0%; Score 13.6; DB 10; Length 25;  
Best local Similarity 80.0%; Pred. No. 4.7e+02;  
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 GTTCCGAGCTGGCCACT 20  
DB 4 GTTCCGAACTGGCCGCT 23

RESULT 4  
US-09-801-274-992  
Sequence 992, Application US/09801274  
Patent No. US20020032319A1  
GENERAL INFORMATION:  
APPLICANT: Cargill, Michele  
APPLICANT: Ireland, James S.  
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS  
FILE REFERENCE: 2825, 2009-001  
CURRENT APPLICATION NUMBER: US/09/801,274  
CURRENT FILING DATE: 2001-03-07  
PRIOR APPLICATION NUMBER: US 60/187,510  
PRIOR FILING DATE: 2000-03-07  
PRIOR APPLICATION NUMBER: US 60/206,129  
PRIOR FILING DATE: 2000-05-22  
NUMBER OF SEQ ID NOS: 1802  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 992  
LENGTH: 31  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-801-274-992

Query Match 66.0%; Score 13.2; DB 10; Length 31;  
Best local Similarity 75.0%; Pred. No. 7.6e+02;  
Matches 15; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 GTTCCGAGCTGGCCACT 20  
DB 10 GTTCCGAGCTGCTCACT 29

RESULT 5

US-09-841-366A-33  
; Sequence 33, Application US/09841366A  
; Patent No. US20020058265A1  
; GENERAL INFORMATION:  
; APPLICANT: Bacher, Jeffery W.  
; APPLICANT: Flanagan, Laura  
; APPLICANT: Nassif, Nadine  
; TITLE OF INVENTION: DETECTION OF MICROSATELLITE INSTABILITY AND ITS USE IN  
; FILE REFERENCE: 16026-9267  
; CURRENT APPLICATION NUMBER: US/09/841,366A  
; CURRENT FILING DATE: 2001-07-16  
; PRIOR APPLICATION NUMBER: 09/663,020  
; PRIOR FILING DATE: 2000-09-15  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 33  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: D9S2169 primer  
US-09-841-366A-33

Query Match 63.0%; Score 12.6; DB 10; Length 20;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 2 TTCCGAGCCTTGCACCT 20  
DB 1 TTCCCAAACTTGCACCT 19

RESULT 6  
US-09-216-393-289  
; Sequence 289, Application US/09216393  
; Patent No. US2001001447A1  
; GENERAL INFORMATION:  
; APPLICANT: Milhausen, Michael James  
; TITLE OF INVENTION: TOKOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND  
; FILE REFERENCE: TX-1-C2  
; CURRENT APPLICATION NUMBER: US/09/216,393  
; CURRENT FILING DATE: 1998-12-18  
; EARLIER APPLICATION NUMBER: 08/994,825  
; EARLIER FILING DATE: 1997-12-19  
; NUMBER OF SEQ ID NOS: 364  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 289  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-09-216-393-289

Query Match 62.0%; Score 12.4; DB 10; Length 19;  
Best Local Similarity 92.9%; Pred. No. 1.8e+03;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 2 TTCCGAGCCTTGC 15  
DB 2 TTCCGAGCCTTGC 15

RESULT 7  
US-09-944-413-99/C  
; Sequence 99, Application US/09944413  
; Patent No. US20020156004A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin  
; APPLICANT: Botstein, David

APPLICANT: Eaton, Dan  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Geritsen, Mary  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul  
APPLICANT: Grimaldi, Christopher  
APPLICANT: Gurney, Austin  
APPLICANT: Hillan, Kenneth  
APPLICANT: Kljavin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tumas, Daniel  
APPLICANT: Wood, William  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/944,413  
CURRENT FILING DATE: 2001-09-26  
PRIOR APPLICATION NUMBER: 09/866,028  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: 60/067,411  
PRIOR FILING DATE: December 3, 1997  
PRIOR APPLICATION NUMBER: 60/069,334  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,335  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,278  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,425  
PRIOR FILING DATE: December 12, 1997  
PRIOR APPLICATION NUMBER: 60/069,696  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,694  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,702  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,870  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/069,873  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/068,017  
PRIOR FILING DATE: December 18, 1997  
PRIOR APPLICATION NUMBER: 60/070,440  
PRIOR FILING DATE: January 5, 1998  
PRIOR APPLICATION NUMBER: 60/074,086  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/074,092  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/075,945  
PRIOR FILING DATE: February 25, 1998  
PRIOR APPLICATION NUMBER: 60/112,850  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 60/113,296  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 60/146,222  
PRIOR FILING DATE: July 28, 1999  
PRIOR APPLICATION NUMBER: PCT/US98/19330  
PRIOR FILING DATE: September 16, 1998  
PRIOR APPLICATION NUMBER: PCT/US98/25108  
PRIOR FILING DATE: December 1, 1998  
PRIOR APPLICATION NUMBER: 09/216,021  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 09/218,517  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 09/254,311  
PRIOR FILING DATE: March 3, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/12252  
PRIOR FILING DATE: June 22, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: September 15, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28409  
PRIOR FILING DATE: NO. US20020156004A1ember 30, 1999

PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: No. US200201560041ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28301  
PRIOR FILING DATE: December 1, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: December 16, 1999  
PRIOR APPLICATION NUMBER: PCT/US00/03565  
PRIOR FILING DATE: February 11, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: February 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/05841  
PRIOR FILING DATE: March 2, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/08439  
PRIOR FILING DATE: March 30, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/14042  
PRIOR FILING DATE: May 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/20710  
PRIOR FILING DATE: July 28, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/32678  
PRIOR FILING DATE: December 1, 2000  
PRIOR APPLICATION NUMBER: PCT/US01/06520  
PRIOR FILING DATE: February 28, 2001  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-944-413-99

Query Match 61.0%; Score 12.2; DB 9; Length 20;  
Best local Similarity 82.4%; Pred. No. 2.2e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTTCCAGAGCTTGCCA 17  
11111111111111111111  
Db 17 GTTCCAGCTTGCCA 1

RESULT 8  
US-09-944-403-99/c  
Sequence 99, Application US/09944403  
Patent No. US20020165143A1  
GENERAL INFORMATION:  
APPLICANT: Baker, Kevin  
APPLICANT: Botstein, David  
APPLICANT: Eaton, Dan  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Garlisen, Mary  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul  
APPLICANT: Grimaldi, Christopher  
APPLICANT: Gurney, Austen  
APPLICANT: Hillen, Kenneth  
APPLICANT: Kijavlin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tumas, Daniel  
APPLICANT: Wood, William  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/944,403  
CURRENT FILING DATE: 2001-09-26  
PRIOR APPLICATION NUMBER: 09/866,028  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: 60/067,411  
PRIOR FILING DATE: December 3, 1997  
PRIOR APPLICATION NUMBER: 60/069,334  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069335

PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,278  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,425  
PRIOR FILING DATE: December 12, 1997  
PRIOR APPLICATION NUMBER: 60/069,696  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,694  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,702  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,870  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/069,873  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/068,017  
PRIOR FILING DATE: December 18, 1997  
PRIOR APPLICATION NUMBER: 60/070,440  
PRIOR FILING DATE: January 5, 1998  
PRIOR APPLICATION NUMBER: 60/074,086  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/074,092  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/075,945  
PRIOR FILING DATE: February 25, 1998  
PRIOR APPLICATION NUMBER: 60/112,850  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 60/113,296  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 60/146,222  
PRIOR FILING DATE: July 28, 1999  
PRIOR APPLICATION NUMBER: PCT/US98/19330  
PRIOR FILING DATE: September 16, 1998  
PRIOR APPLICATION NUMBER: PCT/US98/25108  
PRIOR FILING DATE: December 1, 1998  
PRIOR APPLICATION NUMBER: 09/216,021  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 09/218,517  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 09/254,311  
PRIOR FILING DATE: March 3, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/12252  
PRIOR FILING DATE: June 22, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: September 15, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28409  
PRIOR FILING DATE: No. US20020165143A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: No. US20020165143A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28301  
PRIOR FILING DATE: December 1, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: December 16, 1999  
PRIOR APPLICATION NUMBER: PCT/US00/03565  
PRIOR FILING DATE: February 11, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: February 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/05841  
PRIOR FILING DATE: March 2, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/08439  
PRIOR FILING DATE: March 30, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/14042  
PRIOR FILING DATE: May 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/20710  
PRIOR FILING DATE: July 28, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/32678  
PRIOR FILING DATE: December 1, 2000  
PRIOR APPLICATION NUMBER: PCT/US01/06520  
PRIOR FILING DATE: February 28, 2001  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-09-944-403-99

Query Match          61.0%; Score 12.2; DB 9; Length 20;
Best Local Similarity 82.4%; Pred. No. 2.2e+03;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1 GTTCCGACGCTTGCCA 17
        ||||| |||||
Db       17 GTTCCATTCTTGCCA 1

RESULT 9
US-09-944-896-99/c
; Sequence 99, Application US/09944896
; Patent No. US20020168715A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin
; APPLICANT: Botstein, David
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gerlitsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul
; APPLICANT: Grimaldi, Christopher
; APPLICANT: Guiney, Austin
; APPLICANT: Hillan, Kenneth
; APPLICANT: Kljavin, Ivar
; APPLICANT: Napier, Mary
; APPLICANT: Roy, Margaret
; APPLICANT: Tumas, Daniel
; APPLICANT: Wood, William
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P2548P1C1
; CURRENT APPLICATION NUMBER: US/09/944,896
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: 09/866,028
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/069,334
; PRIOR FILING DATE: December 11, 1997
; PRIOR APPLICATION NUMBER: 60/069335
; PRIOR FILING DATE: December 11, 1997
; PRIOR APPLICATION NUMBER: 60/069,278
; PRIOR FILING DATE: December 11, 1997
; PRIOR APPLICATION NUMBER: 60/069,425
; PRIOR FILING DATE: December 12, 1997
; PRIOR APPLICATION NUMBER: 60/069,696
; PRIOR FILING DATE: December 16, 1997
; PRIOR APPLICATION NUMBER: 60/069,694
; PRIOR FILING DATE: December 16, 1997
; PRIOR APPLICATION NUMBER: 60/069,702
; PRIOR FILING DATE: December 16, 1997
; PRIOR APPLICATION NUMBER: 60/069,870
; PRIOR FILING DATE: December 17, 1997
; PRIOR APPLICATION NUMBER: 60/069,873
; PRIOR FILING DATE: December 17, 1997
; PRIOR APPLICATION NUMBER: 60/068,017
; PRIOR FILING DATE: December 18, 1997
; PRIOR APPLICATION NUMBER: 60/070,440
; PRIOR FILING DATE: January 5, 1998
; PRIOR APPLICATION NUMBER: 60/074,086
; PRIOR FILING DATE: February 9, 1998
; PRIOR APPLICATION NUMBER: 60/074,092
; PRIOR FILING DATE: February 9, 1998
; PRIOR APPLICATION NUMBER: 60/075,945
; PRIOR FILING DATE: February 25, 1998
; PRIOR APPLICATION NUMBER: 60/112,850
; PRIOR FILING DATE: December 16, 1998
; PRIOR APPLICATION NUMBER: 60/113,296
```

```
; PRIOR FILING DATE: December 22, 1998
; PRIOR APPLICATION NUMBER: 60/146,222
; PRIOR FILING DATE: July 28, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/19330
; PRIOR FILING DATE: September 16, 1998
; PRIOR APPLICATION NUMBER: PCT/US98/25108
; PRIOR FILING DATE: December 1, 1998
; PRIOR APPLICATION NUMBER: 09/216,021
; PRIOR FILING DATE: December 16, 1998
; PRIOR APPLICATION NUMBER: 09/218,517
; PRIOR FILING DATE: December 22, 1998
; PRIOR APPLICATION NUMBER: 09/254,311
; PRIOR FILING DATE: March 3, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/12252
; PRIOR FILING DATE: June 22, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: September 15, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/28409
; PRIOR FILING DATE: No. US20020168715A1member 30, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: No. US20020168715A1member 30, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/28301
; PRIOR FILING DATE: December 1, 1999
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: December 16, 1999
; PRIOR APPLICATION NUMBER: PCT/US00/03565
; PRIOR FILING DATE: February 11, 2000
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: February 22, 2000
; PRIOR APPLICATION NUMBER: PCT/US00/05841
; PRIOR FILING DATE: March 2, 2000
; PRIOR APPLICATION NUMBER: PCT/US00/08439
; PRIOR FILING DATE: March 30, 2000
; PRIOR APPLICATION NUMBER: PCT/US00/14042
; PRIOR FILING DATE: May 22, 2000
; PRIOR APPLICATION NUMBER: PCT/US00/20710
; PRIOR FILING DATE: July 28, 2000
; PRIOR APPLICATION NUMBER: PCT/US00/32678
; PRIOR FILING DATE: December 1, 2000
; PRIOR APPLICATION NUMBER: PCT/US01/06520
; PRIOR FILING DATE: February 28, 2001
; NUMBER OF SEQ ID NOS: 120
; SEQ ID NO 99
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-09-944-896-99

Query Match          61.0%; Score 12.2; DB 9; Length 20;
Best Local Similarity 82.4%; Pred. No. 2.2e+03;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1 GTTCCGACGCTTGCCA 17
        ||||| |||||
Db       17 GTTCCATTCTTGCCA 1

RESULT 10
US-09-944-99/c
; Sequence 99, Application US/09944944
; Patent No. US20020173463A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin
; APPLICANT: Botstein, David
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gerlitsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul
; APPLICANT: Grimaldi, Christopher
```

APPLICANT: Gurney, Austlin  
APPLICANT: Hillan, Kenneth  
APPLICANT: Kljavin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tomas, Daniel  
APPLICANT: Wood, William  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/944,944  
CURRENT FILING DATE: 2001-09-26  
PRIOR APPLICATION NUMBER: 09/866,028  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: 60/067,411  
PRIOR FILING DATE: December 3, 1997  
PRIOR APPLICATION NUMBER: 60/069,334  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,335  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,278  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,425  
PRIOR FILING DATE: December 12, 1997  
PRIOR APPLICATION NUMBER: 60/069,696  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,694  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,702  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,870  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/069,873  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/068,017  
PRIOR FILING DATE: December 18, 1997  
PRIOR APPLICATION NUMBER: 60/070,440  
PRIOR FILING DATE: January 5, 1998  
PRIOR APPLICATION NUMBER: 60/074,086  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/074,092  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/075,945  
PRIOR FILING DATE: February 25, 1998  
PRIOR APPLICATION NUMBER: 60/112,850  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 60/113,296  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 60/146,222  
PRIOR FILING DATE: July 28, 1999  
PRIOR APPLICATION NUMBER: PCT/US98/19330  
PRIOR FILING DATE: September 16, 1998  
PRIOR APPLICATION NUMBER: PCT/US98/25108  
PRIOR FILING DATE: December 1, 1998  
PRIOR APPLICATION NUMBER: 09/216,021  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 09/218,517  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 09/254,311  
PRIOR FILING DATE: March 3, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/12252  
PRIOR FILING DATE: June 22, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: September 15, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28409  
PRIOR FILING DATE: No. US20020173463A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: No. US20020173463A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28301  
PRIOR FILING DATE: December 1, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: December 16, 1999  
PRIOR APPLICATION NUMBER: PCT/US00/03565

PRIOR FILING DATE: February 11, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: February 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/05841  
PRIOR FILING DATE: March 2, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/08439  
PRIOR FILING DATE: March 30, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/14042  
PRIOR FILING DATE: May 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/20710  
PRIOR FILING DATE: July 28, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/32678  
PRIOR FILING DATE: December 1, 2000  
PRIOR APPLICATION NUMBER: PCT/US01/06520  
PRIOR FILING DATE: February 28, 2001  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-944-944-99

Query Match 61.0% Score 12.2: DB 9: Length 20:  
Best Local Similarity 82.4% Pred. No. 2.2e+03:  
Matches 14: Conservative 0: Mismatches 3: Indels 0: Gaps 0:  
QY 1 GTTCCGAGACCTTGCCA 17  
DB 17 GTTCCGATTCCTTGCCA 1

RESULT 11  
US-09-866-028-99/c  
Sequence 99, Application US/09866028  
Patent No. US20020058309A1  
GENERAL INFORMATION:  
APPLICANT: Baker, Kevin  
APPLICANT: Botstein, David  
APPLICANT: Baton, Dan  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Gerltsen, Mary  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul  
APPLICANT: Grimaldi, Christopher  
APPLICANT: Gurney, Austlin  
APPLICANT: Hillan, Kenneth  
APPLICANT: Kljavin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tomas, Daniel  
APPLICANT: Wood, William  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/866,028  
CURRENT FILING DATE: 2001-05-25  
Prior application data removed - consult PALM or file wrapper  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-866-028-99

Query Match 61.0% Score 12.2: DB 10: Length 20:  
Best Local Similarity 82.4% Pred. No. 2.2e+03:  
Matches 14: Conservative 0: Mismatches 3: Indels 0: Gaps 0:



QY 1 GTTCCAGAGCTTGCA 17  
Db 17 GTTCCAGCTCTTGCA 1

RESULT 12  
US-09-944-449-99/c  
Sequence 99, Application US/09944449  
Patent No. US20020102647A1  
GENERAL INFORMATION:  
APPLICANT: Baker, Kevin  
APPLICANT: Botstein, David  
APPLICANT: Baton, Dan  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Gertlisen, Mary  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul  
APPLICANT: Grimaldi, Christopher  
APPLICANT: Gurney, Austin  
APPLICANT: Hillan, Kenneth  
APPLICANT: Kijavlin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tumas, Daniel  
APPLICANT: Wood, William

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE OF INVENTION: ACIDS ENCODING THE SAME  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/944,449  
PRIOR FILING DATE: 2001-09-26  
PRIOR APPLICATION NUMBER: 09/866,028  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: 60/067,411  
PRIOR FILING DATE: December 3, 1997  
PRIOR APPLICATION NUMBER: 60/069,334  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,335  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,278  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,425  
PRIOR FILING DATE: December 12, 1997  
PRIOR APPLICATION NUMBER: 60/069,696  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,694  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,702  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,870  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/069,873  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/068,017  
PRIOR FILING DATE: December 18, 1997  
PRIOR APPLICATION NUMBER: 60/070,440  
PRIOR FILING DATE: January 5, 1998  
PRIOR APPLICATION NUMBER: 60/074,086  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/074,092  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/075,945  
PRIOR FILING DATE: February 25, 1998  
PRIOR APPLICATION NUMBER: 60/112,850  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 60/113,296  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 60/146,222  
PRIOR FILING DATE: July 28, 1999  
PRIOR APPLICATION NUMBER: PCT/US98/19330  
PRIOR FILING DATE: September 16, 1998  
PRIOR APPLICATION NUMBER: PCT/US98/25108  
PRIOR FILING DATE: December 1, 1998

PRIOR APPLICATION NUMBER: 09/216,021  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 09/218,517  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 09/254,311  
PRIOR FILING DATE: March 3, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/12252  
PRIOR FILING DATE: June 22, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: September 15, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28409  
PRIOR FILING DATE: No. US20020102647A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: No. US20020102647A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28301  
PRIOR FILING DATE: December 1, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: December 16, 1999  
PRIOR APPLICATION NUMBER: PCT/US00/03565  
PRIOR FILING DATE: February 11, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: February 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/05841  
PRIOR FILING DATE: March 2, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/08439  
PRIOR FILING DATE: March 30, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/14042  
PRIOR FILING DATE: May 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/20710  
PRIOR FILING DATE: July 28, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/32678  
PRIOR FILING DATE: December 1, 2000  
PRIOR APPLICATION NUMBER: PCT/US01/06520  
PRIOR FILING DATE: February 28, 2001  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-944-449-99

Query Match 61.0%; Score 12.2; DB 10; Length 20;  
Best Local Similarity 82.4%; Pred. No. 2.2e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTTCCAGAGCTTGCA 17  
Db 17 GTTCCAGCTCTTGCA 1

RESULT 13  
US-09-944-457-99/c  
Sequence 99, Application US/09944457  
Patent No. US2002010859A1  
GENERAL INFORMATION:  
APPLICANT: Baker, Kevin  
APPLICANT: Botstein, David  
APPLICANT: Baton, Dan  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Gertlisen, Mary  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul  
APPLICANT: Grimaldi, Christopher  
APPLICANT: Gurney, Austin  
APPLICANT: Hillan, Kenneth  
APPLICANT: Kijavlin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tumas, Daniel  
APPLICANT: Wood, William

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/944,457  
PRIOR FILING DATE: 2001-09-26  
PRIOR APPLICATION NUMBER: 09/866,028  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: 60/067,411  
PRIOR FILING DATE: December 3, 1997  
PRIOR APPLICATION NUMBER: 60/069,334  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,335  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,278  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,425  
PRIOR FILING DATE: December 12, 1997  
PRIOR APPLICATION NUMBER: 60/069,696  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,694  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,702  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,870  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/069,873  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/068,017  
PRIOR FILING DATE: December 18, 1997  
PRIOR APPLICATION NUMBER: 60/070,440  
PRIOR FILING DATE: January 5, 1998  
PRIOR APPLICATION NUMBER: 60/074,086  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/074,092  
PRIOR FILING DATE: February 9, 1998  
PRIOR APPLICATION NUMBER: 60/075,945  
PRIOR FILING DATE: February 23, 1998  
PRIOR APPLICATION NUMBER: 60/112,850  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 60/113,296  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 60/146,222  
PRIOR FILING DATE: July 28, 1999  
PRIOR APPLICATION NUMBER: PCT/US98/19330  
PRIOR FILING DATE: September 16, 1998  
PRIOR APPLICATION NUMBER: PCT/US98/25108  
PRIOR FILING DATE: December 1, 1998  
PRIOR APPLICATION NUMBER: 09/216,021  
PRIOR FILING DATE: December 16, 1998  
PRIOR APPLICATION NUMBER: 09/218,517  
PRIOR FILING DATE: December 22, 1998  
PRIOR APPLICATION NUMBER: 09/254,311  
PRIOR FILING DATE: March 3, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/12252  
PRIOR FILING DATE: June 22, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: September 15, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28409  
PRIOR FILING DATE: No. US20020110859A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: No. US20020110859A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28301  
PRIOR FILING DATE: December 1, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: December 16, 1999  
PRIOR APPLICATION NUMBER: PCT/US00/03565  
PRIOR FILING DATE: February 11, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: February 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/05841  
PRIOR FILING DATE: March 2, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/08439  
PRIOR FILING DATE: March 30, 2000

PRIOR APPLICATION NUMBER: PCT/US00/14042  
PRIOR FILING DATE: May 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/20710  
PRIOR FILING DATE: July 28, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/32678  
PRIOR FILING DATE: December 1, 2000  
PRIOR APPLICATION NUMBER: PCT/US01/06520  
PRIOR FILING DATE: February 28, 2001  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-944,457-99  
Query Match 61.0%; Score 12.2; DB 10; Length 20;  
Best Local Similarity 82.4%; Pred. No. 2, 2e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1 GTTCCGAGACTTGCCA 17  
Db 17 GTTCCGACTTGCCA 1  
RESULT 14  
US-09-945-587-99/c  
Sequence 99, Application US/09945587  
Patent No. US20020127643A1  
GENERAL INFORMATION:  
APPLICANT: Baker, Kevin  
APPLICANT: Botstein, David  
APPLICANT: Eaton, Dan  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Gerltsen, Mary  
APPLICANT: Goddard, Audrey  
APPLICANT: Grimaldi, Christopher  
APPLICANT: Gurney, Austin  
APPLICANT: Hillan, Kenneth  
APPLICANT: Kijavlin, Ivar  
APPLICANT: Napier, Mary  
APPLICANT: Roy, Margaret  
APPLICANT: Tamas, Daniel  
APPLICANT: Wood, William  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P2548P1C1  
CURRENT APPLICATION NUMBER: US/09/945,587  
CURRENT FILING DATE: 2001-09-26  
PRIOR APPLICATION NUMBER: 09/866,028  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: 60/067,411  
PRIOR FILING DATE: December 3, 1997  
PRIOR APPLICATION NUMBER: 60/069,334  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,335  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,278  
PRIOR FILING DATE: December 11, 1997  
PRIOR APPLICATION NUMBER: 60/069,425  
PRIOR FILING DATE: December 12, 1997  
PRIOR APPLICATION NUMBER: 60/069,696  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,694  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,702  
PRIOR FILING DATE: December 16, 1997  
PRIOR APPLICATION NUMBER: 60/069,870  
PRIOR FILING DATE: December 17, 1997  
PRIOR APPLICATION NUMBER: 60/069,873

;; PRIOR FILING DATE: December 17, 1997  
;; PRIOR APPLICATION NUMBER: 60/068,017  
;; PRIOR FILING DATE: December 18, 1997  
;; PRIOR APPLICATION NUMBER: 60/070,440  
;; PRIOR FILING DATE: January 5, 1998  
;; PRIOR APPLICATION NUMBER: 60/074,086  
;; PRIOR FILING DATE: February 9, 1998  
;; PRIOR APPLICATION NUMBER: 60/074,092  
;; PRIOR FILING DATE: February 9, 1998  
;; PRIOR APPLICATION NUMBER: 60/075,945  
;; PRIOR FILING DATE: February 25, 1998  
;; PRIOR APPLICATION NUMBER: 60/112,850  
;; PRIOR FILING DATE: December 16, 1998  
;; PRIOR APPLICATION NUMBER: 60/113,296  
;; PRIOR FILING DATE: December 22, 1998  
;; PRIOR APPLICATION NUMBER: 60/146,222  
;; PRIOR FILING DATE: July 28, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US98/19330  
;; PRIOR FILING DATE: September 16, 1998  
;; PRIOR APPLICATION NUMBER: PCT/US98/25108  
;; PRIOR FILING DATE: December 1, 1998  
;; PRIOR APPLICATION NUMBER: 09/216,021  
;; PRIOR FILING DATE: December 16, 1998  
;; PRIOR APPLICATION NUMBER: 09/218,517  
;; PRIOR FILING DATE: December 22, 1998  
;; PRIOR APPLICATION NUMBER: 09/254,311  
;; PRIOR FILING DATE: March 3, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US99/12252  
;; PRIOR FILING DATE: June 22, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US99/21090  
;; PRIOR FILING DATE: September 15, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US99/28409  
;; PRIOR FILING DATE: NO. US20020127643A1ember 30, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US99/28313  
;; PRIOR FILING DATE: NO. US20020127643A1ember 30, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US99/28301  
;; PRIOR FILING DATE: December 1, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US99/30095  
;; PRIOR FILING DATE: December 16, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US00/03565  
;; PRIOR FILING DATE: February 11, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US00/04414  
;; PRIOR FILING DATE: February 22, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US00/05841  
;; PRIOR FILING DATE: March 2, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US00/08439  
;; PRIOR FILING DATE: March 30, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US00/14042  
;; PRIOR FILING DATE: May 22, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US00/20710  
;; PRIOR FILING DATE: July 28, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US00/32678  
;; PRIOR FILING DATE: December 1, 2000  
;; PRIOR APPLICATION NUMBER: PCT/US01/06520  
;; PRIOR FILING DATE: February 28, 2001  
;; NUMBER OF SEQ ID NOS: 120  
;; SEQ ID NO 99  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-945-587-99

Query Match 61.0%; Score 12.2; DB 10; Length 20;  
Best Local Similarity 82.4%; Pred. No. 2.2e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

0Y 1 GTTCCAGAGCTTGCCA 17  
||||| |||||  
Db 17 GTTCCATCTCTTGCCA 1

RESULT 15  
US-09-945-015-99/c  
;; Sequence 99, Application US/09945015  
;; Patent No. US20020132768A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Baker, Kevin  
;; APPLICANT: Holstein, David  
;; APPLICANT: Eaton, Dan  
;; APPLICANT: Ferrara, Napoleone  
;; APPLICANT: Filvaroff, Ellen  
;; APPLICANT: Gerltsen, Mary  
;; APPLICANT: Goddard, Audrey  
;; APPLICANT: Godowski, Paul  
;; APPLICANT: Grimaldi, Christopher  
;; APPLICANT: Gurney, Austin  
;; APPLICANT: Hillan, Kenneth  
;; APPLICANT: Kijavins, Ivar  
;; APPLICANT: Napier, Mary  
;; APPLICANT: Roy, Margaret  
;; APPLICANT: Tomas, Daniel  
;; APPLICANT: Wood, William  
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
;; TITLE OF INVENTION: ACIDS ENCODING THE SAME  
;; FILE REFERENCE: P2548P1C1  
;; CURRENT APPLICATION NUMBER: US/09/945,015  
;; CURRENT FILING DATE: 2001-09-26  
;; PRIOR APPLICATION NUMBER: 09/866,028  
;; PRIOR FILING DATE: 2001-05-25  
;; PRIOR APPLICATION NUMBER: 60/067,411  
;; PRIOR FILING DATE: December 3, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,334  
;; PRIOR FILING DATE: December 11, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,335  
;; PRIOR FILING DATE: December 11, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,278  
;; PRIOR FILING DATE: December 11, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,425  
;; PRIOR FILING DATE: December 12, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,696  
;; PRIOR FILING DATE: December 16, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,694  
;; PRIOR FILING DATE: December 16, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,702  
;; PRIOR FILING DATE: December 16, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,870  
;; PRIOR FILING DATE: December 17, 1997  
;; PRIOR APPLICATION NUMBER: 60/069,873  
;; PRIOR FILING DATE: December 17, 1997  
;; PRIOR APPLICATION NUMBER: 60/068,017  
;; PRIOR FILING DATE: December 18, 1997  
;; PRIOR APPLICATION NUMBER: 60/070,440  
;; PRIOR FILING DATE: January 5, 1998  
;; PRIOR APPLICATION NUMBER: 60/074,086  
;; PRIOR FILING DATE: February 9, 1998  
;; PRIOR APPLICATION NUMBER: 60/074,092  
;; PRIOR FILING DATE: February 9, 1998  
;; PRIOR APPLICATION NUMBER: 60/075,945  
;; PRIOR FILING DATE: February 25, 1998  
;; PRIOR APPLICATION NUMBER: 60/112,850  
;; PRIOR FILING DATE: December 16, 1998  
;; PRIOR APPLICATION NUMBER: 60/113,296  
;; PRIOR FILING DATE: December 22, 1998  
;; PRIOR APPLICATION NUMBER: 60/146,222  
;; PRIOR FILING DATE: July 28, 1999  
;; PRIOR APPLICATION NUMBER: PCT/US98/19330  
;; PRIOR FILING DATE: September 16, 1998  
;; PRIOR APPLICATION NUMBER: PCT/US98/25108  
;; PRIOR FILING DATE: December 1, 1998  
;; PRIOR APPLICATION NUMBER: 09/216,021  
;; PRIOR FILING DATE: December 16, 1998  
;; PRIOR APPLICATION NUMBER: 09/218,517  
;; PRIOR FILING DATE: December 22, 1998  
;; PRIOR APPLICATION NUMBER: 09/254,311

PRIOR FILING DATE: March 3, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/12252  
PRIOR FILING DATE: June 22, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: September 15, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28409  
PRIOR FILING DATE: No. US20020132768A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: No. US20020132768A1ember 30, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/28301  
PRIOR FILING DATE: December 1, 1999  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: December 16, 1999  
PRIOR APPLICATION NUMBER: PCT/US00/03565  
PRIOR FILING DATE: February 11, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: February 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/05841  
PRIOR FILING DATE: March 2, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/08439  
PRIOR FILING DATE: March 30, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/14042  
PRIOR FILING DATE: May 22, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/20710  
PRIOR FILING DATE: July 28, 2000  
PRIOR APPLICATION NUMBER: PCT/US00/32678  
PRIOR FILING DATE: December 1, 2000  
PRIOR APPLICATION NUMBER: PCT/US01/06520  
PRIOR FILING DATE: February 28, 2001  
NUMBER OF SEQ ID NOS: 120  
SEQ ID NO 99  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic oligonucleotide probe  
US-09-945-015-99

Query Match 61.0%; Score 12.2; DB 10; Length 20;  
Best Local Similarity 82.4%; Pred. No. 2.2e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTTCCAGAGCTTGCCA 17  
||||| |||||  
Db 17 GTTCCATTCCTTGCCA 1

Search completed: November 28, 2002, 19:35:04  
Job time : 43.069 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:12:29 ; Search time 40.3448 Seconds  
(without alignments)  
152.028 Million cell updates/sec

Title: US-09-719-737-2

Perfect score: 20  
Sequence: 1 gtccacagagcttgcacct 20

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 609818

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 08  
Maximum Match 1008  
Listing first 45 summaries

Database :

1: /cgn2\_6/ptodata/2/1na/5A.COMB.seq:\*  
2: /cgn2\_6/ptodata/2/1na/5B.COMB.seq:\*  
3: /cgn2\_6/ptodata/2/1na/6A.COMB.seq:\*  
4: /cgn2\_6/ptodata/2/1na/6B.COMB.seq:\*  
5: /cgn2\_6/ptodata/2/1na/PCFUS.COMB.seq:\*  
6: /cgn2\_6/ptodata/2/1na/Backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	13.4	67.0	17	3	US-08-998-099-89
2	13.4	67.0	20	4	US-09-476-256-5
3	13.4	67.0	20	4	US-09-476-256-11
4	13.4	67.0	20	4	US-09-844-634-158
5	13.2	66.0	45	6	5395760-9
6	13	65.0	35	4	US-09-039-198A-21
7	13	65.0	35	4	US-09-267-574-21
8	12.4	62.0	38	3	US-09-023-082A-40
9	12.2	61.0	18	3	US-09-344-579-22
10	12.2	61.0	19	1	US-08-358-782D-5
11	12.2	61.0	19	1	US-08-764-527A-5
12	12.2	61.0	24	2	US-08-066-325-5
13	12.2	61.0	28	3	US-08-483-316-5
14	12.2	61.0	28	4	US-08-500-306-1
15	12.2	61.0	28	4	US-09-521-668B-7
16	12.2	61.0	28	5	PCT-US95-12624-5
17	12.2	61.0	33	1	US-07-951-715A-59
18	12.2	61.0	33	2	US-08-459-448A-59
19	12.2	61.0	33	3	US-08-459-595A-59
20	12.2	61.0	33	3	US-08-459-504B-59
21	12.2	61.0	33	3	US-08-459-444-59
22	12.2	61.0	33	4	US-09-547-422-59
23	12.2	61.0	35	3	US-08-435-568A-33
24	12.2	61.0	41	3	US-08-483-316-7
25	12.2	61.0	41	5	PCT-US95-12624-7
26	12	60.0	26	2	US-08-887-997B-5
27	12	60.0	27	1	US-08-434-503-41

28	12	60.0	34	4	US-09-432-020B-41	Sequence 41, App1
29	12	60.0	42	1	US-07-834-539A-13	Sequence 13, App1
30	12	60.0	42	1	US-08-053-131-21	Sequence 21, App1
31	12	60.0	42	1	US-08-053-131-65	Sequence 65, App1
32	12	60.0	42	1	US-08-645-641-21	Sequence 21, App1
33	12	60.0	42	1	US-08-645-641-65	Sequence 65, App1
34	12	60.0	42	1	US-07-853-408B-21	Sequence 21, App1
35	12	60.0	42	1	US-07-853-408B-65	Sequence 65, App1
36	12	60.0	42	1	US-08-096-762-21	Sequence 21, App1
37	12	60.0	42	1	US-08-096-762-65	Sequence 65, App1
38	12	60.0	42	2	US-08-800-353-13	Sequence 13, App1
39	12	60.0	42	2	US-08-308-865-21	Sequence 21, App1
40	12	60.0	42	2	US-08-308-865-65	Sequence 65, App1
41	12	60.0	42	4	US-09-042-353-189	Sequence 189, App1
42	12	60.0	42	4	US-09-042-353-226	Sequence 226, App1
43	12	60.0	42	4	US-08-758-417A-37	Sequence 37, App1
44	12	60.0	42	4	US-08-758-417A-74	Sequence 74, App1
45	12	60.0	42	5	PCT-US92-06185-13	Sequence 13, App1

#### ALIGNMENTS

```
RESULT 1
US-08-998-099-89
; Sequence 89, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; EARLIER FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 89
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-89

Query Match          67.0%; Score 13.4; DB 3; Length 17;
Best local similarity 80.0%; Pred. No. 3.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      5 CCAGAGCTTGCACAC 19
        ||||| : |||||
Db       1 CCAGAGGUGCCACAC 15

RESULT 2
US-09-476-256-5/c
; Sequence 5, Application US/09476256
; Patent No. 6228592
; GENERAL INFORMATION:
; APPLICANT: Laboratory of Molecular Biophotonics
; TITLE OF INVENTION: Nucleic Acid Detection in Cytoplasm
; FILE REFERENCE: BBP99-02
; CURRENT APPLICATION NUMBER: US/09/476,256
; CURRENT FILING DATE: 1999-12-30
; NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
```

ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: probe  
US-09-476-256-5

Query Match  
Best Local Similarity 93.3%; Score 13.4; DB 4; Length 20;  
Matches 14; Conservative 0; Pred. No. 3.9e+02; Mismatches 1; Indels 0; Gaps 0;

OY 5 CCAGACCTTGGCCACC 19  
||||| |||||||  
DB 20 CCAGAGCTTGGCCACC 6

RESULT 3  
US-09-476-256-11/c  
Sequence 11, Application US/09476256  
Patent No. 6228592  
GENERAL INFORMATION:  
APPLICANT: Laboratory of Molecular Biophotonics  
TITLE OF INVENTION: Nucleic Acid Detection in Cytoplasm  
FILE REFERENCE: BRP99-02  
CURRENT APPLICATION NUMBER: US/09/476,256  
CURRENT FILING DATE: 1999-12-30  
NUMBER OF SEQ ID NOS: 29  
SEQ ID NO 11  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: probe  
US-09-476-256-11

Query Match  
Best Local Similarity 93.3%; Score 13.4; DB 4; Length 20;  
Matches 14; Conservative 0; Pred. No. 3.9e+02; Mismatches 1; Indels 0; Gaps 0;

OY 5 CCAGACCTTGGCCACC 19  
||||| |||||||  
DB 20 CCAGAGCTTGGCCACC 6

RESULT 4  
US-09-844-634-158/c  
Sequence 158, Application US/09844634  
Patent No. 6410324  
GENERAL INFORMATION:  
APPLICANT: C. Frank Bennett  
TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION  
FILE REFERENCE: RFS-0216  
CURRENT APPLICATION NUMBER: US/09/844,634  
CURRENT FILING DATE: 2001-04-27  
NUMBER OF SEQ ID NOS: 174  
SEQ ID NO 158  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-844-634-158

Query Match  
Best Local Similarity 93.3%; Score 13.4; DB 4; Length 20;  
Matches 14; Conservative 0; Pred. No. 3.9e+02; Mismatches 1; Indels 0; Gaps 0;

OY 1 GTTCCAGAGCTTGC 15  
||||| |||||||  
DB 15 GTACCCAGAGCTTGC 1

RESULT 5  
5395760-9/c

Patent No. 5395760  
APPLICANT: SMITH, CRAIG A.; GOODWIN, RAYMOND G.; BECKMANN, J. M. PATRICIA  
TITLE OF INVENTION: DNA ENCODING TUMOR NECROSIS FACTOR- $\alpha$  AND  $\beta$ -RECEPTORS  
NUMBER OF SEQUENCES: 17  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/523,635  
FILING DATE: 10-MAY-1990  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 421,417  
FILING DATE: 13-OCT-1989  
APPLICATION NUMBER: 405,370  
FILING DATE: 11-SEP-1989  
APPLICATION NUMBER: 403,241  
FILING DATE: 05-SEP-1989  
SEQ ID NO: 9  
LENGTH: 45  
5395760-9

Query Match  
Best Local Similarity 83.3%; Score 13.2; DB 6; Length 45;  
Matches 15; Conservative 0; Pred. No. 5.3e+02; Mismatches 3; Indels 0; Gaps 0;

OY 2 TTCCAGAGCTTGGCCACC 19  
||||| |||||||  
DB 30 TTCCAGAGCTTGGCCACC 13

RESULT 6  
US-09-039-198A-21  
Sequence 21, Application US/09039198A  
Patent No. 620951  
GENERAL INFORMATION:  
APPLICANT: Gray, Patrick W.  
TITLE OF INVENTION: CHITINASE CHITIN-BINDING FRAGMENTS  
NUMBER OF SEQUENCES: 34  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
STREET: 233 South Wacker Drive/6300 Sears Tower  
CITY: Chicago  
STATE: Illinois  
COUNTRY: United States of America  
ZIP: 60606-6402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/039,198A  
FILING DATE:  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Rin-Laures, Li-Hsien  
REGISTRATION NUMBER: 33,547  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
INFORMATION FOR SEQ ID NO: 21:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: /desc = "primer"  
US-09-039-198A-21

Query Match  
Best Local Similarity 100.0%; Score 13; DB 4; Length 35;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TTCCGAGAGCTTG 14  
 |||||  
 Db 8 TTCCGAGAGCTTG 20

RESULT 7  
 US-09-267-574-21  
 ; Sequence 21, Application US/09267574  
 ; Patent No. 6399571  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gray, Patrick W.  
 ; APPLICANT: Tjoelker, Larry W.  
 ; TITLE OF INVENTION: CHITINASE CHITIN-BINDING FRAGMENTS  
 ; FILE REFERENCE: 27866/35407  
 ; CURRENT APPLICATION NUMBER: US/09/267,574  
 ; EARLIER FILING DATE: 1999-03-12  
 ; EARLIER APPLICATION NUMBER: 09/039,198  
 ; NUMBER OF SEQ ID NOS: 39  
 ; SOFTWARE: Patent Ver. 2.0  
 ; SEQ ID NO 21  
 ; LENGTH: 35  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: primer  
 US-09-267-574-21

Query Match 65.0%; Score 13; DB 4; Length 35;  
 Best Local Similarity 100.0%; Pred. No. 6.5e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TTCCGAGAGCTTG 14  
 |||||  
 Db 8 TTCCGAGAGCTTG 20

RESULT 8  
 US-09-023-082A-40/C  
 ; Sequence 40, Application US/09023082A  
 ; Patent No. 6077692  
 ; GENERAL INFORMATION:  
 ; APPLICANT: RUBEN, STEVEN M.  
 ; APPLICANT: JIRENEZ, PABLO  
 ; APPLICANT: DUAN, D. ROXANNE  
 ; APPLICANT: RAMPY, MARK A.  
 ; APPLICANT: MENDRICK, DONNA  
 ; APPLICANT: ZHANG, JUN  
 ; APPLICANT: NI, JIAN  
 ; APPLICANT: MOORE, PAUL A.  
 ; APPLICANT: COLEMAN, TIMOTHY A.  
 ; APPLICANT: GRUBER, JOACHIM R.  
 ; APPLICANT: DILLON, PATRICK J.  
 ; APPLICANT: GENTZ, REINER L.  
 ; TITLE OF INVENTION: KERATINOCYTE GROWTH FACTOR-2  
 ; NUMBER OF SEQUENCES: 148  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: STERNER, KESSLER, GOLDSTEIN & FOX, P.L.L.C.  
 ; STREET: 1100 NEW YORK AVE, NW, SUITE 600  
 ; CITY: WASHINGTON  
 ; STATE: DC  
 ; COUNTRY: USA  
 ; ZIP: 20005-3934  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: Patent Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/023,082A  
 ; FILING DATE: 13-FEB-1998

CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US95/01790  
 ; FILING DATE: 14-FEB-1995  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/461,195  
 ; FILING DATE: 05-JUN-1995  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 60/023,852  
 ; FILING DATE: 13-AUG-1996  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 60/039,045  
 ; FILING DATE: 28-FEB-1997  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/862,432  
 ; FILING DATE: 23-MAY-1997  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/910,875  
 ; FILING DATE: 13-AUG-1997  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 60/055,561  
 ; FILING DATE: 13-AUG-1997  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: STEFFE, ERIC K  
 ; REGISTRATION NUMBER: 36,688  
 ; REFERENCE/DOCKET NUMBER: 1488.0360008/EKS  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 202-371-2600  
 ; TELEFAX: 202-371-2540  
 ; INFORMATION FOR SEQ ID NO: 40:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 38 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: cDNA  
 US-09-023-082A-40

Query Match 62.0%; Score 12.4; DB 3; Length 38;  
 Best Local Similarity 92.9%; Pred. No. 1.3e+03;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 CCCGAGAGCTTGCA 17  
 |||||  
 Db 24 CCCGAGAGCTTGCA 11

RESULT 9  
 US-09-344-579-22  
 ; Sequence 22, Application US/09344579  
 ; Patent No. 6054316  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Brenda F. Baker  
 ; APPLICANT: Lex M. Cowsett  
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF ETS-2 EXPRESSION  
 ; FILE REFERENCE: RTS-0063  
 ; CURRENT APPLICATION NUMBER: US/09/344,579  
 ; CURRENT FILING DATE: 1999-06-25  
 ; NUMBER OF SEQ ID NOS: 47  
 ; SEQ ID NO 22  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Antisense Oligonucleotide  
 US-09-344-579-22

Query Match 61.0%; Score 12.2; DB 3; Length 18;  
 Best Local Similarity 82.4%; Pred. No. 1.5e+03;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTTCCGAGAGCTTGCA 17  
 |||||

DB 2 GTTCCGAGAGATGCA 18

## RESULT 10

US-08-358-782D-5

Sequence 5, Application US/08358782D  
Patent No. 5674682

## GENERAL INFORMATION:

APPLICANT: Croce, Carlo

APPLICANT: Gonnella, Leonard

APPLICANT: Mulholland, S. Grant

APPLICANT: Moreno, Jose

APPLICANT: Fischer, Rainer

TITLE OF INVENTION: Methods of Detecting Micrometastasis of Prostate

NUMBER OF SEQUENCES: 14

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &

STREET: One Liberty Place 46th. Floor

CITY: Philadelphia

STATE: PA

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/358,782D

FILING DATE: 15-DEC-1994

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Beardell, Lori Y.

REGISTRATION NUMBER: 34,293

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: NO

ANTI-SENSE: NO

US-08-358-782D-5

Query Match 61.0%; Score 12.2; DB 1; Length 19;

Best Local Similarity 82.4%; Pred. No. 1.5e+03;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 4 CCCAGAGCTTGCCACCT 20

DB 3 CCCAGAGCTTGCCACCT 19

## RESULT 11

US-08-764-527A-5

Sequence 5, Application US/08764527A  
Patent No. 5939258

## GENERAL INFORMATION:

APPLICANT: Croce, Carlo

APPLICANT: Gonnella, Leonard

APPLICANT: Mulholland, S. Grant

APPLICANT: Moreno, Jose

APPLICANT: Fischer, Rainer

TITLE OF INVENTION: Methods of Detecting Micrometastasis of

NUMBER OF SEQUENCES: 14

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &

STREET: One Liberty Place 46th. Floor

CITY: Philadelphia

STATE: PA

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/764,527A

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/358,782

FILING DATE: 15-DEC-1994

ATTORNEY/AGENT INFORMATION:

NAME: Beardell, Lori Y.

REGISTRATION NUMBER: 34,293

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: NO

ANTI-SENSE: NO

US-08-764-527A-5

Query Match 61.0%; Score 12.2; DB 2; Length 19;

Best Local Similarity 82.4%; Pred. No. 1.5e+03;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 4 CCCAGAGCTTGCCACCT 20

DB 3 CCCAGAGCTTGCCACCT 19

## RESULT 12

US-08-066-325-5

Sequence 5, Application US/08066325  
Patent No. 5667967

## GENERAL INFORMATION:

APPLICANT: Steinman, Lawrence

APPLICANT: Oksenberg, Jorge

APPLICANT: Bernard, Claude

TITLE OF INVENTION: T-CELL RECEPTOR VARIABLE TRANSCRIPTS AS DISEASE RELATED MAR

NUMBER OF SEQUENCES: 157

CORRESPONDENCE ADDRESS:

ADDRESSEE: SEED and BERRY LLP

STREET: 6300 Columbia Center, 701 Fifth Avenue

CITY: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/066,325

FILING DATE: 21-MAY-1993

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: No. 5667967, Leburg, Ph.D., Carol

REGISTRATION NUMBER: 39,317

REFERENCE/DOCKET NUMBER: 690068.408C1

TELECOMMUNICATION INFORMATION:



TELEPHONE: (206) 622-4900  
TELEFAX: (206) 682-6031  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 24 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
US-08-066-325-5

Query Match 61.0%; Score 12.2; DB 1; Length 24;  
Best Local Similarity 82.4%; Pred. No. 1.6e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTTCCAGAGCTTGCCA 17  
Db 3 GTTCCAGAGGAGGACCA 19

RESULT 13  
US-08-483-316-5  
Sequence 5, Application US/08483316  
Patent No. 6045802  
GENERAL INFORMATION:  
APPLICANT: SCHLOM, JEFFREY  
APPLICANT: KANTOR, JUDITH  
TITLE OF INVENTION: ENHANCED IMMUNE RESPONSE  
TITLE OF INVENTION: TO AN ANTIGEN BY A COMPOSITION OF A  
TITLE OF INVENTION: RECOMBINANT VIRUS EXPRESSING THE ANTIGEN WITH  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.  
STREET: 345 PARK AVENUE  
CITY: NEW YORK  
STATE: NEW YORK  
COUNTRY: USA  
ZIP: 10154  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.50 INCH, 1.44 Mb STORAGE  
COMPUTER: IBM PC COMPATIBLE  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WORDPERFECT 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/483,316  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/317,268  
FILING DATE: 03-OCT-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWN, KATHRYN M.  
REGISTRATION NUMBER: 34,556  
REFERENCE/DOCKET NUMBER: 2026-4176US1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 758-4800  
TELEFAX: (212) 751-6849  
TELEX: 421792  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
HYPOTHETICAL: Yes  
ANTI-SENSE: NO  
US-08-483-316-5

Query Match 61.0%; Score 12.2; DB 3; Length 28;  
Best Local Similarity 82.4%; Pred. No. 1.6e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4 CCCAGAGCTTGCCACCT 20  
Db 9 CCCAGAGCTTGCCACCT 25

RESULT 14  
US-08-500-306-1  
Sequence 1, Application US/08500306  
Patent No. 6165460  
GENERAL INFORMATION:  
APPLICANT: SCHLOM, JEFFREY  
APPLICANT: PANICALI, DENNIS  
TITLE OF INVENTION: GENERATION OF IMMUNE RESPONSES TO  
TITLE OF INVENTION: PROSTATE-SPECIFIC ANTIGEN (PSA)  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: SEMALL P. BRONSTEIN, DIKE, BRONSTEIN,  
STREET: 130 WATER STREET  
CITY: BOSTON  
STATE: MASSACHUSETTS  
COUNTRY: US  
ZIP: 02129  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/500,306  
FILING DATE:  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: RESNICK, DAVID S.  
REGISTRATION NUMBER: 34,235  
REFERENCE/DOCKET NUMBER: 44981  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 523-3400  
TELEFAX: (617) 523-6440  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
US-08-500-306-1

Query Match 61.0%; Score 12.2; DB 4; Length 28;  
Best Local Similarity 82.4%; Pred. No. 1.6e+03;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4 CCCAGAGCTTGCCACCT 20  
Db 9 CCCAGAGCTTGCCACCT 25

RESULT 15  
US-09-521-668B-7  
Sequence 7, Application US/09521668B  
Patent No. 6303383  
GENERAL INFORMATION:  
APPLICANT: NAKAMURA, JUN  
APPLICANT: KANO, SOHEI  
APPLICANT: KIMURA, EITICHIRO  
APPLICANT: MATSUI, KAUKIRO  
APPLICANT: NAKAMATSU, TSUYOSHI  
TITLE OF INVENTION: TEMPERATURE SENSITIVE PLASMID FOR CORINFORM BACTERIA  
FILE REFERENCE: 0010-1093-0  
CURRENT APPLICATION NUMBER: US/09/521,668B  
FILING DATE: 2000-03-08  
PRIOR APPLICATION NUMBER: JP 11-69896  
PRIOR FILING DATE: 1999-03-16  
NUMBER OF SEQ ID NOS: 20





PT preventing asthma, allergies, hypersinophilia, inflammation or cancer  
 XX  
 XX  
 PS Clalm 5; Page 17; 72pp; English.  
 CC This is an antisense oligonucleotide directed against the interleukin-4  
 CC (IL-4) receptor, for inhibiting receptor expression. IL-4 is involved in  
 CC immunoglobulin E (Ige) production, the development and persistence of  
 CC asthma and atopy. The invention relates to antisense oligonucleotides  
 CC directed against a nucleic acid sequence encoding either a chemokine  
 CC receptor (CCR3), a common subunit of Interleukin-4 (IL-4) and  
 CC Interleukin-13 (IL-13) receptors, or a common subunit of Interleukin-3  
 CC (IL-3), Interleukin-5 (IL-5) and granulocyte macrophage colony  
 CC stimulating factor (GM-CSF) receptors. The antisense oligonucleotides can  
 CC be used in the treatment or prevention of asthma, allergy,  
 CC hypersinophilia, general inflammation or cancer.  
 CC  
 SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 other;  
 Query Match 100.0%; Score 20; DB 21; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.3;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 GTTCCGAGAGCTTGCACCT 20  
 DB 1 GTTCCGAGAGCTTGCACCT 20  
 RESULT 2  
 AAC73582/c  
 ID AAC73582 standard; DNA; 17 BP.  
 XX  
 AC AAC73582;  
 XX  
 DT 02-FEB-2001 (first entry)  
 XX  
 DE Reverse primer #128 used in multiplexing PCR/SBE assay.  
 XX  
 KM Oligonucleotide array: genotyping; single base extension reaction; SBE;  
 KM PCR primer: polymorphic locus; single nucleotide polymorphism; ss.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200058516-A2.  
 XX  
 PD 05-OCT-2000.  
 XX  
 PF 27-MAR-2000; 2000WO-US08069.  
 XX  
 PR 26-MAR-1999; 99US-0126473.  
 PR 23-JUN-1999; 99US-0140359.  
 XX  
 PA (WIRED) WHITEHEAD INST BIOMEDICAL RES.  
 PA (AFRY-) AFREYMETRIX INC.  
 XX  
 PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;  
 PI Ryder T, Sklar P;  
 XX  
 DR WPI; 2000-656171/63.  
 XX  
 PT Universal array of oligonucleotides tags attached to a solid substrate  
 PT along with locus-specific tagged oligonucleotides useful in genotyping  
 PT using single base extension reactions -  
 XX  
 PS Example 7; Page 62; 83pp; English.  
 CC The present invention relates to an oligonucleotide array comprising  
 CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide  
 CC array is useful for genotyping a nucleic acid sample at one or more loci  
 CC via single base extension (SBE) reactions. A pair of primers is used to  
 CC amplify a polymorphic locus in a sample e.g. a single nucleotide  
 CC polymorphism (SNP). The present sequence is one of the primers used in  
 CC the method of the present invention to amplify a polymorphic sample. The

CC amplified nucleic acid product is then used as a template in a SBE  
 CC reaction with an extension primer. The SBE reaction products are used to  
 CC form the oligonucleotide array.  
 CC  
 XX  
 XX  
 SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 other;  
 Query Match 69.0%; Score 13.8; DB 21; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.7e+03;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 4 CCCAGAGCTTGCACCT 20  
 DB 17 CCCAGAGCTTGCACCT 1  
 RESULT 3  
 AA167449  
 ID AA167449 standard; DNA; 25 BP.  
 XX  
 AC AA167449;  
 XX  
 DT 11-FEB-2002 (first entry)  
 XX  
 DE Probe sequence used for real-time RT-PCR analysis.  
 XX  
 KM ARP; angiogenesis; vascular endothelial growth factor; VEGF; cytosolic;  
 KM arginine-rich protein; cardiant; antirheumatic; antiarthritic; human;  
 KM antiatherosclerotic; vasotropic; gynecological; antidiabetic; vulnary;  
 KM anticancer; dermatological; ophthalmological; antipsoriatic; apoptosis;  
 KM gene therapy; RT-PCR; primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200170174-A2.  
 XX  
 PD 27-SEP-2001.  
 XX  
 PF 21-MAR-2001; 2001WO-US09043.  
 XX  
 PR 21-MAR-2000; 2000US-191201P.  
 XX  
 PA (CURA-) CURAGEN CORP.  
 PA (GERTH) GENENTECH INC.  
 XX  
 PI Rastelli IK, Gerber H;  
 XX  
 DR WPI; 2001-639087/73.  
 XX  
 PT Modulating angiogenesis and/or apoptosis for preventing or treating  
 PT cancer, myocardial infarction and promoting healing, by modulating the  
 PT activity of vascular endothelial growth factor-modulated gene  
 PT polypeptide -  
 XX  
 PS Example 2; Page 103; 155pp; English.  
 CC The invention relates to modulating angiogenesis and cell survival that  
 CC involves modulating the activity of at least one vascular endothelial  
 CC growth factor (VEGF)-modulated gene polypeptide. The method is useful for  
 CC modulating angiogenesis and cell survival, for treating tumour and cancer  
 CC by decreasing angiogenesis in cancerous tumours and treating myocardial  
 CC infarction and promoting healing, by increasing angiogenesis. Transgenic  
 CC non-human animals, having disrupted arginine-rich protein (ARP), are  
 CC useful for determining the clinical stage of ovarian tumours, which is  
 CC useful for determining if the tumour has potential for metastasis. ARP is  
 CC useful in gene therapy and in diagnostic applications. VEGF proteins  
 CC are useful in the treatment of tumours, neoplasias, hemangiomas,  
 CC rheumatoid arthritis, atherosclerosis, idiopathic pulmonary fibrosis,  
 CC vascular stenosis, arteriovenous malformations, meningioma, neovascular  
 CC glaucoma, psoriasis, hemophilic joints, hypertrophic scars, Osler-Weber  
 CC syndrome, scleroderma, vascular adhesion pathologies, synovitis,  
 CC dermatitis, endometriosis, diabetic retinopathy, neovascularization  
 CC associated with corneal injury or grafts, wound, sore, and ulcer healing.  
 CC Sequences AA167449-487 represent probe primer sets used for real-time

CC RT-PCR analysis of differential gene expression.  
XX Sequence 25 BP; 6 A; 7 C; 6 G; 6 T; 0 other;  
SQ

Query Match 68.0%; Score 13.6; DB 22; Length 25;  
Best Local Similarity 80.0%; Pred. No. 2.2e+03;  
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 GTTCCACAGCTTGCACCT 20  
          ||||| 11 1111 11  
Db 4 GTTCCCAAGTTGCCGCGCT 23

RESULT 4  
AAH22292  
ID AAH22292 standard; DNA; 25 BP.  
XX  
XX AAH22292;  
XX  
XX 21-AUG-2001 (first entry)  
XX  
XX Tissue factor pathway inhibitor-2 hybridisation probe SEQ ID NO:38.  
XX  
XX Human; differentially expressed gene; angiogenesis; diagnosis;  
XX angiogenic disorder; wound healing; cancer; cardiovascular; psoriasis;  
XX vascular tumour; proliferative tumour; proliferative vitreoretinopathy;  
XX rheumatoid arthritis; Crohn's disease; atherosclerosis; endometriosis;  
XX neovascularisation; restenosis; hypertension; aneurysm; angina;  
XX myocardial infarction; chronic heart condition; osteoporosis;  
XX PCR primer; hybridisation; probe; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX WO200132926-A2.  
XX  
XX 10-MAY-2001.  
XX  
XX 01-NOV-2000; 2000MO-US30051.  
XX  
XX 01-NOV-1999; 9905-0162699.  
XX 13-APR-2000; 2000US-0196802.  
XX 31-OCT-2000; 2000US-0703350.  
XX  
XX (CURA-) CURAGEN CORP.  
XX (GETH) GENENTECH INC.  
XX  
XX Mehraban F, Gerritsen M, Rastelli L;  
XX  
XX WPI; 2001-291056/30.  
XX  
XX Differentially expressed genes involved in angiogenesis, useful for  
XX treating e.g. vascular tumors, atherosclerosis and/or restenosis  
XX subsequent to balloon angioplasty -  
XX  
XX Example 19; Page 148; 182pp; English.

CC The present invention describes differentially expressed genes involved  
CC in angiogenesis (1), and the polypeptides that encode them. (1) have  
CC cardiovascular activity, and can be used in the modulation of  
CC angiogenesis. The nucleic acids and polypeptides may be used in the  
CC prevention, diagnosis and treatment of diseases associated with  
CC inappropriate angiogenesis. The polypeptides may also be used in the  
CC in the production of antibodies against them and in assays to identify  
CC modulators of their expression and activity. The antibodies and  
CC antagonists may also be used to down regulate expression and activity  
CC and modulate angiogenesis. The antibodies may also be used as diagnostic  
CC agents for detecting the presence of the polypeptides in samples.  
CC disorders that may be prevented, diagnosed and/or treated by the above  
CC methods include, for example vascular tumours, proliferative tumours,  
CC proliferative vitreoretinopathy, rheumatoid arthritis, Crohn's disease,  
CC atherosclerosis, ovarian hyperstimulation, psoriasis, endometriosis  
CC associated with neovascularisation, restenosis subsequent to balloon

CC angioplasty, scar tissue over production, peripheral vascular disease,  
CC hypertension, inflammatory vasculitides, Reynaud's disease and  
CC Reynaud's phenomenon, aneurysms, arterial restenosis, thrombophlebitis,  
CC lymphangitis, lymphedema, wound healing and tissue repair, ischaemia  
CC reperfusion injury, angina, myocardial infarctions, chronic heart  
CC conditions, heart failure such as congestive heart failure, age-related  
CC muscular degeneration and osteoporosis. AAH22255 to AAH22325 and AAB98322  
CC to AAB98325 represent sequence used in the exemplification of the  
CC present invention.  
XX  
XX Sequence 25 BP; 6 A; 7 C; 6 G; 6 T; 0 other;  
XX  
XX

Query Match 68.0%; Score 13.6; DB 22; Length 25;  
Best Local Similarity 80.0%; Pred. No. 2.2e+03;  
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 GTTCCACAGCTTGCACCT 20  
          ||||| 11 1111 11  
Db 4 GTTCCCAAGTTGCCGCGCT 23

RESULT 5  
AAV95349  
ID AAV95349 standard; RNA; 17 BP.  
XX  
XX AAV95349;  
XX  
XX 24-FEB-1999 (first entry)  
XX  
XX Human c-fos target sequence nucleotide position 845.  
XX  
XX  
XX Human; c-fos; hammerhead ribozyme; hairpin ribozyme; target site;  
XX cancer; oncogene; leukaemia; neuroblastoma; diagnosis; genetic drift;  
XX mutation; diseased cell; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO9832846-A2.  
XX  
XX 30-JUL-1998.  
XX  
XX 20-JAN-1998; 98MO-US01017.  
XX  
XX 23-JAN-1997; 97US-0037658.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Jarvis T, McSwiggen JA, Stinchcomb DT;  
XX  
XX WPI; 1998-427942/36.  
XX  
XX Enzymatic nucleic acid molecules which specifically cleave RNA  
XX derived from a c-fos gene - useful for treating conditions related  
XX to levels of c-fos, especially cancer  
XX  
XX Claim 2; Page 51; 72pp; English.

CC The present invention describes an enzymatic nucleic acid molecule which  
CC specifically cleaves RNA derived from a c-fos gene. AAV95401 to AAV95540  
CC and AAV95541 to AAV95584 represent hammerhead ribozymes and hairpin  
CC ribozymes, respectively, which specifically cleave human c-fos.  
CC to AAV95400 and AAV95585 to AAV95628 represent human c-fos target  
CC sequences. The enzymatic nucleic acid molecules can be used for treating  
CC cancer associated with elevated levels of c-fos oncogene, especially  
CC leukaemias, neuroblastomas and lung, breast and colon cancers. The  
CC ribozymes may also be used as diagnostic tools to examine genetic drift  
CC and mutations within diseased cells, or to detect the presence of c-fos  
CC RNA in a cell.  
XX  
XX Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;  
XX  
XX

Query Match 67.0%; Score 13.4; DB 19; Length 17;  
Best Local Similarity 80.0%; Pred. No. 2.7e+03;

Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 5 CCAGAGCTTGCACAC 19  
 Db 1 CCAGAGCTTGCACAC 15

## RESULT 6

AC83618/c  
 ID AAC83618 standard; DNA: 20 BP.

AC AAC83618;

DT 27-FEB-2001 (first entry)

DE Human c-fos oligo DNA D3.

XX Human; c-fos; fluorescent probe; cytoplasmic-nucleic acid detection; ss.

XX Homo sapiens.

PN EPI052293-A1.

PD 15-NOV-2000.

PF 27-DEC-1999; 99EP-0126030.

PK 12-MAY-1999; 99JP-0131838.

PA (MOLE-) LAB MOLECULAR BIOPHOTONICS.

PI Tsuji A, Hirano M, Koshimoto H, Ishibashi K;

DR WPI; 2001-018062/03.

PT Detection of a target nucleic acid in the cytoplasm of a living cell  
 PT comprises using a fluorescent probe linked to a component that cannot  
 permeate through the nuclear membrane -

PS Example 1; Page 11; 53pp; English.

XX The present sequence is a probe which was used in a method for nucleic  
 CC acid detection in cytoplasm. The method comprises detecting a target  
 CC nucleic acid using a fluorescent hybridisation probe linked to a  
 CC component that cannot permeate through the nuclear membrane of the  
 CC cell. The present sequence was used for detecting cytoplasmic human  
 CC c-fos mRNA molecules. The detection probe of this method is not  
 CC readily degraded by endogenous cytoplasmic nucleases unlike currently  
 CC available detection probes, as it has a specified structure which does  
 CC not rapidly move to the nucleus when introduced into the cytoplasm of a  
 CC living cell.

SO Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 other;

Query Match 67.0%; Score 13.4; DB 22; Length 20;

Best Local Similarity 93.3%; Pred. No. 2.7e+03;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 CCAGAGCTTGCACAC 19  
 Db 20 CCAGAGCTTGCACAC 6

## RESULT 7

AC83624/c  
 ID AAC83624 standard; DNA: 20 BP.

AC AAC83624;

DT 27-FEB-2001 (first entry)

DE Human c-fos Bodipy493/503-labelled oligo DNA D3F.

KW Human; c-fos; fluorescent probe; cytoplasmic nucleic acid detection; ss.  
 XX Homo sapiens.

FT Key Location/Qualifiers  
 FT modified\_base 1

FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "attached to fluorescent dye Bodipy493/503"

PN EPI052293-A1.

PD 15-NOV-2000.

PF 27-DEC-1999; 99EP-0126030.

PK 12-MAY-1999; 99JP-0131838.

PA (MOLE-) LAB MOLECULAR BIOPHOTONICS.

PI Tsuji A, Hirano M, Koshimoto H, Ishibashi K;

DR WPI; 2001-018062/03.

PT Detection of a target nucleic acid in the cytoplasm of a living cell  
 PT comprises using a fluorescent probe linked to a component that cannot  
 permeate through the nuclear membrane -

PS Example 1; Page 13; 53pp; English.

XX The present sequence is a probe which was used in a method for nucleic  
 CC acid detection in cytoplasm. The method comprises detecting a target  
 CC nucleic acid using a fluorescent hybridisation probe linked to a  
 CC component that cannot permeate through the nuclear membrane of the  
 CC cell. The present sequence was used for detecting cytoplasmic human  
 CC c-fos mRNA molecules. The detection probe of this method is not  
 CC readily degraded by endogenous cytoplasmic nucleases unlike currently  
 CC available detection probes, as it has a specified structure which does  
 CC not rapidly move to the nucleus when introduced into the cytoplasm of a  
 CC living cell.

SO Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 other;

Query Match 67.0%; Score 13.4; DB 22; Length 20;

Best Local Similarity 93.3%; Pred. No. 2.7e+03;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 CCAGAGCTTGCACAC 19  
 Db 20 CCAGAGCTTGCACAC 6

## RESULT 8

AB195431  
 ID AB195431 standard; DNA: 20 BP.

AC AB195431;

DT 16-FEB-2002 (first entry)

DE Capture oligonucleotide zip ID#2518 oligo #9.

XX Human; K-ras; PCR primer; probe; capture probe; mutation detection;  
 KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;  
 KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity;  
 KW cancer; oncogene; tumour suppressor; human papillomavirus; forensic;  
 KW environmental monitoring; food industry; feed industry; ss.

OS Synthetic.

PN WO200179548-A2.

PD 25-OCT-2001.

```
XX 04-APR-2001; 2001WO-US10958.
PF
XX
XX 14-APR-2000; 2000US-197271P.
PR
XX
XX (CORR ) CORNELL RES FOUND INC.
PA
XX
XX Barany F, Zlrvi M, Gerry NP, Favis R, Kilman R;
PI
XX WPI: 2002-034366/04.
DR
XX
XX
XX Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch -
PS
XX Example 5; Fig 29; 300pp; English.
PS
XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridise with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents,
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
CC of the present invention.
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 other;
SQ
Query Match 66.0%; Score 13.2; DB 24; Length 20;
Best Local Similarity 83.3%; Pred. No. 3.4e+03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3 TCCGAGAGCTTGGCAGCT 20
DB 1 TCCCGGAGCTTGGCAGCT 18
RESULT 9
AB187432
ID AB187432 standard; DNA: 24 BP.
XX
XX AC AB187432;
XX
XX
XX 15-FEB-2002 (first entry)
DT
XX
XX Capture oligonucleotide zip ID#2518 oligo #1.
DE
XX
XX Human: K-ras; PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity;
KW cancer; oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.
XX
XX Synthetic.
OS
XX
XX WO200179548-A2.
XX
XX
XX 25-OCT-2001.
```

```
XX 04-APR-2001; 2001WO-US10958.
PF
XX
XX 14-APR-2000; 2000US-197271P.
PR
XX
XX (CORR ) CORNELL RES FOUND INC.
PA
XX
XX Barany F, Zlrvi M, Gerry NP, Favis R, Kilman R;
PI
XX WPI: 2002-034366/04.
DR
XX
XX
XX Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch -
PS
XX Example 5; Fig 25; 300pp; English.
PS
XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridise with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents,
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
CC of the present invention.
XX
XX Sequence 24 BP; 4 A; 10 C; 4 G; 6 T; 0 other;
SQ
Query Match 66.0%; Score 13.2; DB 24; Length 24;
Best Local Similarity 83.3%; Pred. No. 3.5e+03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3 TCCGAGAGCTTGGCAGCT 20
DB 1 TCCCGGAGCTTGGCAGCT 18
RESULT 10
AB187433/C
ID AB187433 standard; DNA: 24 BP.
XX
XX AC AB187433;
XX
XX
XX 15-FEB-2002 (first entry)
DT
XX
XX Capture oligonucleotide zip ID#2518 oligo #2.
DE
XX
XX Human: K-ras; PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity;
KW cancer; oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.
XX
XX Synthetic.
OS
XX
XX WO200179548-A2.
XX
XX
XX 25-OCT-2001.
```

```
XX 04-APR-2001: 2001WO-US10958.
PF
XX
XX 14-APR-2000: 2000US-197271P.
PR
XX
XX (CORR ) CORNELL RES FOUND INC.
PA
XX
XX Barany F, Zilvi M, Gerry NP, Favls R, Kliman R;
PI
XX WPI: 2002-034366/04.
DR
XX
XX Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch -
XX
XX Example 5: Fig 25: 300pp: English.
PS
XX
XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridise with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying (using a computer) identified ligation to a
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
CC of the present invention.
XX
XX Sequence 24 BP: 6 A: 4 C: 10 G: 4 T: 0 other:
SQ
Query Match 66.0%; Score 13.2; DB 24; Length 24;
Best Local Similarity 83.3%; Pred. No. 3.5e+03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 3 TCCGAGAGCTTGGCACCCT 20
Db 24 TCCCGGACCTTGGCACCCT 7
RESULT 11
AB188068
ID AB188068 standard; DNA: 24 BP.
XX
XX AB188068;
AC
XX
XX 15-FEB-2002 (first entry)
DT
XX
XX Capture oligonucleotide zip ID#2836 oligo #1.
DE
XX
XX Human: K-ras: PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity;
KW cancer; oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.
XX
XX Synthetic.
OS
XX
XX WO200179548-A2.
PN
XX
XX 25-OCT-2001.
PD
```

```
XX 04-APR-2001: 2001WO-US10958.
PF
XX
XX 14-APR-2000: 2000US-197271P.
PR
XX
XX (CORR ) CORNELL RES FOUND INC.
PA
XX
XX Barany F, Zilvi M, Gerry NP, Favls R, Kliman R;
PI
XX WPI: 2002-034366/04.
DR
XX
XX Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch -
XX
XX Example 5: Fig 25: 300pp: English.
PS
XX
XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridise with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying (using a computer) identified ligation to a
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
CC of the present invention.
XX
XX Sequence 24 BP: 5 A: 7 C: 6 G: 6 T: 0 other:
SQ
Query Match 66.0%; Score 13.2; DB 24; Length 24;
Best Local Similarity 83.3%; Pred. No. 3.5e+03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 3 TCCGAGAGCTTGGCACCCT 20
Db 5 TCCCAAGAGCTTGGCACCCT 22
RESULT 12
AB188069/C
ID AB188069 standard; DNA: 24 BP.
XX
XX AB188069;
AC
XX
XX 15-FEB-2002 (first entry)
DT
XX
XX Capture oligonucleotide zip ID#2836 oligo #2.
DE
XX
XX Human: K-ras: PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity;
KW cancer; oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.
XX
XX Synthetic.
OS
XX
XX WO200179548-A2.
PN
XX
XX 25-OCT-2001.
PD
```



```

XX 04-APR-2001; 2001MO-US10958.
PF 14-APR-2000; 2000US-197271P.
XX (CORR ) CORNELL RES FOUND INC.
XX
XX Barany F, Zilvi M, Gerry NP, Favlis R, Kilman R;
XX WPI; 2002-034366/04.
XX
XX Designing capture oligonucleotide probes for use on a support to which
XX complementary oligonucleotides hybridize with little mismatch -
XX
XX Example 5; Fig 25; 300pp; English.
XX
XX The present invention describes a method (M1) for designing capture
XX oligonucleotide probes (i) for use on a support to which complementary
XX oligonucleotide probes (ii) will hybridise with little mismatch, where
XX (i) have melting temperatures within a narrow range. The method is useful
XX for detecting infectious diseases caused by bacterial infectious agents
XX e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
XX infectious agents e.g. Cryptococcus neoformans, Candida albicans and
XX Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
XX Epstein-Barr virus and polio virus, and parasitic infectious agents,
XX selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
XX medinensis. The method is also useful for detecting genetic diseases such
XX as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
XX Detecting cancer involving oncogenes, tumour suppressor genes, or genes
XX involved in DNA amplification, replication, recombination or repair, the
XX cancer is specifically associated with a gene selected from BCL1 gene,
XX p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
XX method is also used for environmental monitoring, forensics and the food
XX electron microscope, detecting comprises scanning (using e.g. a scanning
XX electron microscope and infrared microscope) the support at the
XX particular sites and identifying if ligation of the oligonucleotide probe
XX sets occurred and correlating (using a computer) identified ligation to a
XX presence or absence of the target nucleotide sequences. AB182074 to
XX CC AB197546 represent oligonucleotide sequences used in the exemplification
XX of the present invention.
XX
XX Sequence 24 BP; 6 A; 6 C; 7 G; 5 T; 0 other;
XX
XX Query Match 66.0%; Score 13.2; DB 24; Length 24;
XX Best Local Similarity 83.3%; Pred. No. 3.5e+03;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 3 TCCCAAGCTTGGCACCCT 20
XX 20 TCCCAAGCTTGGCACCCT 3
XX
XX RESULT 13
XX AAN91567
XX ID AAN91567 standard; DNA; 28 BP.
XX
XX AAN91567;
XX
XX 02-MAR-1990 (first entry)
XX
XX Neisseria gonorrhoea group 17 probe DNA.
XX
XX Escherichia coli; probe.
XX
XX Neisseria gonorrhoea.
XX
XX EP337896-A.
XX
XX 18-OCT-1989.
XX
XX 14-APR-1989; 88EP-0401045.
XX
XX 15-APR-1988; 88EP-0400929.

```

```

XX (INNO ) INNOGENETICS NV SA.
XX
XX Rossau R, Van Heuverswijn;
XX
XX WPI; 1989-302611/42.
XX
XX Hybridisation probes for detecting Neisseria strains
XX - some being specific for Neisseria gonorrhoeae
XX
XX Claim 1; page 27; 60pp; English.
XX
XX This probe, its complementary RNA, or its derivs. can be used to
XX CC specifically detect N. gonorrhoea, and can differentiate at the
XX CC sub-species level (eliminating Southern blotting).
XX
XX Sequence 28 BP; 10 A; 9 C; 3 G; 6 T; 0 other;
XX
XX Query Match 66.0%; Score 13.2; DB 10; Length 28;
XX Best Local Similarity 61.1%; Pred. No. 3.5e+03;
XX Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;
XX
XX 2 TCCCAAGCTTGGCACC 19
XX 7 TCCCAAGCTTGGCACC 24
XX
XX RESULT 14
XX AAN91568
XX ID AAN91568 standard; RNA; 28 BP.
XX
XX AAN91568;
XX
XX 02-MAR-1990 (first entry)
XX
XX Neisseria gonorrhoea 17bis probe RNA.
XX
XX Escherichia coli; probe.
XX
XX Neisseria gonorrhoea.
XX
XX EP337896-A.
XX
XX 18-OCT-1989.
XX
XX 14-APR-1989; 88EP-0401045.
XX
XX 15-APR-1988; 88EP-0400929.
XX
XX (INNO ) INNOGENETICS NV SA.
XX
XX Rossau R, Van Heuverswijn;
XX
XX WPI; 1989-302611/42.
XX
XX Hybridisation probes for detecting Neisseria strains
XX - some being specific for Neisseria gonorrhoeae
XX
XX Claim 1; page 28; 60pp; English.
XX
XX This probe, its complementary DNA, or its derivs. can be used to
XX CC specifically detect N. gonorrhoea, and can differentiate at the
XX CC sub-species level (eliminating Southern blotting).
XX
XX Sequence 28 BP; 10 A; 9 C; 3 G; 6 T; 0 other;
XX
XX Query Match 66.0%; Score 13.2; DB 10; Length 28;
XX Best Local Similarity 61.1%; Pred. No. 3.5e+03;
XX Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;
XX
XX 2 TCCCAAGCTTGGCACC 19
XX 7 TCCCAAGCTTGGCACC 24

```

```
RESULT 15
AAN91569/C
ID AAN91569 standard: DNA; 28 BP.
XX
AC AAN91569;
XX
DT 02-MAR-1990 (first entry)
XX
DE Neisseria gonorrhoea 17ter probe DNA.
XX
KM Escherichia coli; probe.
XX
OS Neisseria gonorrhoea.
XX
PN EP337896-A.
XX
PD 18-OCT-1989.
XX
PF 14-APR-1989; 89EP-0401045.
XX
PR 15-APR-1988; 88EP-0400929.
XX
PA (INNO ) INNOGENETICS NV SA.
XX
PI Rossau R, Van Heuverswijn;
XX
DR WPI; 1989-302611/42.
XX
PT Hybridisation probes for detecting Neisseria strains
PT - some being specific for Neisseria gonorrhoeae
XX
PS Claim 1; page 28; 60pp; English.
XX
CC This probe, its complementary RNA, or its derivs. can be used to
CC specifically detect N. gonorrhoea, and can differentiate at the
CC sub-species level (eliminating Southern blotting).
XX
SQ Sequence 28 BP; 6 A; 3 C; 9 G; 10 T; 0 other;
Query Match 66.0%; Score 13.2; DB 10; Length 28;
Best Local Similarity 83.3%; Pred. No. 3; Set 03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2 TTCCAGAGCTTGCAC 19
DB 22 TTCCAGAGCTTGCAC 5
```

Search completed: November 28, 2002, 17:24:11  
Job time : 186.851 secs

Gencore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 16:42:34 ; Search time 1162.07 Seconds

(without alignments)  
500.879 Million cell updates/sec

Title: US-09-719-737-2

Sequence: 1 gtccacagagcttcacacct 20

Scoring table: IDENTITY-NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2054640 segs, 14551402878 residues

Total number of hits satisfying chosen parameters: 841850

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

1: gb\_ba:\*  
2: gb\_htg:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_om:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vl:\*  
30: em\_hg\_hum:\*  
31: em\_hg\_inv:\*  
32: em\_hg\_other:\*  
33: em\_hg\_mus:\*  
34: em\_hg\_pln:\*  
35: em\_hg\_rod:\*  
36: em\_hg\_mam:\*  
37: em\_hg\_vrt:\*  
38: em\_sy:\*  
39: em\_hggo\_hum:\*  
40: em\_hggo\_mus:\*  
41: em\_hggo\_other:\*

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	6	AX008649
2	13.4	67.0	20	6	AR149434
3	13.4	67.0	20	6	AR149440
4	13.4	67.0	20	6	E49406
5	13.4	67.0	20	6	E49412
6	13.2	66.0	20	6	AX295389
7	13.2	66.0	24	6	AX290756
8	13.2	66.0	24	6	AX291074
9	13.2	66.0	28	6	A14537
10	13.2	66.0	28	6	A14538
11	13.2	66.0	28	6	A14539
12	13.2	66.0	28	6	A14540
13	13.2	66.0	31	6	AX248913
14	13.2	65.0	35	6	AR212154
15	12.8	64.0	26	6	AX370542
16	12.8	64.0	26	6	AX453540
17	12.8	64.0	50	6	AX161154
18	12.6	63.0	20	6	AX412207
19	12.6	63.0	25	6	AX067206
20	12.6	63.0	29	6	A47119
21	12.4	62.0	32	6	AX281557
22	12.4	62.0	32	6	AX281565
23	12.4	62.0	38	6	AR099158
24	12.2	61.0	19	6	I67855
25	12.2	61.0	21	6	AX096742
26	12.2	61.0	21	6	E23807
27	12.2	61.0	24	6	I65283
28	12.2	61.0	25	6	E06786
29	12.2	61.0	27	6	AX455026
30	12.2	61.0	28	6	AR122021
31	12.2	61.0	28	6	AR173104
32	12.2	61.0	28	6	AX323159
33	12.2	61.0	31	6	AX425940
34	12.2	61.0	33	6	AR029549
35	12.2	61.0	33	6	AR098502
36	12.2	61.0	33	6	AX441428
37	12.2	61.0	33	6	AX453924
38	12.2	61.0	33	6	I41462
39	12.2	60.0	21	6	AX096363
40	12.2	60.0	26	6	AX090084
41	12.2	60.0	27	6	I39768
42	12.2	60.0	31	6	BD002915
43	12.2	60.0	33	6	AX004493
44	12.2	60.0	40	6	AX138897
45	12.2	60.0	40	6	BD000662

ALIGNMENTS

RESULT 1  
AX008649  
LOCUS AX008649 20 bp DNA linear PAT 06-SEP-2000  
DEFINITION Sequence 2 from Patent WO966037.  
ACCESSION AX008649  
VERSION AX008649.1 GI:9996173  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct.  
synthetic construct  
artificial sequences.  
REFERENCE  
1 (bases 1 to 20)  
Renzl P.  
TITLE  
Antisense oligonucleotides for treating or preventing atopic  
diseases and neoplastic cell proliferation  
Patent: WO 966037-A 2 23-DEC-1999;  
JOURNAL

RENTI PAOLO (CA): RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES Location/Qualifiers  
source 1..20  
/organism="synthetic construct"  
/db\_xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common subunit of IL-4 and IL-13 human receptor"  
BASE COUNT 3 a 8 c 4 g 5 t  
ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 20;  
Best Local Similarity 100.0%; Pred. No. 17;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTCCAGAGCTTGCCACCT 20  
Db 1 GTTCCAGAGCTTGCCACCT 20

RESULT 2  
LOCUS ARI49434/c 20 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 5 from patent US 6228592.  
ACCESSION ARI49434  
VERSION ARI49434.1 GI:15114025  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.  
TITLE Nucleic acid detection in cytoplasm  
JOURNAL Patent: US 6228592-A 5 08-MAY-2001;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
BASE COUNT 2 a 6 c 8 g 4 t  
ORIGIN

Query Match 67.0%; Score 13.4; DB 6; Length 20;  
Best Local Similarity 93.3%; Pred. No. 5e+04;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 CCAGAGCTTGCCACC 19  
Db 20 CCAGAGCTTGCCACC 6

RESULT 3  
LOCUS ARI49440/c 20 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 11 from patent US 6228592.  
ACCESSION ARI49440  
VERSION ARI49440.1 GI:15114031  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.  
TITLE Nucleic acid detection in cytoplasm  
JOURNAL Patent: US 6228592-A 11 08-MAY-2001;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
BASE COUNT 2 a 6 c 8 g 4 t  
ORIGIN

Query Match 67.0%; Score 13.4; DB 6; Length 20;  
Best Local Similarity 93.3%; Pred. No. 5e+04;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 CCAGAGCTTGCCACC 19  
Db 20 CCAGAGCTTGCCACC 6

Db 20 CCAGAGCTTGCCACC 6  
IIIIII IIIIIII  
RESULT 4  
LOCUS E49406/c 20 bp DNA linear PAT 31-JAN-2002  
DEFINITION Method for detecting cytoplasmic target nucleic acid in living cell.  
ACCESSION E49406  
VERSION E49406.1 GI:18629305  
KEYWORDS JP 2001025400-A/5.  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.  
TITLE Method for detecting cytoplasmic target nucleic acid in living cell  
JOURNAL Patent: JP 2001025400-A 5 30-JAN-2001;  
COMMENT BUNSHI BIO HONONIKUSU KENKYUSHO  
OS Artificial Sequence  
PN JP 2001025400-A/5  
PD 30-JAN-2001  
PF 28-DEC-1999 JP 1999373904  
PR  
PI AKIHICO TSUJI,MASAHICO HIRANO,HIROYUKI KOSHIMOTO, PI KANAME  
ISHIBASHI  
PC C1201/68,C12N15/09//G01N21/78,C12N15/00  
FH Key Location/Qualifiers  
FT source 1..20  
/organism="Artificial Sequence".  
FEATURES Location/Qualifiers  
source 1..20  
/organism="synthetic construct"  
/db\_xref="taxon:32630"  
BASE COUNT 2 a 6 c 8 g 4 t  
ORIGIN

Query Match 67.0%; Score 13.4; DB 6; Length 20;  
Best Local Similarity 93.3%; Pred. No. 5e+04;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 CCAGAGCTTGCCACC 19  
Db 20 CCAGAGCTTGCCACC 6

RESULT 5  
LOCUS E49412/c 20 bp DNA linear PAT 31-JAN-2002  
DEFINITION Method for detecting cytoplasmic target nucleic acid in living cell.  
ACCESSION E49412  
VERSION E49412.1 GI:18629311  
KEYWORDS JP 2001025400-A/11.  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.  
TITLE Method for detecting cytoplasmic target nucleic acid in living cell  
JOURNAL Patent: JP 2001025400-A 11 30-JAN-2001;  
COMMENT BUNSHI BIO HONONIKUSU KENKYUSHO  
OS Artificial Sequence  
PN JP 2001025400-A/11  
PD 30-JAN-2001  
PF 28-DEC-1999 JP 1999373904  
PR  
PI AKIHICO TSUJI,MASAHICO HIRANO,HIROYUKI KOSHIMOTO, PI KANAME  
ISHIBASHI  
PC C1201/68,C12N15/09//G01N21/78,C12N15/00

FH Key Location/Qualifiers  
 FT source 1..20  
 /organism="Artificial Sequence".  
 FEATURES  
 source Location/Qualifiers  
 1..20  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"  
 BASE COUNT 2 a 6 c 8 g 4 t  
 ORIGIN  
 Query Match 67.0%; Score 13.4; DB 6; Length 20;  
 Best Local Similarity 93.3%; Pred. No. 5e+04;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 5 CCAGAGCTTGCACAC 19  
 ||||| |||||  
 Db 20 CCAGAGCTTGCACAC 6  
 RESULT 6  
 AX295389 20 bp DNA linear PAT 21-NOV-2001  
 LOCUS Sequence 7151 from Patent WO0179548.  
 ACCESSION AX295389  
 VERSION AX295389.1 GI:17057078  
 KEYWORDS  
 SOURCE synthetic construct.  
 ORGANISM synthetic construct.  
 artificial sequences.  
 REFERENCE 1  
 AUTHORS Barany, F., Zhirvi, M., Gerry, N.P., Favis, R. and Kliman, R.  
 TITLE Method of designing addressable array for detection of nucleic acid  
 JOURNAL sequence differences using ligase detection reaction  
 CORNELL RESEARCH FOUNDATION, INC. (US)  
 FEATURES  
 source Location/Qualifiers  
 1..20  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"  
 /note="Hypothetical probe Sequence"  
 BASE COUNT 3 a 9 c 3 g 5 t  
 ORIGIN  
 Query Match 66.0%; Score 13.2; DB 6; Length 20;  
 Best Local Similarity 83.3%; Pred. No. 6.4e+04;  
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 3 TCCGAGCTTGCACCT 20  
 ||||| ||||| |||||  
 Db 1 TCCGAGCTTGCACCT 18  
 RESULT 7  
 AX290756 24 bp DNA linear PAT 21-NOV-2001  
 LOCUS Sequence 2518 from Patent WO0179548.  
 ACCESSION AX290756  
 VERSION AX290756.1 GI:17052439  
 KEYWORDS  
 SOURCE synthetic construct.  
 ORGANISM synthetic construct.  
 artificial sequences.  
 REFERENCE 1  
 AUTHORS Barany, F., Zhirvi, M., Gerry, N.P., Favis, R. and Kliman, R.  
 TITLE Method of designing addressable array for detection of nucleic acid  
 JOURNAL sequence differences using ligase detection reaction  
 CORNELL RESEARCH FOUNDATION, INC. (US)  
 FEATURES  
 source Location/Qualifiers  
 1..24  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"  
 /note="Hypothetical Probe Sequence"

BASE COUNT 4 a 10 c 4 g 6 t  
 ORIGIN  
 Query Match 66.0%; Score 13.2; DB 6; Length 24;  
 Best Local Similarity 83.3%; Pred. No. 6.3e+04;  
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 3 TCCGAGCTTGCACCT 20  
 ||||| ||||| |||||  
 Db 1 TCCGAGCTTGCACCT 18  
 RESULT 8  
 AX291074 24 bp DNA linear PAT 21-NOV-2001  
 LOCUS Sequence 2836 from Patent WO0179548.  
 ACCESSION AX291074  
 VERSION AX291074.1 GI:17052757  
 KEYWORDS  
 SOURCE synthetic construct.  
 ORGANISM synthetic construct.  
 artificial sequences.  
 REFERENCE 1  
 AUTHORS Barany, F., Zhirvi, M., Gerry, N.P., Favis, R. and Kliman, R.  
 TITLE Method of designing addressable array for detection of nucleic acid  
 JOURNAL sequence differences using ligase detection reaction  
 CORNELL RESEARCH FOUNDATION, INC. (US)  
 FEATURES  
 source Location/Qualifiers  
 1..24  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"  
 /note="Hypothetical probe Sequence"  
 BASE COUNT 5 a 7 c 6 g 6 t  
 ORIGIN  
 Query Match 66.0%; Score 13.2; DB 6; Length 24;  
 Best Local Similarity 83.3%; Pred. No. 6.3e+04;  
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 3 TCCGAGCTTGCACCT 20  
 ||||| ||||| |||||  
 Db 5 TCCGAGCTTGCACCT 22  
 RESULT 9  
 A14537 28 bp DNA linear PAT 29-SEP-1994  
 LOCUS Group 17 hybridization probe for detecting Neisseria strains.  
 ACCESSION A14537  
 VERSION A14537.1 GI:640858  
 KEYWORDS  
 SOURCE synthetic construct.  
 ORGANISM synthetic construct.  
 artificial sequences.  
 REFERENCE 1 (bases 1 to 28)  
 AUTHORS Rossau, R. and Van Heuverswijn, H.  
 TITLE Hybridization probes for detecting neisseria strains  
 JOURNAL Patent: EP 0337896-A 68 18-OCT-1989;  
 N.V. INNOGENETICS S.A.  
 FEATURES  
 source Location/Qualifiers  
 1..28  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"  
 BASE COUNT 10 a 9 c 3 g 6 t  
 ORIGIN  
 Query Match 66.0%; Score 13.2; DB 6; Length 28;  
 Best Local Similarity 83.3%; Pred. No. 6.3e+04;  
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 2 TTCCGAGCTTGCACAC 19  
 ||||| ||||| |||||

Db 7 TTCCACAGCCTTGCCAC 24

RESULT 10

LOCUS A14538 28 bp DNA Linear PAT 29-SEP-1994

DEFINITION Group 17 bis hybridization probe for detecting Neisseria strains.

ACCESSION A14538

VERSION A14538.1 GI:640859

KEYWORDS

SOURCE synthetic construct.

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 28)

AUTHORS Rossau,R. and Van Heuverswijn,H.

TITLE Hybridization probes for detecting neisseria strains

JOURNAL Patent: EP 0337896-A 69 18-OCT-1989;

N.V. INNOGENETICS S.A

FEATURES

Location/Qualifiers

1..28

BASE COUNT 10 a 9 c 3 g 6 t

ORIGIN

Query Match 66.0%; Score 13.2; DB 6; Length 28;

Best Local Similarity 83.3%; Pred. No. 6.3e+04;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 TTCCACAGCCTTGCCACC 19

Db 7 TTCCACAGCCTTGCCAC 24

RESULT 11

LOCUS A14539 28 bp DNA Linear PAT 29-SEP-1994

DEFINITION Group 17 ter hybridization probe for detecting Neisseria strains.

ACCESSION A14539

VERSION A14539.1 GI:640860

KEYWORDS

SOURCE synthetic construct.

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 28)

AUTHORS Rossau,R. and Van Heuverswijn,H.

TITLE Hybridization probes for detecting neisseria strains

JOURNAL Patent: EP 0337896-A 70 18-OCT-1989;

N.V. INNOGENETICS S.A

FEATURES

Location/Qualifiers

1..28

BASE COUNT 6 a 3 c 9 g 10 t

ORIGIN

Query Match 66.0%; Score 13.2; DB 6; Length 28;

Best Local Similarity 83.3%; Pred. No. 6.3e+04;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 TTCCACAGCCTTGCCACC 19

Db 22 TTCCACAGCCTTGCCAC 5

RESULT 12

LOCUS A14540 28 bp DNA Linear PAT 29-SEP-1994

DEFINITION Group 17 quater hybridization probe for detecting Neisseria strains.

ACCESSION A14540

VERSION A14540.1 GI:640861

KEYWORDS

SOURCE

SOURCE synthetic construct.

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 28)

AUTHORS Rossau,R. and Van Heuverswijn,H.

TITLE Hybridization probes for detecting neisseria strains

JOURNAL Patent: EP 0337896-A 71 18-OCT-1989;

N.V. INNOGENETICS S.A

FEATURES

Location/Qualifiers

1..28

BASE COUNT 6 a 3 c 9 g 10 t

ORIGIN

Query Match 66.0%; Score 13.2; DB 6; Length 28;

Best Local Similarity 83.3%; Pred. No. 6.3e+04;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 TTCCACAGCCTTGCCACC 19

Db 22 TTCCACAGCCTTGCCAC 5

RESULT 13

LOCUS AX248913 31 bp DNA Linear PAT 28-SEP-2001

DEFINITION Sequence 992 from Patent WO0166800.

ACCESSION AX248913

VERSION AX248913.1 GI:15863536

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 31)

AUTHORS Cargill,M., Ireland,J.S. and Lander,E.S.

TITLE Human single nucleotide polymorphisms

JOURNAL Patent: WO 0166800-A 992 13-SEP-2001;

WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)

FEATURES

Location/Qualifiers

1..31

BASE COUNT 2 a 14 c 7 g 7 t 1 others

ORIGIN

Query Match 66.0%; Score 13.2; DB 6; Length 31;

Best Local Similarity 75.0%; Pred. No. 6.2e+04;

Matches 15; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 GTTCCAGAGCTTGCCACCT 20

Db 10 GTTCCAGAGCTTGCCACCT 29

RESULT 14

LOCUS AR212154 35 bp DNA Linear PAT 20-JUN-2002

DEFINITION Sequence 21 from patent US 6399571.

ACCESSION AR212154

VERSION AR212154.1 GI:21515663

KEYWORDS

SOURCE unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 35)

AUTHORS Gray,P.W. and Tjoelker,L.W.

TITLE Chitinase chitin-binding fragments

JOURNAL Patent: US 6399571-A 21 04-JUN-2002;

FEATURES

Location/Qualifiers

1..35

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

RESULT 14

LOCUS AR212154 35 bp DNA Linear PAT 20-JUN-2002

DEFINITION Sequence 21 from patent US 6399571.

ACCESSION AR212154

VERSION AR212154.1 GI:21515663

KEYWORDS

SOURCE unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 35)

AUTHORS Gray,P.W. and Tjoelker,L.W.

TITLE Chitinase chitin-binding fragments

JOURNAL Patent: US 6399571-A 21 04-JUN-2002;

FEATURES

Location/Qualifiers

1..35

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

BASE COUNT 13 a 8 c 6 g 8 t  
 ORIGIN

Query Match 65.0%; Score 13; DB 6; Length 35;  
 Best Local Similarity 100.0%; Pred. No. 7.9e+04;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TTCCGAGAGCTTG 14  
 |||||  
 Db 8 TTCCGAGAGCTTG 20

# RESULT 15

AX370542

LOCUS AX370542 24 bp DNA 1 linear PAT 16-FEB-2002  
 DEFINITION Sequence 61 from Patent WO0196371.  
 ACCESSION AX370542  
 VERSION AX370542.1 GI:18857578

KEYWORDS  
 SOURCE  
 ORGANISM

synthetic construct.  
 synthetic construct.  
 artificial sequences.

REFERENCE  
 1 Broenner, G., Closssek, T., Dohrmann, C., Haeder, T. and Rothe, M.  
 Adipose-related gene  
 Patent: WO 0196371-A 61 20-DEC-2001;  
 Develogen AG (DE)

FEATURES  
 source Location/Qualifiers  
 1..24  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"

BASE COUNT 7 a 9 c 6 g 2 t  
 ORIGIN

Query Match 64.0%; Score 12.8; DB 6; Length 24;  
 Best Local Similarity 87.5%; Pred. No. 1e+05;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GTTCCGAGAGCTGCC 16  
 |||||  
 Db 3 GTTCCGAGAGAGGCC 18

Search completed: November 28, 2002, 18:20:36  
 Job time : 1164.07 secs





GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:10:34 ; Search time 1372.59 Seconds

(without alignments)  
224.186 Million cell updates/sec

Title: US-09-719-737-9

Perfect score: 19  
Sequence: 1 gggctgcgcagcgagatgct 19

Scoring table: IDENTITY\_NUC  
Gapox 10.0 , Gapext 1.0

Searched: 16154066 segs, 8097743376 residues

Total number of hits satisfying chosen parameters: 102860

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST: \*  
1: em\_estda: \*  
2: em\_esthm: \*  
3: em\_estin: \*  
4: em\_estnu: \*  
5: em\_estov: \*  
6: em\_estpl: \*  
7: em\_estro: \*  
8: em\_hic: \*  
9: gb\_estl: \*  
10: gb\_estc2: \*  
11: gb\_hic: \*  
12: gb\_estc3: \*  
13: gb\_estc4: \*  
14: gb\_estc5: \*  
15: em\_estfun: \*  
16: em\_estcom: \*  
17: gb\_gss: \*  
18: em\_gss\_hum: \*  
19: em\_gss\_inv: \*  
20: em\_gss\_pln: \*  
21: em\_gss\_vrt: \*  
22: em\_gss\_fun: \*  
23: em\_gss\_mam: \*  
24: em\_gss\_mus: \*  
25: em\_gss\_other: \*  
26: em\_gss\_pro: \*  
27: em\_gss\_rod: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	13.2	69.5	41	17	A2619291 1M0451N02
C 2	13.2	69.5	43	9	A1036497 nb65g12.r
C 3	13.2	69.5	50	9	AU107642 AU107642
C 4	13.2	69.5	50	9	AU107643 AU107643
C 5	12.6	66.3	43	17	A2834659 AU105954
C 6	12.4	65.3	50	9	AU105954 AU105954

7	12.2	64.2	38	12	BE736376
8	12.2	64.2	39	13 <td>B1665248</td>	B1665248
9	12	63.2	39	12 <td>BF788284</td>	BF788284
10	12	63.2	43	9	A1197706
11	12	63.2	46	9	AU107049
12	11.8	62.1	48	17 <td>A0026239</td>	A0026239
13	11.8	62.1	50	9	AU107919
14	11.6	61.1	21	17 <td>TA236120</td>	TA236120
15	11.6	61.1	23	17 <td>A2351113</td>	A2351113
16	11.6	61.1	33	17 <td>A2972050</td>	A2972050
17	11.6	61.1	36	17 <td>A2581836</td>	A2581836
18	11.6	61.1	40	14 <td>W66527</td>	W66527
19	11.6	61.1	40	14 <td>W87969</td>	W87969
20	11.6	61.1	46	17 <td>A2377453</td>	A2377453
21	11.6	61.1	50	9	AU104493
22	11.6	61.1	40	9	AA711545
23	11.4	60.0	43	10 <td>AW247061</td>	AW247061
24	11.4	60.0	45	17 <td>TA388A10Q</td>	TA388A10Q
25	11.4	60.0	50	9	AU103929
26	11.4	60.0	38	9	AA108281
27	11.2	58.9	38	14 <td>H51687</td>	H51687
28	11.2	58.9	45	17 <td>BH643822</td>	BH643822
29	11.2	58.9	46	17 <td>BH803079</td>	BH803079
30	11.2	58.9	50	9	AU102320
31	11.2	58.9	50	9	AU103464
32	11.2	58.9	50	9	AU104693
33	11.2	58.9	50	9	AU104722
34	11.2	58.9	50	9	AU104725
35	11.2	58.9	50	9	AU104728
36	11.2	58.9	19	17 <td>A2510143</td>	A2510143
37	11	57.9	37	13 <td>B1080927</td>	B1080927
38	11	57.9	37	14 <td>W73807</td>	W73807
39	11	57.9	40	9	AA928933
40	11	57.9	41	17 <td>A2842109</td>	A2842109
41	11	57.9	42	17 <td>A2818778</td>	A2818778
42	11	57.9	43	9	AA974942
43	11	57.9	46	9	AA530925
44	11	57.9	46	9	AA568369
45	11	57.9	46	9	AA568369

#### ALIGNMENTS

RESULT 1  
LOCUS A2619291/c  
DEFINITION 1M0451N02F Mouse 10kb plasmid UGCLM library Mus musculus genomic  
ACCESSION A2619291  
VERSION A2619291.1 GI:11741481  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus  
REFERENCE Eukariyota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beecorn,T., Duval,B., Hamli,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Kelly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausen,A. and Wright,D., Weiss,R.  
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss  
University of Utah Genome Center  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00



Query Match 69.5%; Score 13.2; DB 9; Length 50;  
Best Local Similarity 83.3%; Pred. No. 5.7e+04;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGGTCTGCACGGGATGG 18  
||| ||||| ||||| ||  
Db 45 GGGACTGCATCGGAGAG 28

RESULT 4  
AUI07643/c 50 bp mRNA linear EST 30-AUG-2001  
LOCUS AUI07643 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
DEFINITION ZR66769, mRNA sequence.  
ACCESSION AUI07643  
VERSION AUI07643.1 GI:13557164  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 50)  
AUTHORS Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata  
,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki  
,Y., Nakamura,Y., Suyama,A. and Sugano,S.  
Diverse transcriptional initiation revealed by fine, large-scale  
mapping of mRNA start sites  
EMBO Rep. 2 (5), 388-393 (2001)  
21270072  
COMMENT Contact: Yutaka Suzuki  
Department of Virology  
Institute of Medical Science, University of Tokyo  
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
Email: yusuzuki@ims.u-tokyo.ac.jp  
Suzuki,Y., Yoshimoto-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano  
,S. Construction and characterization of a full length-enriched and  
a 5'-end-enriched cDNA library. Gene 200 (1-2), 145-156 (1997).

FEATURES  
source  
1..50  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="ZR6C769"  
/clone\_lib="Sugano Homo sapiens cDNA library"  
/note="Differential display comparison of untreated and  
dimethylulmarate treated U937 cells"

BASE COUNT 9 a 21 c 10 g 10 t

ORIGIN

Query Match 69.5%; Score 13.2; DB 9; Length 50;  
Best Local Similarity 83.3%; Pred. No. 5.7e+04;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGGTCTGCACGGGATGG 18  
||| ||||| ||||| ||  
Db 42 GGGACTGCATCGGAGAG 25

RESULT 5  
A2834659/c 43 bp DNA linear GSS 20-FEB-2001  
LOCUS A2834659 2M011760R Mouse 10kb plasmid UUGC1M library Mus musculus genomic  
DEFINITION clone UUGC2M0117601 R, DNA sequence.  
ACCESSION A2834659  
VERSION A2834659.1 GI:13004567  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 43)  
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,  
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly

JOURNAL  
COMMENT  
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.  
and Wright,D.,Weiss,R.  
Mouse whole genome scaffolding with paired end reads from 10kb  
plasmid inserts  
Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0117 Row: B Column: 01  
Seq primer: CACACGAAACACGCTATGACC  
Class: plasmid ends  
High quality sequence stop: 43.

FEATURES  
source  
1..43  
/organism="Mus musculus"  
/strain="C57Bl/6J"  
/db\_xref="taxon:10090"  
/clone="UUGC2M0117601"  
/clone\_lib="Mouse 10kb plasmid UUGC1M library"  
/sex="Male"  
/lab\_host="E. coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: pMD42ny; Purified genomic DNA from M.  
musculus C57Bl/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adaptor DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of pMD42 (g11473211419b/AF129072.1), a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adaptor mouse DNA was annealed to  
adaptor vector DNA, and transformed into  
chemically-competent E. coli XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."

BASE COUNT 7 a 17 c 6 g 13 t

ORIGIN

Query Match 66.3%; Score 12.6; DB 17; Length 43;  
Best Local Similarity 78.9%; Pred. No. 1e+05;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GGGTCTGCACGGGATGGT 19  
| | | | | | | | | | | | | | | | |  
Db 22 GAGGTGTCACGGGATGT 4

RESULT 6  
AUI05954 50 bp mRNA linear EST 30-AUG-2001  
LOCUS AUI05954 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
DEFINITION INEB0085, mRNA sequence.  
ACCESSION AUI05954  
VERSION AUI05954.1 GI:13555475  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 50)  
AUTHORS Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata  
,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki



5', mRNA sequence.  
 ACCESSION BF788284  
 VERSION BF788284.1 GI:12093320  
 KEYWORDS EST.  
 SOURCE house mouse.  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 39)  
 NIH-MGC <http://mgi.nci.nih.gov/>.  
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
 JOURNAL Unpublished (1999)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Email: [cgapds-remail.nih.gov](mailto:cgapds-remail.nih.gov)  
 Tissue Procurement: Jeffrey E. Green, M.D.  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Plate: LHAM9859 row: b column: 06  
 High quality sequence stop: 39.  
 Location/Qualifiers  
 1..39  
 /organism="Mus musculus"  
 /strain="FVB/N"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:4241957"  
 /clone\_lib="NCI CGAP Library"  
 /lab\_host="DH10B (TI phage-resistant)"  
 /note="Organ: Kidney; Vector: pCMV-Sport6; Site: 1; NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.75 kb. Constructed by Life Technologies. Note: this is a NCI CGAP library. 1"  
 7 a 10 c 15 g 7 t

Query Match 63.2%; Score 12; DB 12; Length 39;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+05;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 6 TGCACCGGATG 17  
 |||||  
 Db 9 TGCACCGGATG 20

RESULT 10  
 LOCUS A1197706 43 bp mRNA linear EST 14-OCT-1998  
 DEFINITION uc8e12.f1 Soares\_mammary\_gland\_NMLMG Mus musculus cDNA clone  
 IMAGE:1494382 5' similar to TR:016786 016786 T21D12.3 PROTEIN. ;  
 mRNA sequence.  
 A1197706  
 A1197706.1 GI:3750312  
 EST.  
 house mouse.  
 SOURCE house mouse.  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 43)  
 Matra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisler, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.  
 TITLE The WashU-HMI Mouse EST Project  
 JOURNAL Unpublished (1996)  
 COMMENT Contact: Marra M/Mouse EST Project  
 WashU-HMI Mouse EST Project  
 Washington University School of Medicine  
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
 Tel: 314 286 1800

Fax: 314 286 1810  
 Email: [mousesest@wustl.edu](mailto:mousesest@wustl.edu)  
 This clone is available royalty-free through LLNL; contact the IMAGE Consortium ([image.llnl.gov](http://image.llnl.gov)) for further information.  
 MGI:931986  
 Trace considered overall poor quality  
 Possible reversed clone; similarity on wrong strand  
 Seq primer: -28m13 rev2 ET from Amersham  
 High quality sequence stop: 1.  
 Location/Qualifiers  
 1..43  
 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:1494382"  
 /clone\_lib="Soares\_mammary\_gland\_NMLMG"  
 /sex="female (lactating)"  
 /tissue\_type="mammary gland"  
 /lab\_host="DH10B"  
 /note="Vector: pT7T30-Pac (Pharmacia) with a modified polylinker; 1st strand cDNA was prepared from mammary gland tissue from a lactating female, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library is normalized. Library was constructed by Bento Soares and M. Fatima Bonaldi."  
 5 a 14 c 16 g 8 t

Query Match 63.2%; Score 12; DB 9; Length 43;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+05;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GGCTCGCAGCG 12  
 |||||  
 Db 26 GGCTCTGCACGC 15

RESULT 11  
 LOCUS A107049/c 50 bp mRNA linear EST 30-AUG-2001  
 DEFINITION A107049 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
 KAT03213, mRNA sequence.  
 A107049  
 A107049.1 GI:13556570  
 EST.  
 KEYWORDS human.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 1 (bases 1 to 50)  
 Suzuki, Y., Taira, H., Tsunoda, T., Mizushima-Sugano, J., Sese, J., Hata, H., Ota, T., Isogai, T., Yanaka, T., Morishita, S., Okubo, K., Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.  
 Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites  
 EMBO Rep. 2 (5), 388-393 (2001)  
 21270072  
 TITLE Contact: Yutaka Suzuki  
 JOURNAL Department of Virology  
 Institute of Medical Science, University of Tokyo  
 4-6-1, Shirokane-dai, Minato-ku, Tokyo 108-8639, Japan  
 Email: [ysuzuki@ims.u-tokyo.ac.jp](mailto:ysuzuki@ims.u-tokyo.ac.jp)  
 Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and Sugano, S.  
 Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).  
 Location/Qualifiers  
 1..50  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone="KAT03213"  
 /clone\_lib="Sugano Homo sapiens cDNA library"  
 /note="Differential display comparison of untreated and

BASE COUNT 9 a 14 c 22 g 5 t  
 ORIGIN  
 Query Match 63.2%; Score 12; DB 9; Length 50;  
 Best Local Similarity 100.0%; Pred. No. 1.9e+05;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GGGTCGACCG 12  
 DB 49 GGGTCGACCG 38

RESULT 12  
 LOCUS A1188328 46 bp mRNA linear EST 28-OCT-1998  
 DEFINITION qd13c07.x1 Soares-placenta\_8tc9weeks\_2NDHP8CO5W Homo sapiens CDNA  
 clone IMAGE:1723596 3' similar to SW:GA45\_CR110 P24523 GROWTH  
 ARREST AND DNA-DAMAGE-INDUCIBLE PROTEIN GADD45.; mRNA sequence.  
 A1188328  
 VERSION A1188328.1 GI:3739537  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE NCI-CCGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
 AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
 Tumor Gene Index  
 JOURNAL Unpublished (1997)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Email: cgaaps-remail.nih.gov  
 This clone is available royalty-free through LBNL; contact the  
 IMAGE Consortium (Info@image.llnl.gov) for further information.  
 Insert Length: 1083 Std Error: 0.00  
 Seq primer: -40UP from G1bco  
 High quality sequence stop: 1.  
 FEATURES  
 SOURCE Location/Qualifiers  
 1. 46  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:1723596"  
 /clone\_1lb="Soares-placenta\_8tc9weeks\_2NDHP8CO5W"  
 /dev\_stage="two placentae: one from 8 weeks and another  
 from 9 weeks post conception"  
 /lab\_host="DH10B (ampicillin resistant)"  
 /note="Organ: Placenta; Vector: pT7T3 (Pharmacia) with a  
 modified polylinker; Site.1: Not I; Site.2: Eco RI; 1st  
 strand cDNA was primed with a Not I - oligo(dT) primer [5'  
 TGTACCAATCTCAAGTCGACCGACCGCCCGCATTTTCTTTTCTTTT 3'],  
 double-stranded cDNA was size selected, ligated to Eco RI  
 adapters (Pharmacia), digested with Not I and cloned into  
 the Not I and Eco RI sites of a modified pT7T3 vector  
 (Pharmacia). Library constructed by Bento Soares and  
 M. Fatima Bonaldo."

BASE COUNT 13 a 10 c 14 g 9 t  
 ORIGIN  
 Query Match 62.1%; Score 11.8; DB 9; Length 46;  
 Best Local Similarity 86.7%; Pred. No. 2.3e+05;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 GGGTCGACCGCGA 15  
 DB 31 GGATCTCGACCGCA 45

RESULT 13  
 LOCUS A0026239/c 48 bp DNA linear GSS 30-JUN-1998  
 DEFINITION 1(3)11170 Drosophila melanogaster P lethal line Drosophila

melanogaster genomic Sequence recovered from 5' end of P element,  
 DNA sequence.  
 A0026239  
 A0026239.1 GI:326524  
 GSS.  
 KEYWORDS fruit fly.  
 SOURCE Drosophila melanogaster  
 ORGANISM Drosophila melanogaster  
 Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 Ephydroidea; Drosophilidae; Drosophila.  
 1 (bases 1 to 48)  
 Spradling, A.C., Stern, D., Beaton, A., Rehm, E.J., Laverly, T., Modden  
 N., Mistra, S. and Rubin, G.M.  
 The DDP gene disruption project: Single P element insertions  
 mutating 30% of Drosophila autosomal genes  
 Unpublished (1998)  
 JOURNAL Contact: Gerald Rubin  
 Berkeley Drosophila Genome Project  
 University of California, Berkeley  
 USA Building Berkeley, CA 94720-3200, USA  
 Fax: 5106439947  
 Email: gerry@fruitfly.berkeley.edu  
 Sequence recovery method was Inverse PCR.  
 Sequence orientation is forward strand relative to 5' end of P  
 element

FEATURES  
 SOURCE Location/Qualifiers  
 1. 48  
 /organism="Drosophila melanogaster"  
 /db\_xref="taxon:7227"  
 /clone\_1lb="Drosophila melanogaster P lethal line"  
 /note="Inverse PCR was performed on Drosophila  
 melanogaster strains each of which contains a single P  
 transposable element insertion. That is thought to cause  
 either lethality or sterility. The resultant fragment for  
 each strain was directly sequenced to determine the  
 genomic sequence at the site of insertion. Details of the  
 protocols used can be found at  
 http://fruitfly.berkeley.edu/p-disrupt/inverse\_pcr.html."

BASE COUNT 15 a 13 c 18 g 2 t  
 ORIGIN  
 Query Match 62.1%; Score 11.8; DB 17; Length 48;  
 Best Local Similarity 86.7%; Pred. No. 2.3e+05;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 5 CTGACGCGGATGCT 19  
 DB 48 CTGACGCGCGATGCT 34

RESULT 14  
 LOCUS AUI07919/c 50 bp mRNA linear EST 30-AUG-2001  
 DEFINITION AUI07919 Sugano Homo sapiens CDNA library Homo sapiens CDNA clone  
 ZRV61844, mRNA sequence.  
 AUI07919  
 AUI07919.1 GI:13557441  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 50)  
 Suzuki, Y., Taira, H., Tsunoda, T., Mizushima-Sugano, J., Sese, J., Hata  
 S., Ota, T., Isega, T., Tanaka, T., Morishita, S., Okubo, K., Sakaki  
 Y., Nakamura, Y., Suyama, A. and Sugano, S.  
 Diverse transcriptional initiation revealed by fine, large-scale







GenCore version 5.1.3  
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:15:39 ; Search time 39.9655 Seconds

(without alignments)  
183.088 Million cell updates/sec

Title: US-09-719-737-9

Perfect score: 19

Sequence: 1 ggcttcgacggcgatggt 19

Scoring table: IDENTITY\_NUC

Searched: 341543 seqs, 192557720 residues

Total number of hits satisfying chosen parameters: 177872

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: /cgnt2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgnt2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq:\*  
3: /cgnt2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgnt2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgnt2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgnt2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq:\*  
7: /cgnt2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgnt2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgnt2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*  
10: /cgnt2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*  
11: /cgnt2\_6/ptodata/1/pubpna/US10\_NEW\_PUB.seq:\*  
12: /cgnt2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*  
13: /cgnt2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*  
14: /cgnt2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	14.2	74.7	20	10	US-09-733-294A-63
2	13.2	69.5	38	10	US-09-349-954A-13
3	13.2	69.5	38	10	US-09-907-007-13
4	12.6	66.3	30	10	US-09-730-716-11
5	12.6	66.3	35	9	US-09-826-025-6
6	12.6	66.3	38	10	US-09-850-165-61
7	12.6	66.3	41	9	US-09-925-664-66
8	12.6	66.3	43	10	US-09-766-378A-2
9	12.6	66.3	44	10	US-09-848-164-40
10	12.2	64.2	21	10	US-09-838-785-8
11	12.2	64.2	31	10	US-09-801-274-1241
12	12.2	63.2	31	10	US-09-801-274-1005
13	12.2	63.2	31	10	US-09-801-274-1006
14	11.8	62.1	20	8	US-08-591-486B-100
15	11.8	62.1	20	10	US-09-752-639-110
16	11.8	62.1	20	10	US-09-984-198-110
17	11.8	62.1	26	10	US-09-872-761-9
18	11.6	61.1	20	10	US-09-838-785-17
19	11.6	61.1	45	10	US-09-850-165-24

20	11.4	60.0	16	12	US-10-007-628-13	Sequence 13, Appl
21	11.4	60.0	29	10	US-09-729-674-250	Sequence 250, Appl
22	11.2	58.9	20	10	US-09-727-198-3	Sequence 3, Appl
23	11.2	58.9	24	10	US-09-947-770-34	Sequence 34, Appl
24	11.2	58.9	30	9	US-09-252-150-58	Sequence 58, Appl
25	11.2	58.9	31	10	US-09-801-274-1098	Sequence 1098, Ap
26	11.2	58.9	31	10	US-09-801-274-1217	Sequence 1217, Ap
27	11.2	58.9	36	10	US-09-896-852-34	Sequence 34, Appl
28	11.2	58.9	36	12	US-10-020-139-7	Sequence 7, Appl
29	11.2	58.9	39	9	US-09-430-029-12	Sequence 12, Appl
30	11.2	58.9	40	9	US-10-113-246-3	Sequence 3, Appl
31	11.2	58.9	40	9	US-10-113-238-3	Sequence 3, Appl
32	11.2	58.9	40	10	US-09-896-852-32	Sequence 32, Appl
33	11.2	58.9	40	10	US-09-865-807-40	Sequence 40, Appl
34	11.2	58.9	40	10	US-09-944-604-7	Sequence 7, Appl
35	11.2	58.9	40	10	US-09-757-207-2	Sequence 2, Appl
36	11.2	58.9	40	10	US-09-757-207-6	Sequence 5, Appl
37	11.2	58.9	40	10	US-09-757-207-3	Sequence 6, Appl
38	11.2	58.9	41	10	US-09-757-207-1	Sequence 1, Appl
39	11.2	58.9	41	10	US-09-757-207-7	Sequence 7, Appl
40	11.2	58.9	42	10	US-09-778-168-12	Sequence 12, Appl
41	11.2	58.9	42	10	US-09-778-175-12	Sequence 12, Appl
42	11.2	58.9	42	10	US-09-335-218-12	Sequence 12, Appl
43	11.2	58.9	44	10	US-09-778-168-6	Sequence 6, Appl
44	11.2	58.9	44	10	US-09-778-175-6	Sequence 6, Appl
45	11.2	58.9	44	10	US-09-335-218-6	Sequence 6, Appl

#### ALIGNMENTS

RESULT 1  
US-09-733-294A-63  
Sequence 63, Appl  
Patent No. US20020045588A1  
GENERAL INFORMATION:  
APPLICANT: Brett P. Monia  
APPLICANT: William Gaarde  
APPLICANT: Susan M. Freier  
APPLICANT: Edward V. Manciewicz  
TITLE OF INVENTION: ANTISENSE MODULATION OF TEXT EXPRESSION  
FILE REFERENCE: ISPH-0527  
CURRENT APPLICATION NUMBER: US/09/733,294A  
PRIOR FILING DATE: 2000-12-07  
PRIOR APPLICATION NUMBER: 09/572,423  
PRIOR FILING DATE: 2000-05-16  
NUMBER OF SEQ ID NOS: 108  
SEQ ID NO 63  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-733-294A-63  
Query Match  
Best local similarity 74.7%; Score 14.2; DB 10;  
Matches 16; Conservativity 0; Mismatches 3; Indels 0; Gaps 0;  
DB 1 GGCTTCGACGCGGATGCT 19  
OY 1 GGCTTCGACGCGGATGCT 19  
RESULT 2  
US-09-349-954A-13  
Sequence 13, Appl  
Patent No. US20020019027A1  
GENERAL INFORMATION:  
APPLICANT: Hayward, Nicholas K.  
APPLICANT: Weber, Gunther  
APPLICANT: Grimmond, Sean  
APPLICANT: No. US20020019027A1denskjold, Magnus

```

: APPLICANT: Larsson, Catharina
: TITLE OF INVENTION: A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE ENCODING
: FILE REFERENCE: SAME
: CURRENT APPLICATION NUMBER: US/09/349,954A
: PRIOR FILING DATE: 1999-07-08
: PRIOR APPLICATION NUMBER: 08/765,588
: PRIOR FILING DATE: 1996-02-22
: NUMBER OF SEQ ID NOS: 22
: SOFTWARE: PatentIn Ver. 2.1
: SEQ ID NO 13
: LENGTH: 38
: TYPE: DNA
: ORGANISM: Oligonucleotide
US-09-349-954A-13

Query Match      69.5%; Score 13.2; DB 10; Length 38;
Best Local Similarity 83.3%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGGCTGCGACGGGATCG 18
    ||| ||| ||| ||| ||| |||
Db 7 GGGCTGCGACTGGGATCG 24

RESULT 3
US-09-907-007-13
: Sequence 13, Application US/09907007
: Patent No. US20020142395A1
: GENERAL INFORMATION:
: APPLICANT: Hayward, Nicholas K.
: APPLICANT: Weber, Gunther
: APPLICANT: Grimmond, Sean
: APPLICANT: No. US20020142395A1denskjold, Magnus
: APPLICANT: Larsson, Catharina
: TITLE OF INVENTION: A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE ENCODING
: FILE REFERENCE: DAVIES
: CURRENT APPLICATION NUMBER: US/09/907,007
: CURRENT FILING DATE: 2001-07-17
: PRIOR APPLICATION NUMBER: 08/765,588
: PRIOR FILING DATE: 1996-02-22
: NUMBER OF SEQ ID NOS: 22
: SOFTWARE: PatentIn Ver. 2.1
: SEQ ID NO 13
: LENGTH: 38
: TYPE: DNA
: ORGANISM: Oligonucleotide
US-09-907-007-13

Query Match      69.5%; Score 13.2; DB 10; Length 38;
Best Local Similarity 83.3%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGGCTGCGACGGGATCG 18
    ||| ||| ||| ||| ||| |||
Db 7 GGGCTGCGACTGGGATCG 24

RESULT 4
US-09-730-716-11/C
: Sequence 11, Application US/09730716
: Patent No. US20010004531A1
: GENERAL INFORMATION:
: APPLICANT: Young, Chul Sung
: APPLICANT: You Suk Suh
: TITLE OF INVENTION: AIDS DNA VACCINE THAT PREVENTS SYMPTOMS
: FILE REFERENCE: 118-6-US-01
: CURRENT APPLICATION NUMBER: US/09/730,716
: CURRENT FILING DATE: 2000-12-06
: PRIOR APPLICATION NUMBER: KR 1999-55129
: PRIOR FILING DATE: 1999-12-06

```

```

: NUMBER OF SEQ ID NOS: 12
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 11
: LENGTH: 30
: TYPE: DNA
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: hcm-CSF specific primer (forward)
US-09-730-716-11

Query Match      66.3%; Score 12.6; DB 10; Length 30;
Best Local Similarity 78.9%; Pred. No. 1.9e+03;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GGGCTGCGACGGGATGCT 19
    || ||| ||| ||| ||| |||
Db 22 GGCTGCGACCCCATGCT 4

RESULT 5
US-09-826-025-6/C
: Sequence 6, Application US/09826025
: Patent No. US20020162123A1
: GENERAL INFORMATION:
: APPLICANT: Chang, Lung-Ji
: TITLE OF INVENTION: Combination Immunogene Therapy
: NUMBER OF SEQUENCES: 25
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Medien & Carroll, LLP
: STREET: 220 Montgomery Street, Suite 2200
: CITY: San Francisco
: STATE: California
: COUNTRY: United States of America
: ZIP: 94104
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/826,025
: FILING DATE: 04-Apr-2001
: CLASSIFICATION: <Unknown>
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/838,702
: FILING DATE: <Unknown>
: ATTORNEY/AGENT INFORMATION:
: NAME: Ingolia, Diane E.
: REGISTRATION NUMBER: 40,027
: REFERENCE/DOCKET NUMBER: CHANG-02687
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 705-8410
: TELEFAX: (415) 397-8338
: INFORMATION FOR SEQ ID NO: 6:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 35 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: other nucleic acid
: DESCRIPTION: /desc = "DNA"
: SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-826-025-6

Query Match      66.3%; Score 12.6; DB 9; Length 35;
Best Local Similarity 78.9%; Pred. No. 1.9e+03;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GGGCTGCGACGGGATGCT 19
    || ||| ||| ||| ||| |||
Db 33 GGCTGCGACCCCATGCT 15

```



```

NUMBER OF SEQUENCES: 124
CORRESPONDENCE ADDRESS:
ADDRESS: Dade International, Inc.
STREET: 1717 Deerfield Road
CITY: Deerfield
STATE: Illinois
COUNTRY: USA
ZIP: 60015
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/848,164
FILING DATE: 03-MAY-2001
CLASSIFICATION: <unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/067,615
FILING DATE: <unknown>
APPLICATION NUMBER: US 08/382,454
FILING DATE: 01-FEB-1995
APPLICATION NUMBER: US 08/283,302
FILING DATE: 29-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Pearson, Louise S.
REGISTRATION NUMBER: 32,369
REFERENCE/DOCKET NUMBER: STR-4665-CTP2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708) 267-5300
TELEFAX: (708) 267-5376
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 44 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
SEQUENCE DESCRIPTION: SEQ ID NO: 40:
US-09-848-164-40
Query Match 66.3% Score 12.6; DB 10; Length 44;
Best Local Similarity 78.9% Pred. No. 1.9e+03;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 GGCTCTGCAGCGGATGCT 19
IIIIIIIIIIIIIIIIII
DB 39 GGATCTGCAGGCCATGCT 21
RESULT 10
US-09-838-785-8/C
Sequence 8, Application US/09838785
Patent No. US2002009455A1
GENERAL INFORMATION:
APPLICANT: Lau, Ted
APPLICANT: Lin, Rick
APPLICANT: Parkes, Debbie
APPLICANT: Schmeider, Douglas
APPLICANT: Steinhilber, Renate
APPLICANT: Van Heult, Pam J
APPLICANT: Wu, John
TITLE OF INVENTION: DNA Encoding a No. US2002009455A1el PROST 03
FILE REFERENCE: 5181AUSM1
CURRENT FILING DATE: 2001-04-20
PRIOR APPLICATION NUMBER: 60/200,065
PRIOR FILING DATE: 2000-04-27
NUMBER OF SEQ ID NOS: 26
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 8
LENGTH: 21
TYPE: DNA

```

```

: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-838-785-B
Query Match      64.2%: Score 12.2; DB 10; Length 21;
Best Local Similarity 82.4%: Pred. No. 2.9e+03;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      2  GGTCTGCAGCGCGATCG 18
          | | | | | | | | | | |
DB      17  GCTGTGCAGCTGGATCG 1

RESULT 11
US-09-801-274-1241/C
: Sequence 1241, Application US/09801274
: Patent No. US20020032319A1
: GENERAL INFORMATION:
: APPLICANT: Cargill, Michele
: APPLICANT: Ireland, James S.
: TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
: FILE REFERENCE: 2825, 2009-001
: CURRENT APPLICATION NUMBER: US/09/801,274
: PRIOR FILING DATE: 2001-03-07
: PRIOR APPLICATION NUMBER: US 60/187,510
: PRIOR FILING DATE: 2000-03-07
: PRIOR APPLICATION NUMBER: US 60/206,129
: PRIOR FILING DATE: 2000-05-22
: NUMBER OF SEQ ID NOS: 1802
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 1241
: LENGTH: 31
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-801-274-1241

Query Match      64.2%: Score 12.2; DB 10; Length 31;
Best Local Similarity 82.4%: Pred. No. 2.9e+03;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      2  GGTCTGCAGCGCGATCG 18
          | | | | | | | | | | |
DB      25  GGTCTGTAGGCGGTGG 9

RESULT 12
US-09-801-274-1005/C
: Sequence 1005, Application US/09801274
: Patent No. US20020032319A1
: GENERAL INFORMATION:
: APPLICANT: Cargill, Michele
: APPLICANT: Ireland, James S.
: APPLICANT: Lander, Eric S.
: TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
: FILE REFERENCE: 2825, 2009-001
: CURRENT APPLICATION NUMBER: US/09/801,274
: CURRENT FILING DATE: 2001-03-07
: PRIOR APPLICATION NUMBER: US 60/187,510
: PRIOR FILING DATE: 2000-03-07
: PRIOR APPLICATION NUMBER: US 60/206,129
: PRIOR FILING DATE: 2000-05-22
: NUMBER OF SEQ ID NOS: 1802
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 1005
: LENGTH: 31
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-801-274-1005

Query Match      63.2%: Score 12; DB 10; Length 31;
Best Local Similarity 85.7%: Pred. No. 3.6e+03;

```

Matches 12: Conservative 1: Mismatches 1: Indels 0: Gaps 0:

QY 2 GGTCTCAGCGGGA 15  
|||||  
Db 28 GGTCTCAGCGGGA 15

## RESULT 13

US-09-801-274-1006/c  
Sequence 1006, Application US/09801274  
Patent No. US2002032319A1  
GENERAL INFORMATION:  
APPLICANT: Carell, Michele  
APPLICANT: Ireland, James S.  
APPLICANT: Lander, Eric S.  
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS  
FILE REFERENCE: 2825.2009-001  
CURRENT APPLICATION NUMBER: US/09/801,274  
PRIOR FILING DATE: 2001-03-07  
PRIOR APPLICATION NUMBER: US 60/187,510  
PRIOR FILING DATE: 2000-03-07  
PRIOR APPLICATION NUMBER: US 60/206,129  
NUMBER OF SEQ ID NOS: 1802  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 1006  
LENGTH: 31  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-801-274-1006

Query Match 63.2%: Score 12: DB 10: Length 31:  
Best Local Similarity 85.7%: Pred. No. 3.6e+03;  
Matches 12: Conservative 1: Mismatches 1: Indels 0: Gaps 0:

QY 2 GGTCTCAGCGGGA 15  
|||||  
Db 21 GGTCTCAGCGGGA 8

## RESULT 14

US-08-591-486B-100  
Sequence 100, Application US/08591486B  
Patent No. US2002003786A1  
GENERAL INFORMATION:  
APPLICANT: Schlingensiepen, Georg F.  
APPLICANT: Schlingensiepen, Reinmar  
APPLICANT: Schlingensiepen, Karl-Hermann  
APPLICANT: Gollingen, Wolfgang Brysch  
TITLE OF INVENTION: A Pharmaceutical Composition  
TITLE OF INVENTION: Comprising Antisense-Nucleic Acid for Prevention and/or Treatment  
TITLE OF INVENTION: of Neuronal Injury, Degeneration and Cell Death and for the  
NUMBER OF SEQUENCES: 185  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Jacobson, Price, Holman & Stern  
STREET: 400 Seventh Street, N.W.  
CITY: Washington, D.C.  
COUNTRY: U.S.A.  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/591,486B  
FILING DATE: 11-JAN-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: EP 93111059.7  
FILING DATE: 10-JUL-1993  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/EP94/02218  
FILING DATE: 6-JUL-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Player, William E.  
REGISTRATION NUMBER: 31,409  
REFERENCE/DOCKET NUMBER: 10496/P60122  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 638-6666  
TELEFAX: (202) 393-9350  
TELEX: RCA 248593 IDEA UR  
INFORMATION FOR SEQ ID NO: 100:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA (genomic)  
ANTI-SENSE: YES  
US-08-591-486B-100

Query Match 62.1%: Score 11.8: DB 8: Length 20:  
Best Local Similarity 86.7%: Pred. No. 4.4e+03;  
Matches 13: Conservative 0: Mismatches 2: Indels 0: Gaps 0:

QY 5 CTGCAGCGGATGAT 19  
|||||  
Db 2 CTGCAGCGGATGAT 16

## RESULT 15

US-09-752-639-110  
Sequence 110, Application US/09752639  
Patent No. US20020091243A1  
GENERAL INFORMATION:  
APPLICANT: Gatanaga, T.  
APPLICANT: Granger, G.A.  
TITLE OF INVENTION: Factors Altering Tumor Necrosis  
TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods  
TITLE OF INVENTION: of Use Thereof  
NUMBER OF SEQUENCES: 154  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORRISON & FOERSTER  
STREET: 755 PAGE MILL ROAD  
CITY: Palo Alto  
STATE: CA  
COUNTRY: USA  
ZIP: 94304-1018  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows  
SOFTWARE: FastSeq for Windows Version 2.0b  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/752,639  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/US99/10793  
FILING DATE:  
APPLICATION NUMBER: 09/081,385  
FILING DATE:  
APPLICATION NUMBER: 08/964,747  
FILING DATE: 05-NOV-1997  
APPLICATION NUMBER: 60/030,761  
FILING DATE: 06-NOV-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Wu, Frank  
REGISTRATION NUMBER: 41,386  
REFERENCE/DOCKET NUMBER: 22000-20577.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-813-5600  
TELEFAX: 650-494-0792  
TELEX: 706141

INFORMATION FOR SEQ ID NO: 110:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-752-639-110

Query Match 62.1%; Score 11.8; DB 10; Length 20;  
Best Local Similarity 86.7%; Pred. No. 4.4e+03;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 4 TCTGCACGGGATCG 18  
11111111111111111111  
Db 4 TCTGCACGGGATCG 18

Search completed: November 28, 2002, 19:35:04  
Job time : 39.9655 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:12:29 ; Search time 38.3276 Seconds

(without alignments)  
152.028 Million cell updates/sec

Title: US-09-719-737-9

Perfect score: 19

Sequence: 1 gggctgcagcgagtgct 19

Scoring table: IDENTITY\_NUC

Gapop 10.0 ; Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 609818

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :  
1: /cgn2\_6/plodata/2/lna/5A.COMB.seq:\*  
2: /cgn2\_6/plodata/2/lna/5B.COMB.seq:\*  
3: /cgn2\_6/plodata/2/lna/6A.COMB.seq:\*  
4: /cgn2\_6/plodata/2/lna/6B.COMB.seq:\*  
5: /cgn2\_6/plodata/2/lna/PCRUS.COMB.seq:\*  
6: /cgn2\_6/plodata/2/lna/backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	12.6	66.3	32	4	US-09-194-285-5
2	12.6	66.3	35	4	US-08-848-760B-6
3	12.6	66.3	38	1	US-08-478-039-37
4	12.6	66.3	38	1	US-08-478-039-37
5	12.6	66.3	38	3	US-08-803-085-8
6	12.6	66.3	38	3	US-08-523-894-30
7	12.6	66.3	41	2	US-08-761-277A-66
8	12.6	66.3	43	4	US-08-960-190A-2
9	12.6	66.3	43	4	US-09-042-353-399
10	12.6	66.3	44	4	US-08-758-417A-249
11	12.6	66.3	44	2	US-08-596-387B-40
12	12.6	66.3	44	4	US-09-067-615-40
13	12.6	66.3	44	4	PCT-US95-09816A-40
14	12.6	65.3	20	2	US-08-332-766A-78
15	12.4	65.3	20	3	US-09-418-640-56
16	12.4	65.3	28	1	US-07-959-946-19
17	12.4	65.3	28	1	US-08-333-577-19
18	12.4	65.3	28	5	PCT-US92-08634-19
19	12.4	65.3	47	4	US-09-641-638-1073
20	12.2	64.2	27	6	525545-27
21	12.2	64.2	34	1	US-08-318-193-54
22	12.2	64.2	34	1	US-08-707-793A-12
23	12.2	64.2	34	1	US-08-707-792A-12
24	12.2	63.2	42	1	US-08-318-193-20
25	12.2	63.2	42	6	5200327-9
26	12.2	63.2	45	2	US-08-406-855A-17
27	12.2	63.2	45	3	US-09-206-899-17

28	12	63.2	45	4	US-09-688-415-22	Sequence 22, Appl
29	12	63.2	46	2	US-08-406-855A-18	Sequence 18, Appl
30	12	63.2	46	3	US-09-206-899-18	Sequence 18, Appl
31	12	63.2	46	4	US-09-688-415-23	Sequence 23, Appl
32	12	63.2	50	1	US-08-318-193-21	Sequence 21, Appl
33	11.8	62.1	18	2	US-09-161-015-32	Sequence 21, Appl
34	11.8	62.1	18	4	US-09-387-341-175	Sequence 175, Appl
35	11.8	62.1	26	4	US-09-086-483A-10	Sequence 10, Appl
36	11.8	62.1	29	4	US-08-823-999-8	Sequence 8, Appl
37	11.8	62.1	29	4	US-09-056-285A-11	Sequence 11, Appl
38	11.8	62.1	30	4	US-09-025-769B-342	Sequence 342, Appl
39	11.6	61.1	18	2	US-09-256-456-85	Sequence 85, Appl
40	11.6	61.1	25	2	US-08-859-998-1017	Sequence 1017, Appl
41	11.6	61.1	25	4	US-09-225-928-1017	Sequence 1017, Appl
42	11.6	61.1	32	1	US-08-471-033-37	Sequence 37, Appl
43	11.6	61.1	32	2	US-08-471-044-37	Sequence 37, Appl
44	11.6	61.1	32	2	US-08-463-483A-37	Sequence 37, Appl
45	11.6	61.1	32	2	US-08-471-046A-37	Sequence 37, Appl

## ALIGNMENTS

```
RESULT 1
US-09-194-285-5/c
; Sequence 5, Application US/09194285
; Patent No. 6355479
; GENERAL INFORMATION:
; APPLICANT: Webb, Susan R.
; APPLICANT: Wingqvist, Ola
; APPLICANT: Karlsson, Lars
; APPLICANT: Jackson, Michael R.
; APPLICANT: Peterson, Per A.
; TITLE OF INVENTION: MHC Class II Antigen Presenting Systems
; FILE REFERENCE: TSRI 536.1
; CURRENT APPLICATION NUMBER: US/09/194,285
; CURRENT FILING DATE: 1999-04-12
; PRIOR APPLICATION NUMBER: PCT/US97/08697
; PRIOR FILING DATE: 1997-05-22
; PRIOR APPLICATION NUMBER: US 60/018,175
; PRIOR FILING DATE: 1996-05-23
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-194-285-5

Query Match      66.3%  Score 12.6:  DB 4:  Length 32:
Best Local Similarity 78.9%:  Pred. No. 1.4e+03:
Matches 15:  Conservative 0:  Mismatches 4:  Indels 0:  Gaps 0:

OY      1  GGGTCTGCAGCGCATGCT 19
        11 11111111 11111
Db      29  GGATCTGCAGCGCATGCT 11

RESULT 2
US-08-848-760B-6/c
; Sequence 6, Application US/08848760B
; Patent No. 6248721
; GENERAL INFORMATION:
; APPLICANT: Chang, Lung-Ji
; TITLE OF INVENTION: Animal Model For Evaluation Of Vaccines
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Saliwanchik, Lloyd & Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
```

STATE: Florida  
COUNTRY: United States of America  
ZIP: 32606  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/848,760B  
FILING DATE: 25-Jan-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/838,702  
FILING DATE: 09-APR-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: PACE, DORAN R.  
REGISTRATION NUMBER: 38,261  
REFERENCE/DOCKET NUMBER: CNG-100C1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (352) 375-8100  
TELEFAX: (352) 372-5800  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: /dasc = "DNA"  
SEQUENCE DESCRIPTION: SEQ ID NO: 6:  
US-08-848-760B-6

Query Match	66.3%	Score 12.6	DB 4	Length 35
Best Local Similarity	78.9%	Pred. No. 1.4e+03		
Matches 15	Conservative 0	Mismatches 4	Indels 0	Gaps 0

QY	1	GGGCTGCAGCGGATGCT	19
		1111111111111111	
Db	33	GGCTCTGCAGCCACATGCT	15

RESULT 3  
 US-08-478-039-37/G  
 Sequence 37, Application US/08478039  
 Patent No. 5681722  
 GENERAL INFORMATION:  
 APPLICANT: Newman, Roland A.  
 APPLICANT: Hanna, Nabli  
 APPLICANT: Raab, Ronald W.  
 TITLE OF INVENTION: Recombinant Antibodies for Human "therapy"  
 NUMBER OF SEQUENCES: 114  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: BURNS, DOANE, SWECKER & MATHEIS  
 STREET: 699 Prince St.  
 CITY: Alexandria  
 STATE: VA  
 COUNTRY: USA  
 ZIP: 22313-1404  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: patentin Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/478,039  
 FILING DATE: 07-JUN-1995  
 CLASSIFICATION: 435  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/379,072  
 FILING DATE: 25-JAN-1995  
 PRIOR APPLICATION DATA: US 07/912,292

```

1      FILING DATE: 10-JUL-1992
2      PRIOR APPLICATION DATA:
3      APPLICATION NUMBER: US 07/856,281
4      FILING DATE: 23-MAR-1992
5      PRIOR APPLICATION DATA:
6      APPLICATION NUMBER: US 07/735,064
7      FILING DATE: 25-JUL-1991
8      ATTORNEY/AGENT INFORMATION:
9      NAME: Teskin Esq., Robln L.
10     REGISTRATION NUMBER: 35,030
11     REFERENCE/DOCKET NUMBER: 012712-160
12     TELECOMMUNICATION INFORMATION:
13     TELEPHONE: 703-836-6620
14     TELEFAX: 703-836-2021
15     INFORMATION FOR SEQ ID NO: 37:
16     SEQUENCE CHARACTERISTICS:
17     LENGTH: 38 base pairs
18     TYPE: nucleic acid
19     STRANDEDNESS: single
20     TOPOLOGY: linear
21     MOLECULE TYPE: CDNA
22     ANTI-SENSE: NO
23     ORIGINAL SOURCE:
24     ORGANISM: Homo sapiens or Monkey
25     POSITION IN GENOME:
26     CHROMOSOME/SEGMENT: kappa light chain primer with BglII site
27     US-08-478-039-37
28
29     Query Match      66.3%; Score 12.6; DB 1; Length 38;
30     Best Local Similarity 78.9%; Pred. No. 1.4e+03;
31     Matches 15: Conservative 0; Mismatches 4; Indels 0; Gaps 0

```

QY	1	GGGCTGTGACGGCGATG	19
Db	33	GGGTCTGCACACCATG	15

Db 33 GGCTCTGCACACCA<sup>T</sup>GGT 15

RESULT 4  
 US-08-476-349A-37/c  
 Sequence 37, Application US/08476349A  
 Patent No. 5750105  
 GENERAL INFORMATION:  
 APPLICANT: Newman, Roland A.  
 APPLICANT: Hanna, Nabil  
 APPLICANT: Raab, Ronald W.  
 TITLE OR INVENTION: Recombinant Antibodies for Human Therapy  
 NUMBER OF SEQUENCES: 114  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS  
 STREET: 699 Prince St.  
 CITY: Alexandria  
 STATE: VA  
 COUNTRY: USA  
 ZIP: 22313-1404  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: patentin Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/476.349A  
 FILING DATE: 07-JUN-1995  
 CLASSIFICATION: 514  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/379,072  
 FILING DATE: 25-JAN-1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 07/912,292  
 FILING DATE: 10-JUL-1992  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 07/856,281  
 FILING DATE: 23-MAR-1992  
 PRIOR APPLICATION DATA:



APPLICATION NUMBER: US 07/735,064  
FILING DATE: 25-JUL-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Teskin Esq., Robin L.  
REGISTRATION NUMBER: 35,030  
REFERENCE/DOCKET NUMBER: 012712-161  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 703-836-6620  
TELEFAX: 703-836-2021  
INFORMATION FOR SEQ ID NO: 37:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 38 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens or Monkey  
POSITION IN GENOME:  
CHROMOSOME/SEGMENT: kappa light chain primer with BglII site  
US-08-476-349A-37

Query Match 66.3%; Score 12.6; DB 1; Length 38;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 GGGTCTGCAGCGGATGCT 19  
||||||| 1 |||||  
DB 33 GGGTCTGCACACCATGCT 15

RESULT 5  
US-08-803-085-8/C  
Sequence 8, Application US/08803085  
Patent No. 6011138  
GENERAL INFORMATION:  
APPLICANT: REFF, Mitchell E.  
APPLICANT: KLOETZER, William S.  
TITLE OF INVENTION: GAMMA-1 ANTI-HUMAN CD23 MONOCLONAL  
NUMBER OF INVENTION: ANTIBODIES AND USE THEREOF AS THERAPEUTICS  
NUMBER OF SEQUENCES: 35  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS  
STREET: P.O. Box 1404  
CITY: Alexandria  
STATE: Virginia  
COUNTRY: United States  
ZIP: 22313-1404  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: PC-DOS/MS-DOS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/803,085  
FILING DATE: 20-FEB-1997  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Teskin, Robin L.  
REGISTRATION NUMBER: 35,030  
REFERENCE/DOCKET NUMBER: 012712-353  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 836-6620  
TELEFAX: (703) 836-2021  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 38 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)

US-08-803-085-8

Query Match 66.3%; Score 12.6; DB 3; Length 38;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 GGGTCTGCAGCGGATGCT 19  
||||||| 1 |||||  
DB 33 GGGTCTGCACACCATGCT 15

RESULT 6  
US-08-523-894-30/C  
Sequence 30, Application US/08523894  
Patent No. 6136310  
GENERAL INFORMATION:  
APPLICANT: Hanna, Nabil  
APPLICANT: Newman, Roland A.  
TITLE OF INVENTION: Recombinant Anti-CD4 Antibodies for Human  
NUMBER OF SEQUENCES: 59  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS  
STREET: 699 Prince Street  
CITY: Alexandria  
STATE: VA  
COUNTRY: USA  
ZIP: 22314-3187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: PC-DOS/MS-DOS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/523,894  
FILING DATE: 06-SEP-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Teskin, Robin L.  
REGISTRATION NUMBER: 35,030  
REFERENCE/DOCKET NUMBER: 012712-165  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 703-836-6620  
TELEFAX: 703-836-2021  
INFORMATION FOR SEQ ID NO: 30:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 38 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Human or Monkey  
POSITION IN GENOME:  
CHROMOSOME/SEGMENT: kappa light chain primer with Bgl II site  
US-08-523-894-30

Query Match 66.3%; Score 12.6; DB 3; Length 38;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 GGGTCTGCAGCGGATGCT 19  
||||||| 1 |||||  
DB 33 GGGTCTGCACACCATGCT 15

RESULT 7  
US-08-761-277A-66/C  
Sequence 66, Application US/08761277A  
Patent No. 5972334  
GENERAL INFORMATION:

APPLICANT: Denney Jr., Dan W.  
TITLE OF INVENTION: Vaccines for Treatment Of Lymphoma And  
TITLE OF INVENTION: Leukemia  
NUMBER OF SEQUENCES: 80  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Medlen & Carroll, LLP  
STREET: 220 Montgomery Street, Suite 2200  
CITY: San Francisco  
STATE: California  
COUNTRY: United States Of America  
ZIP: 94104  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/761,277A  
FILING DATE: 06-DEC-1996  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/644,664  
FILING DATE: 01-MAY-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Macknight, Kamryn T.  
REGISTRATION NUMBER: 38,230  
REFERENCE/DOCKET NUMBER: GENIOTPE-02406  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 705-8410  
TELEFAX: 397-8338  
INFORMATION FOR SEQ ID NO: 66:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 41 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-761-277A-66

Query Match 66.3%; Score 12.6; DB 2; Length 41;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GCGTCTGCAGCGCATGCT 19  
DB 37 GCGTCTGCAGCACCATGCT 19

RESULT 8  
US-08-960-190A-2/C  
Sequence 2, Application US/08960190A  
Patent No. 6232445  
GENERAL INFORMATION:  
APPLICANT: Rhode, Peter R.  
APPLICANT: Acevedo, Jorge  
APPLICANT: Burkhardt, Martin  
APPLICANT: Jiao, Jin-an  
APPLICANT: Wong, Hing C.  
TITLE OF INVENTION: SOLUBLE MHC COMPLEXES AND  
TITLE OF INVENTION: METHODS OF USE THEREOF  
NUMBER OF SEQUENCES: 38  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dike, Bronsteijn, Roberts & Cushman, LLP  
STREET: 130 Water Street  
CITY: Boston  
STATE: MA  
COUNTRY: usa  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/960,190A  
FILING DATE: 29-OCT-1997  
CLASSIFICATION: 536  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Corless, Peter F.  
REGISTRATION NUMBER: 33,860  
REFERENCE/DOCKET NUMBER: 48002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-523-3400  
TELEFAX: 617-523-6440  
TELEX:  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 43 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-960-190A-2

Query Match 66.3%; Score 12.6; DB 4; Length 43;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GCGTCTGCAGCGCATGCT 19  
DB 38 GCGTCTGCAGCACCATGCT 20

RESULT 9  
US-09-042-353-399/C  
Sequence 399, Application US/09042353  
Patent No. 6253458  
GENERAL INFORMATION:  
APPLICANT: Lonberg, Nils  
APPLICANT: Kay, Robert M.  
TITLE OF INVENTION: Transgenic No. 6253458-Human Animals for  
TITLE OF INVENTION: Producing Heterologous Antibodies  
NUMBER OF SEQUENCES: 421  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94111-3834  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/042,353  
FILING DATE: 13-MAR-1998  
CLASSIFICATION: 800  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/810,279  
FILING DATE: 17-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/853,408  
FILING DATE: 18-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/904,068  
FILING DATE: 23-JUN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/990,860  
FILING DATE: 16-DEC-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/053,131  
FILING DATE: 26-APR-1993

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/096,762  
FILING DATE: 22-JUL-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/155,301  
FILING DATE: 18-NOV-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/161,739  
FILING DATE: 03-DEC-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/165,699  
FILING DATE: 10-DEC-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/209,741  
FILING DATE: 09-MAR-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/352,322  
FILING DATE: 07-DEC-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/544,404  
FILING DATE: 10-OCT-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/728,463  
FILING DATE: 10-OCT-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/US96/16433  
FILING DATE: 10-OCT-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/758,417  
FILING DATE: 02-DEC-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/US97/21803  
FILING DATE: 01-DEC-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Apple, Randolph T.  
REGISTRATION NUMBER: 36,429  
REFERENCE/DOCKET NUMBER: 014643-009040US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 399:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 43 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-09-042-353-399

Query Match 66.3% Score 12.6; DB 4; Length 43;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1 GGGCTGCGAGCGGATGCT 19  
DB 22 GGGCTGCGAGCGGATGCT 4  
RESULT 10  
US-08-758-417A-249/C  
Sequence 249, Application US/08758417A  
Patent No. 6300129  
GENERAL INFORMATION:  
APPLICANT: Lonberg, Nils  
Kay, Robert M.  
TITLE OF INVENTION: Transgenic No. 6300129-Human Animals for  
Producing Heterologous Antibodies  
NUMBER OF SEQUENCES: 417  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: California

COUNTRY: USA  
ZIP: 94111-3834  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/758,417A  
FILING DATE: 02-DEC-1996  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/728,463  
FILING DATE: 10-OCT-1996  
APPLICATION NUMBER: US 08/544,404  
FILING DATE: 10-OCT-1995  
APPLICATION NUMBER: US 08/352,322  
FILING DATE: 07-DEC-1994  
APPLICATION NUMBER: US 08/209,741  
FILING DATE: 09-MAR-1994  
APPLICATION NUMBER: US 08/165,699  
FILING DATE: 10-DEC-1993  
APPLICATION NUMBER: US 08/161,739  
FILING DATE: 03-DEC-1993  
APPLICATION NUMBER: US 08/155,301  
FILING DATE: 18-NOV-1993  
APPLICATION NUMBER: US 08/096,762  
FILING DATE: 22-JUL-1993  
APPLICATION NUMBER: US 08/053,131  
FILING DATE: 26-APR-1993  
APPLICATION NUMBER: US 07/990,860  
FILING DATE: 16-DEC-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Serafini, Andrew T.  
REGISTRATION NUMBER: 41,303  
REFERENCE/DOCKET NUMBER: 014643-009030US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 249:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 43 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
SEQUENCE DESCRIPTION: SEQ ID NO: 249:  
US-08-758-417A-249

Query Match 66.3% Score 12.6; DB 4; Length 43;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1 GGGCTGCGAGCGGATGCT 19  
DB 22 GGGCTGCGAGCGGATGCT 4  
RESULT 11  
US-08-596-387B-40/C  
Sequence 40, Application US/08596387B  
Patent No. 5869270  
GENERAL INFORMATION:  
APPLICANT: Rhode, Peter R.  
APPLICANT: Zhao, Jin-An  
APPLICANT: Burkhardt, Martin  
APPLICANT: Wong, Hing  
TITLE OF INVENTION: MHC COMPLEXES AND USES THEREOF  
NUMBER OF SEQUENCES: 124  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dade International, Inc.  
STREET: 1717 Deerfield Road  
CITY: Deerfield

STATE: Illinois  
COUNTRY: USA  
ZIP: 60015  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/596,387B  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/US95/09816  
FILING DATE: 31-JUL-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/382,454  
FILING DATE: 01-FEB-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/283,302  
FILING DATE: 29-JUL-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Pearson, Louise S.  
REGISTRATION NUMBER: 32,369  
REFERENCE/DOCKET NUMBER: STR-4665-CIP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (708) 267-5300  
TELEFAX: (708) 267-5376  
INFORMATION FOR SEQ ID NO: 40:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 44 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
US-08-596-387B-40

Query Match 66.3%; Score 12.6; DB 2; Length 44;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GGCTCTGCAGCGGATGCT 19  
|| ||||| || |||||  
DB 39 GGATCTGCAGCGCATGCT 21

RESULT 12  
US-09-067-615-40/c  
Sequence 40, Application US/09067615  
Patent No. 6309645  
GENERAL INFORMATION:  
APPLICANT: Rhode, Peter R.  
APPLICANT: Jiao, Jin-An  
APPLICANT: Burkhardt, Martin  
APPLICANT: Wong, Hing  
TITLE OF INVENTION: MHC COMPLEXES AND USES THEREOF  
NUMBER OF SEQUENCES: 124  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dade International, Inc.  
STREET: 1717 Deerfield Road  
CITY: Deerfield  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60015  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/067,615  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/596,387  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/382,454  
FILING DATE: 01-FEB-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/283,302  
FILING DATE: 29-JUL-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Pearson, Louise S.  
REGISTRATION NUMBER: 32,369  
REFERENCE/DOCKET NUMBER: STR-4665-CIP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (708) 267-5300  
TELEFAX: (708) 267-5376  
INFORMATION FOR SEQ ID NO: 40:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 44 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
US-09-067-615-40

Query Match 66.3%; Score 12.6; DB 4; Length 44;  
Best Local Similarity 78.9%; Pred. No. 1.4e+03;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GGCTCTGCAGCGGATGCT 19  
|| ||||| || |||||  
DB 39 GGATCTGCAGCGCATGCT 21

RESULT 13  
PCT-US95-09816A-40/c  
Sequence 40, Application PC/TUS9509816A  
GENERAL INFORMATION:  
APPLICANT: Wong, Hing C.  
APPLICANT: Rhode, Peter R.  
APPLICANT: Widanz, Jon A.  
APPLICANT: Grammer, Susan  
APPLICANT: Edwards, Ana C.  
APPLICANT: Chavallier, Pierre-Andre  
APPLICANT: Jiao, Jin-An  
TITLE OF INVENTION: MHC COMPLEXES AND USES THEREOF  
NUMBER OF SEQUENCES: 123  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dade International, Inc.  
STREET: 1717 Deerfield Road  
CITY: Deerfield  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60015  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US95/09816A  
FILING DATE: 31-JUL-1995  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/382,454  
FILING DATE: 01-FEB-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/283,302  
FILING DATE: 29-JUL-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Pearson, Louise S.  
REGISTRATION NUMBER: 32,369  
REFERENCE/DOCKET NUMBER: STR-4665-CIP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (708) 267-5300

## RESULT 15

Search completed: November 28, 2002, 19:32:50  
Job time : 39.3276 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 15:32:44 : Search time 176.241 Seconds

(without alignments)  
242.780 Million cell updates/sec

Title: US-09-719-737-9

Sequence: 1 gggctgcgcgcggatggt 19

Scoring table: IDENTITY\_NUC

Gapop 10.0, Gapept 1.0

Searched: 2185239 segs, 112599159 residues

Total number of hits satisfying chosen parameters: 2166140

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: /SID2/gcgdata/geneseq/emb1/NA1980.DAT:\*  
2: /SID2/gcgdata/geneseq/emb1/NA1981.DAT:\*  
3: /SID2/gcgdata/geneseq/emb1/NA1982.DAT:\*  
4: /SID2/gcgdata/geneseq/emb1/NA1983.DAT:\*  
5: /SID2/gcgdata/geneseq/emb1/NA1984.DAT:\*  
6: /SID2/gcgdata/geneseq/emb1/NA1985.DAT:\*  
7: /SID2/gcgdata/geneseq/emb1/NA1986.DAT:\*  
8: /SID2/gcgdata/geneseq/emb1/NA1987.DAT:\*  
9: /SID2/gcgdata/geneseq/emb1/NA1988.DAT:\*  
10: /SID2/gcgdata/geneseq/emb1/NA1989.DAT:\*  
11: /SID2/gcgdata/geneseq/emb1/NA1990.DAT:\*  
12: /SID2/gcgdata/geneseq/emb1/NA1991.DAT:\*  
13: /SID2/gcgdata/geneseq/emb1/NA1992.DAT:\*  
14: /SID2/gcgdata/geneseq/emb1/NA1993.DAT:\*  
15: /SID2/gcgdata/geneseq/emb1/NA1994.DAT:\*  
16: /SID2/gcgdata/geneseq/emb1/NA1995.DAT:\*  
17: /SID2/gcgdata/geneseq/emb1/NA1996.DAT:\*  
18: /SID2/gcgdata/geneseq/emb1/NA1997.DAT:\*  
19: /SID2/gcgdata/geneseq/emb1/NA1998.DAT:\*  
20: /SID2/gcgdata/geneseq/emb1/NA1999.DAT:\*  
21: /SID2/gcgdata/geneseq/emb1/NA2000.DAT:\*  
22: /SID2/gcgdata/geneseq/emb1/NA2001A.DAT:\*  
23: /SID2/gcgdata/geneseq/emb1/NA2001B.DAT:\*  
24: /SID2/gcgdata/geneseq/emb1/NA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	19	21	AA256193
2	18	94.7	19	21	AA256194
3	18	94.7	19	21	AA256195
4	17	89.5	19	21	AA256199
5	16	84.2	19	21	AA256196
6	14.8	77.9	27	22	AAH45301
7	14.2	74.7	20	24	AA256640
8	14.2	74.7	34	21	AAA30293
9	13.4	70.5	20	24	ABA81692

10	13.4	70.5	42	22	AA256193	HBV gene hybridisa
11	13.4	70.5	47	17	AA256193	PCR primer OPR141
12	13.2	69.5	27	22	AAH45300	Human Bcl-2 mutagen
13	13.2	69.5	27	24	AAH45300	Adenovirus vector
14	13.2	69.5	33	16	AAQ97259	ATF-2 5' bridging
15	13.2	69.5	38	17	AA256197	Murine VRF167 mRNA
16	13	68.4	19	21	AA256197	Oligonucleotide 10
17	12.8	67.4	25	18	AAH85301	Human chemotactic
18	12.8	67.4	50	22	AAH85301	Human coding sequ
19	12.6	66.3	32	19	AAH62345	GRIK1 polymorphism
20	12.6	66.3	33	22	AAV12065	Murine IAD beta ch
21	12.6	66.3	33	22	AAV55037	PCR primer used to
22	12.6	66.3	33	22	AAV55037	PCR primer RG972.
23	12.6	66.3	33	22	AAV55037	Porcine GM-CSF RT-
24	12.6	66.3	35	20	AAV83185	Primer for amplify
25	12.6	66.3	35	21	AAV83185	Human GM-CSF PCR p
26	12.6	66.3	36	22	AAV56666	Human GM-CSF CDNA
27	12.6	66.3	37	21	AA255603	Feline GM-CSF sense
28	12.6	66.3	38	14	AAQ35916	Human/monkey kappa
29	12.6	66.3	38	18	AAV5141	Human or monkey Ig
30	12.6	66.3	38	18	AAV5141	Monkey/human kappa
31	12.6	66.3	38	18	AAV92217	Human or monkey ka
32	12.6	66.3	38	19	AAV3314	Anil-CD23 5E8 ant
33	12.6	66.3	38	19	AAV3314	Human or monkey ka
34	12.6	66.3	38	19	AAV3314	Primer for Anil-CD
35	12.6	66.3	38	19	AAV3314	Human/monkey kappa
36	12.6	66.3	39	20	AAV3314	Human RAD1 gene pr
37	12.6	66.3	39	21	AAV3314	Single base extens
38	12.6	66.3	41	18	AAV3314	Kappa chain variab
39	12.6	66.3	43	18	AAV3314	Gamma heavy chain
40	12.6	66.3	43	18	AAV3314	Primer O-543 used
41	12.6	66.3	43	20	AAV3314	Oligonucleotide us
42	12.6	66.3	43	20	AAV3314	PCR primer OPR132
43	12.6	66.3	44	17	AAV3314	PCR primer OPR132
44	12.6	66.3	44	18	AAV3314	Primer used in MHC
45	12.6	66.3	44	23	AAV3314	Equine GM-CSF gene

#### ALIGNMENTS

RESULT 1	AA256193	standard; DNA; 19 BP.
ID	AA256193	
AC	AA256193	
XX		
DF	28-MAR-2000	(first entry)
XX		
DE	Oligonucleotide 107A for IL-3/IL-5/GM-CSF receptor expression inhibition.	
XX		
KW	Interleukin-3; IL-3; interleukin-5; IL-5; antisense oligonucleotide;	
KW	asthma; allergy; cancer; receptor expression inhibitor; cytokine;	
KW	inflammation; hypereosinophilia; eosinophil proliferation;	
KW	granulocyte macrophage colony stimulating factor; GM-CSF; ss.	
XX		
OS	Homio sapiens	
XX		
PN	WO9966037-A2	
XX		
PD	23-DEC-1999	
XX		
PF	17-JUN-1999	99WO-CA00572.
XX		
PR	17-JUN-1998	98CA-2235420.
XX		
PA	(REEX-) RECH EXPERTISES & DEV MEDICAUX PARENZ IN.	
XX		
PI	Renzi P;	
XX		
DR	WPI; 2000-097743/08.	
XX		
PT	Antisense oligonucleotides directed to CCR3, interleukin or granulocyte	

PT macrophage colony stimulating factor receptors, used for treating or  
PT preventing asthma, allergies, hypereosinophilia, inflammation or cancer  
PT  
XX  
PS Claim 5: Page 23; 72pp: English.  
XX  
CC This is an antisense oligonucleotide directed against the common beta  
CC subunit of the interleukin-3 (IL-3) receptor, the interleukin-5 (IL-5)  
CC receptor and the granulocyte macrophage colony stimulating factor  
CC (GM-CSF) receptor. The antisense oligonucleotide inhibits IL-3, IL-5  
CC and GM-CSF receptor expression. IL-3, IL-5 and GM-CSF are cytokines  
CC involved in eosinophil proliferation and survival, they are increased in  
CC asthma and atopic diseases, and are also involved in the indefinite  
CC proliferation of certain neoplastic diseases. The invention relates to  
CC antisense oligonucleotides directed against a nucleic acid sequence  
CC encoding either a chemokine receptor (CCR3), a common subunit of  
CC interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense  
CC oligonucleotides can be used in the treatment or prevention of asthma,  
CC allergy, hypereosinophilia, general inflammation or cancer.  
XX  
SQ Sequence 19 BP; 2 A; 3 C; 10 G; 4 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 19;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTGCAGCGCGATGCT 19  
|||||  
DB 1 GCGCTGCAGCGCGATGCT 19

RESULT 2  
AAZ56194  
ID AAZ56194 standard; DNA: 19 BP.  
XX  
AC AAZ56194;  
XX  
DT 28-MAR-2000 (first entry)  
XX  
DE Oligonucleotide 106 for IL-3/IL-5/GM-CSF receptor expression inhibition.  
XX  
XX  
KW Interleukin-3; IL-3; interleukin-5; IL-5; antisense oligonucleotide;  
KW asthma; allergy; cancer; receptor expression inhibitor; cytokine;  
KW inflammation; hypereosinophilia; eosinophil proliferation;  
KW granulocyte macrophage colony stimulating factor; GM-CSF; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO966037-A2.  
XX  
PD 23-DEC-1999.  
XX  
PF 17-JUN-1999: 99WO-CA00572.  
XX  
PR 17-JUN-1998: 98CA-2235420.  
XX  
PA (REEX-) RECH EXPERTISES & DEV MEDICAUX PARENZ IN.  
XX  
PI Renzl P;  
XX  
DR WPI: 2000-097743/08.  
XX  
PT Antisense oligonucleotides directed to CCR3, interleukin or granulocyte  
PT macrophage colony stimulating factor receptors, used for treating or  
PT preventing asthma, allergies, hypereosinophilia, inflammation or cancer  
PT  
XX  
XX Claim 5: Page 25; 72pp: English.  
XX  
CC This is an antisense oligonucleotide directed against the common beta  
CC subunit of the interleukin-3 (IL-3) receptor, the interleukin-5 (IL-5)  
CC receptor and the granulocyte macrophage colony stimulating factor  
CC (GM-CSF) receptor. The antisense oligonucleotide inhibits IL-3, IL-5  
CC and GM-CSF receptor expression. IL-3, IL-5 and GM-CSF are cytokines  
CC involved in eosinophil proliferation and survival, they are increased in  
CC asthma and atopic diseases, and are also involved in the indefinite  
CC proliferation of certain neoplastic diseases. The invention relates to  
CC antisense oligonucleotides directed against a nucleic acid sequence  
CC encoding either a chemokine receptor (CCR3), a common subunit of  
CC interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense

CC (GM-CSF) receptor. The antisense oligonucleotide inhibits IL-3, IL-5  
CC and GM-CSF receptor expression. IL-3, IL-5 and GM-CSF are cytokines  
CC involved in eosinophil proliferation and survival, they are increased in  
CC asthma and atopic diseases, and are also involved in the indefinite  
CC proliferation of certain neoplastic diseases. The invention relates to  
CC antisense oligonucleotides directed against a nucleic acid sequence  
CC encoding either a chemokine receptor (CCR3), a common subunit of  
CC interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense  
CC oligonucleotides can be used in the treatment or prevention of asthma,  
CC allergy, hypereosinophilia, general inflammation or cancer.  
XX  
SQ Sequence 19 BP; 2 A; 3 C; 9 G; 5 T; 0 other;

Query Match 94.7%; Score 18; DB 21; Length 19;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 GCGTGCAGCGCGATGCT 19  
|||||  
DB 1 GCGTGCAGCGCGATGCT 18

RESULT 3  
AAZ56195  
ID AAZ56195 standard; DNA: 19 BP.  
XX  
AC AAZ56195;  
XX  
DT 28-MAR-2000 (first entry)  
XX  
DE Oligonucleotide 108 for IL-3/IL-5/GM-CSF receptor expression inhibition.  
XX  
XX  
KW Interleukin-3; IL-3; interleukin-5; IL-5; antisense oligonucleotide;  
KW asthma; allergy; cancer; receptor expression inhibitor; cytokine;  
KW inflammation; hypereosinophilia; eosinophil proliferation;  
KW granulocyte macrophage colony stimulating factor; GM-CSF; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO966037-A2.  
XX  
PD 23-DEC-1999.  
XX  
PF 17-JUN-1999: 99WO-CA00572.  
XX  
PR 17-JUN-1998: 98CA-2235420.  
XX  
PA (REEX-) RECH EXPERTISES & DEV MEDICAUX PARENZ IN.  
XX  
PI Renzl P;  
XX  
DR WPI: 2000-097743/08.  
XX  
PT Antisense oligonucleotides directed to CCR3, interleukin or granulocyte  
PT macrophage colony stimulating factor receptors, used for treating or  
PT preventing asthma, allergies, hypereosinophilia, inflammation or cancer  
PT  
XX  
XX Claim 5: Page 25; 72pp: English.  
XX  
CC This is an antisense oligonucleotide directed against the common beta  
CC subunit of the interleukin-3 (IL-3) receptor, the interleukin-5 (IL-5)  
CC receptor and the granulocyte macrophage colony stimulating factor  
CC (GM-CSF) receptor. The antisense oligonucleotide inhibits IL-3, IL-5  
CC and GM-CSF receptor expression. IL-3, IL-5 and GM-CSF are cytokines  
CC involved in eosinophil proliferation and survival, they are increased in  
CC asthma and atopic diseases, and are also involved in the indefinite  
CC proliferation of certain neoplastic diseases. The invention relates to  
CC antisense oligonucleotides directed against a nucleic acid sequence  
CC encoding either a chemokine receptor (CCR3), a common subunit of  
CC interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense



CC oligonucleotides can be used in the treatment or prevention of asthma,  
 CC allergy, hyper eosinophilia, general inflammation or cancer.  
 XX  
 SO Sequence 19 BP; 3 A; 3 C; 10 G; 3 T; 0 other:

Query Match 94.7%; Score 18; DB 21; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 25;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGCTCTGCACGGGATGC 18  
 |||||  
 DB 2 GGCTCTGCACGGGATGC 19

## RESULT 4

AA256199  
 ID AA256199 standard; DNA; 19 BP.

AC AA256199;

DT 28-MAR-2000 (first entry)

DE Oligonucleotide 105 for IL-3/IL-5/GM-CSF receptor expression inhibition.

XX Interleukin-3; IL-3; interleukin-5; IL-5; antisense oligonucleotide;

KW asthma; allergy; cancer; receptor expression inhibitor; cytokine;

KM inflammation; hyper eosinophilia; eosinophil proliferation;

KW granulocyte macrophage colony stimulating factor; GM-CSF; ss.

XX Homo sapiens.

OS

PN WO966037-A2.

XX 23-DEC-1999.

XX 17-JUN-1999; 99WO-CA00572.

XX 17-JUN-1998; 98CA-2235420.

XX (REEX-) RECH EXPERTISES & DEV MEDICAUX PARENZ IN.

XX Renzi P;

XX WPI: 2000-097743/08.

PS Claim 5; Page 25; 72pp; English.

CC This is an antisense oligonucleotide directed against the common beta  
 CC subunit of the interleukin-3 (IL-3) receptor, the interleukin-5 (IL-5)  
 CC receptor and the granulocyte macrophage colony stimulating factor  
 CC (GM-CSF) receptor. The antisense oligonucleotide inhibits IL-3, IL-5  
 CC and GM-CSF receptor expression. IL-3, IL-5 and GM-CSF are cytokines  
 CC involved in eosinophil proliferation and survival, they are increased in  
 CC asthma and atopic diseases, and are also involved in the indefinite  
 CC proliferation of certain neoplastic diseases. The invention relates to  
 CC antisense oligonucleotides directed against a nucleic acid sequence  
 CC encoding either a chemokine receptor (CCR3), a common subunit of  
 CC interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
 CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense  
 CC oligonucleotides can be used in the treatment or prevention of asthma,  
 CC allergy, hyper eosinophilia, general inflammation or cancer.

SO Sequence 19 BP; 2 A; 3 C; 8 G; 6 T; 0 other;

Query Match 89.5%; Score 17; DB 21; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 76;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GTCCTGCACGGGATGCT 19  
 |||||  
 DB 1 GTCCTGCACGGGATGCT 17

## RESULT 5

AA256196  
 ID AA256196 standard; DNA; 19 BP.

AC AA256196;

DT 28-MAR-2000 (first entry)

DE Oligonucleotide 110 for IL-3/IL-5/GM-CSF receptor expression inhibition.

XX Interleukin-3; IL-3; interleukin-5; IL-5; antisense oligonucleotide;

KW asthma; allergy; cancer; receptor expression inhibitor; cytokine;

KM inflammation; hyper eosinophilia; eosinophil proliferation;

KW granulocyte macrophage colony stimulating factor; GM-CSF; ss.

XX Homo sapiens.

OS

PN WO966037-A2.

XX 23-DEC-1999.

XX 17-JUN-1999; 99WO-CA00572.

XX 17-JUN-1998; 98CA-2235420.

XX (REEX-) RECH EXPERTISES & DEV MEDICAUX PARENZ IN.

XX Renzi P;

XX WPI: 2000-097743/08.

CC This is an antisense oligonucleotide directed against the common beta  
 CC subunit of the interleukin-3 (IL-3) receptor, the interleukin-5 (IL-5)  
 CC receptor and the granulocyte macrophage colony stimulating factor  
 CC (GM-CSF) receptor. The antisense oligonucleotide inhibits IL-3, IL-5  
 CC and GM-CSF receptor expression. IL-3, IL-5 and GM-CSF are cytokines  
 CC involved in eosinophil proliferation and survival, they are increased in  
 CC asthma and atopic diseases, and are also involved in the indefinite  
 CC proliferation of certain neoplastic diseases. The invention relates to  
 CC antisense oligonucleotides directed against a nucleic acid sequence  
 CC encoding either a chemokine receptor (CCR3), a common subunit of  
 CC interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
 CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense  
 CC oligonucleotides can be used in the treatment or prevention of asthma,  
 CC allergy, hyper eosinophilia, general inflammation or cancer.

SO Sequence 19 BP; 3 A; 4 C; 9 G; 3 T; 0 other;

Query Match 84.2%; Score 16; DB 21; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 23e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGCTCTGCACGGGAT 16  
 |||||  
 DB 4 GGCTCTGCACGGGAT 19

## RESULT 6

AAH45301  
 ID AAH45301 standard; DNA; 27 BP.

```

AC  AAH45301;
XX
XX  10-SEP-2001 (first entry)
DT
XX
XX  Human Bcl-2 mutagenic primer oligo-4 for S70D substitution.
DE
XX
XX  Human; Bcl-2; gene therapy; apoptosis inhibitor; mutant; primer; ss.
XX
OS  Homo sapiens.
OS  Synthetic.
XX  WO200142459-A1.
XX
XX  14-JUN-2001.
PD
XX
XX  07-DEC-2000; 2000WO-JP08667.
PR
XX  09-DEC-1999; 99JP-0350427.
XX
XX  (HISM ) HISAMITSU PHARM CO LTD.
PA
XX  Shibaazaki F, Kuma H;
PI
XX  WPI; 2001-381681/40.
XX
XX  New apoptosis inhibitors, useful for treating apoptosis related
PT  disorders -
PT
XX  Example 1; Page 10; 43pp; Japanese.
PS
XX
XX  The invention relates to an apoptosis inhibitor comprising the
CC  amino acid sequence of Bcl-2 protein in which at least one serine
CC  residue is substituted by alanine or aspartic acid. The protein has
CC  increased apoptosis inhibitory activity compared with the wild type
CC  Bcl-2 protein. The mutated Bcl-2 protein is useful in the treatment
CC  of disorders caused by apoptosis. The present sequence was used to
CC  create a mutant Bcl-2 protein of the invention.
XX
SQ  Sequence 27 BP; 2 A; 8 C; 12 G; 5 T; 0 other;

Query Match      77.9%; Score 14.8; DB 22; Length 27;
Best Local Similarity 88.9%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2 GGCTCTGCACGGGATGCT 19
    |||||
DB  1 GGCTCTGCACGGGATGCT 18

RESULT 7
AAS96640
ID  AAS96640 standard; DNA; 20 BP.
XX
AC  AAS96640;
XX
XX  09-APR-2002 (first entry)
DT
XX
XX  Telomerase reverse transcriptase, antisense oligonucleotide #50.
DE
XX
XX  Telomerase reverse transcriptase; TERT; cytosolic; apoptosis;
XX  cell growth inhibitor; antisense oligonucleotide;
XX  antisense technology; ss.
XX
OS  Homo sapiens.
OS  Synthetic.
XX  WO200188198-A1.
XX
XX  22-NOV-2001.
PD
XX
XX  15-MAY-2001; 2001WO-US15774.
PF
XX  16-MAY-2000; 2000US-0572423.
PR

```

```

PR  07-DEC-2000; 2000US-0733294.
XX
XX  (ISIS-) ISIS PHARM INC.
PA
XX
XX  Monla BP, Gaarde WA, Freier SM, Wancewicz E;
PI
XX  WPI; 2002-075321/10.
XX
XX  New compound targeted to nucleic acid molecule encoding telomerase
PT  transcriptase (TERT), which specifically hybridises with and inhibits
PT  expression of TERT, useful for modulating apoptosis and inhibiting cell
PT  growth -
PT
XX  Example 19; Page 91; 154pp; English.
PS
XX
XX  The invention describes a compound, 8-50 nucleobases in length targeted
CC  to a nucleic acid molecule encoding human TERT (telomerase reverse
CC  transcriptase), where the compound specifically hybridises with and
CC  inhibits the expression of TERT. A series of oligonucleotides were
CC  designed to target different regions of the human TERT RNA. These were
CC  20 nucleotides in length and composed of a central gap region consisting
CC  of ten 2'-deoxynucleotides, flanked on both sides (5' and 3' directions)
CC  by five-nucleotide wings. The wings were composed of 2'-methoxyethyl
CC  (2'-MOE) nucleotides. The compounds were analysed for their effect on
CC  human TERT mRNA levels by reverse transcriptase (RT)-polymerase chain
CC  reaction (PCR). The compound is useful for inhibiting the expression of
CC  TERT in cells or tissues, for treating a human having disease or
CC  condition associated with TERT, for modulating apoptosis, for inhibiting
CC  cell growth (preferably, cancer cell growth), in antisense therapy and
CC  for diagnostics and therapeutics. This sequence is an antisense
CC  oligonucleotide used to modulate the activity of nucleic acid molecules
XX  encoding TERT, described in the method of the invention.
XX
SQ  Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 other;

Query Match      74.7%; Score 14.2; DB 24; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY  1 GGCTCTGCACGGGATGCT 19
    |||||
DB  1 GGCTCTGCACCTGGATGCT 19

RESULT 8
AAA30293/C
ID  AAA30293 standard; DNA; 34 BP.
XX
XX  AAA30293;
XX
XX  11-SEP-2000 (first entry)
DT
XX
XX  R. eutropha toluene monooxygenase tomk primer, tom-K.
DE
XX
XX  Toluene monooxygenase; carcinogen; halogenated aliphatic hydrocarbon;
XX  halogenated aromatic hydrocarbon; environmental pollution;
XX  environmental remediation; enzyme; tomk primer;
XX  site-directed mutagenesis; ss.
XX
OS  Ralstonia eutropha strain TB64.
XX
XX  EP1006191-A2.
XX
XX  07-JUN-2000.
PD
XX
XX  03-DEC-1999; 99EP-0124209.
PF
XX  03-DEC-1998; 98JP-0344506.
XX
XX  (CANO ) CANON KK.
PA
XX
XX  Yano T, Nomoto T, Imamura T;
PI
XX

```

DR WPI: 2000-378265/33.  
 XX  
 PT New polynucleotide encoding toluene monooxygenase for generating  
 PT transformants useful for decontaminating environments polluted with  
 PT e.g. aromatic hydrocarbons -  
 XX  
 PS Example 6; Page 20; 54pp; English.  
 XX  
 CC Toluene monooxygenase catalyzes the degradation of environmental  
 CC pollutants such as halogenated aliphatic compounds e.g.  
 CC tetrachloroethylene (PCE), trichloroethylene (TCE) and dichloroethylene  
 CC (DCE) and/or aromatic hydrocarbons e.g. toluene, benzene, phenol,  
 CC cresol. These pollutants are considered to be potential carcinogens. A  
 CC DNA fragment of about 5.3 kb containing a toluene monooxygenase (tom)  
 CC gene from *Ralstonia eutropha* strain T864 has been isolated (AAA30292).  
 CC The sequence in AAA30292 contains seven coding sequences, one of which  
 CC is tomK. TomK protein is an enhancer of toluene monooxygenase activity.  
 CC The present sequence is the tom-K primer. This primer was used to  
 CC introduce a NcoI restriction site into the tomK coding sequence by PCR.  
 CC After the introduction of the restriction sites, the coding sequence  
 CC could be cloned into expression vectors pSE280 and pSE380. These  
 CC recombinant vectors were then used in the transformation of microbial  
 CC cells conferring them with toluene monooxygenase activity. These  
 CC recombinant cells would therefore be useful in environmental  
 CC remediation.  
 CC  
 SO Sequence 34 BP; 8 A; 14 C; 7 G; 5 T; 0 other:  
 XX  
 XX  
 Query Match 74.7%; Score 14.2; DB 21; Length 34;  
 Best Local Similarity 84.2%; Pred. No. 1.7e+03;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 OY 1 GGGTCTGCGCGGATGCT 19  
 Db 31 GGCTCTGCGCGCATGCT 13  
 |||||  
 RESULT 9  
 ID ABA81692/C  
 XX ABA81692 standard; DNA; 20 BP.  
 AC ABA81692;  
 XX  
 DT 25-JAN-2002 (first entry)  
 XX  
 DE PCR primer KP108.  
 XX  
 XX Aldehyde-dehydrogenase; enzyme; phenanthrene; anthracene; PCR primer;  
 KW aromatic dihydrodiol dehydrogenase; aromatic diol oxygenase;  
 KW hydratase-aldoase; ss.  
 XX  
 OS Nocardioides sp. KP7.  
 XX  
 PN JP2001245662-A.  
 XX  
 PD 11-SEP-2001.  
 XX  
 PF 03-MAR-2000; 2000JP-0059523.  
 XX  
 PR 03-MAR-2000; 2000JP-0059523.  
 XX  
 PA (KAIY-) KAIYO BIOTECHNOLOGY KENKUYUSHO KK.  
 DR WPI: 2002-002935/01.  
 XX  
 PT Genes and proteins involved in the upstream of the pathway of  
 PT degradation of a polycyclic aromatic compound -  
 XX  
 PS Example 4; Page 6; 47pp; Japanese.  
 XX  
 CC The present invention relates to coding sequences for proteins such as  
 CC aromatic dihydrodiol dehydrogenase, aromatic diol oxygenase,  
 CC hydratase-aldoase and aldehyde-dehydrogenase (ABA01198-ABA01201 and

CC AAM52344-AAM52347), which are involved in the degradation of polycyclic  
 CC aromatic compounds. The enzymes are useful as reagents for converting the  
 CC metabolite intermediates of polycyclic aromatic compounds such as  
 CC phenanthrene and anthracene. The present sequence is a PCR primer, which  
 CC was used in an example from the present invention.  
 XX  
 SO Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 other:  
 XX  
 XX  
 Query Match 70.5%; Score 13.4; DB 24; Length 20;  
 Best Local Similarity 93.3%; Pred. No. 4e+03;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 2 GGTCTGCGCGCGAT 16  
 Db 15 GGCTCTGCGCGGGTT 1  
 |||||  
 RESULT 10  
 ID AAF81879  
 XX AAF81879 standard; DNA; 42 BP.  
 AC AAF81879;  
 XX  
 DT 08-JUN-2001 (first entry)  
 XX  
 DE HBV gene hybridisation detection related probe/primer #12.  
 XX  
 KW Hepatitis B virus; HBV; gene hybridisation; detection; probe; primer;  
 KW amplification; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN CN1274847-A.  
 XX  
 PD 29-NOV-2000.  
 XX  
 PF 02-JUN-2000; 2000CN-0116306.  
 XX  
 PR 02-JUN-2000; 2000CN-0116306.  
 XX  
 PA (CHAN-) CHANGZHENG HOSPITAL SHANGHAI.  
 XX  
 PT Miao X, Kong X, Qi Z;  
 XX  
 DR WPI: 2001-211778/22.  
 XX  
 PT Making a marker signal amplifying probe for gene hybridization  
 PT detection of e.g. hepatitis B, comprises a polymerase chain reaction -  
 XX  
 PS Example 2; Page 9; 18pp; Chinese.  
 XX  
 CC The present invention describes a method for the design and synthesis of  
 CC a marker signal amplifying probe and primer. The method comprises:  
 CC (a) connecting the probe and primer through a connecting arm;  
 CC (b) polymerase chain reaction (PCR) of probe/primer as an upstream  
 CC primer, one gene template and a downstream primer to obtain some DNA  
 CC section with one single-chain end and other double-chainpart; and  
 CC (c) PCR to add a marker into double chain. The amplifying probe may be  
 CC used in various in vitro gene hybridisation detecting technology. The  
 CC method of the present invention is simple and has adjustable  
 CC amplification, and when used in detecting hepatitis B virus (HBV)  
 CC genome, it has high sensitivity and strong specificity. AAF81868 to  
 CC exemplification of the present invention.  
 XX  
 SO Sequence 42 BP; 12 A; 8 C; 13 G; 9 T; 0 other:  
 XX  
 XX  
 Query Match 70.5%; Score 13.4; DB 22; Length 42;  
 Best Local Similarity 93.3%; Pred. No. 4.1e+03;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 5 CTGCGCGGCGGATGCT 19  
 |||||

DB 18 CTCGACGCGTATGCT 32

## RESULT 11

AAT34741

ID AAT34741 standard; DNA; 47 BP.

XX AAT34741;

DT 23-SEP-1996 (first entry)

DE PCR primer OPRI41 used in construction of MHC fusion complex vector.

XX MHC; major histocompatibility complex; PCR; polymerase chain reaction;

KW T cell activity modulator; antagonist; immune disorder; allergy;

KW multiple sclerosis; insulin-dependent diabetes mellitus;

KW rheumatoid arthritis; myasthenia gravis; ss.

XX OS Synthetic.

PN WO9604314-A1.

PD 15-FEB-1996.

PF 31-JUL-1995; 95WO-US09816.

XX 01-FEB-1995; 95US-0382454.

PR 29-JUL-1994; 94US-0283302.

XX (DADE-) DADE INT INC.

PI Chavallier P-A, Edwards AC, Grammer S, Jiao J-A, Rhode PR;

PI Weidanz JA, Wong HC;

DR WPI: 1996-129343/13.

PT Major histocompatibility complex fusion complex for modulating T

PT cell activity - used in the treatment of immune disorders, e.g.

PT multiple sclerosis, IDDM and rheumatoid arthritis

XX Example 1; Fig 8; 210pp; English.

CC AAT34735-T34750 are PCR primers used in the construction of MHC fusion

CC complexes capable of modulating T cell activity. The MHC fusion complex

CC comprises a MHC molecule containing a peptide-binding groove and a

CC presenting peptide covalently linked to the MHC molecule and opt. a

CC transmembrane domain. Multivalent MHC fusion complexes may also be

CC made comprising 2 or more linked MHC fusion complexes. DNA encoding

CC a MHC fusion complex may be cloned into a host cell to express the

CC complex. The transformed cells may then be used to identify peptides

CC that modulate, pref. antagonise, T cell activity. DNA encoding a MHC

CC fusion complex or a single chain fusion molecule may be used to

CC vaccinate a mammal against a targeted disorder. The fusion

CC complexes may be used to suppress an immune response in an animal

CC suffering from an immune disorder e.g. multiple sclerosis, insulin-

CC dependent diabetes mellitus, rheumatoid arthritis, myasthenia

CC gravis or chronic allergies. The complexes may also be used in the

CC treatment of livestock and pets such as cats and dogs. The MHC

CC fusion complexes can be produced such that they contain a single

CC antigenic peptide including one of known structure, additionally a

CC wide range of peptides can be presented for T cell interaction.

XX Sequence 47 BP; 9 A; 11 C; 18 G; 8 T; 1 other;

Query Match 70.5%; Score 13.4; DB 17; Length 47;

Best Local Similarity 78.9%; Pred. No. 4.1e+03;

Matches 15; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

OY 1 GCGCTGCAGCGGATGCT 19

DB 18 GCGCTGCAGCGGATGCT 36

## RESULT 12

AAH45300

ID AAH45300 standard; DNA; 27 BP.

XX AAH45300;

DT 10-SEP-2001 (first entry)

DE Human Bcl-2 mutagenic primer oligo-3 for 570A substitution.

XX Human; Bcl-2; gene therapy; apoptosis inhibitor; mutant; primer; ss.

XX Homo sapiens.

OS Synthetic.

PN WO200142459-A1.

PD 14-JUN-2001.

PF 07-DEC-2000; 2000WO-JP08667.

PR 09-DEC-1999; 99JP-0350427.

XX (HISM ) HISAMITSU PHARM CO LTD.

PI Shibazaki F, Kuma H;

DR WPI: 2001-381681/40.

XX New apoptosis inhibitors, useful for treating apoptosis related

XX disorders -

PS Example 1; Page 10; 43pp; Japanese.

CC The invention relates to an apoptosis inhibitor comprising the

CC amino acid sequence of Bcl-2 protein in which at least one serine

CC residue is substituted by alanine or aspartic acid. The protein has

CC increased apoptosis inhibitory activity compared with the wild type

CC Bcl-2 protein. The mutated Bcl-2 protein is useful in the treatment

CC of disorders caused by apoptosis. The present sequence was used to

CC create a mutant Bcl-2 protein or the invention.

XX Sequence 27 BP; 2 A; 9 C; 12 G; 4 T; 0 other;

Query Match 69.5%; Score 13.2; DB 22; Length 27;

Best Local Similarity 83.3%; Pred. No. 5e+03; Mismatches 3; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 GCGTGCAGCGGATGCT 19

DB 1 GCGTGCAGCGGATGCT 18

## RESULT 13

ABK47064

ID ABK47064 standard; DNA; 27 BP.

XX ABK47064;

DT 05-JUN-2002 (first entry)

DE Adenovirus vector E3 region deletion PCR primer 4.

XX Adenovirus vector library; ss; primer; high throughput screening;

KW RCA; replication competent adenovirus; PCR.

XX Mastadenovirus Ad5.

OS US6340595-B1.

PN 22-JAN-2002.

XX 21-JUL-1999; 99US-0358036.

```

XX 12-JUN-1998; 98US-0097239.
PR (GALA-) GALAPAGOS GENOMICS NV.
PA
XX
XX
XX Vogels R, Bout A, Van Es H, Schouten G;
PI WPI; 2002-224926/28.
DR
XX
XX Library of expressible nucleic acids, useful for determining nucleic
PT acid function, comprises one or more adenoviral vectors capable of
PT transfecting a host cell with the nucleic acid
XX
XX Example 18; Column 63; 11pp; English.
PS
XX The invention relates to a library (I) of a multitude of unique
CC expressible nucleic acids (NA), comprises a number of compartments
CC (II), each consisting of one or more adenoviral vectors (III)
CC comprising at least one unique NA of (I) in an aqueous medium, where
CC (III) is capable of introducing the NA into a host cell (IV), is
CC capable of expressing the product of the NA in (IV), and is deleted in
CC a portion of the adenoviral genome necessary for replication. Also
CC included is a method for producing the library. The library is useful for
CC determining the function of at least one nucleic acid that is present.
CC The library uses high throughput generation of recombinant adenoviral
CC vector libraries containing one or more sample nucleic acids, followed by
CC high throughput screening of the adenoviral vector libraries in a host to
CC alter the phenotype of the host as a means of assigning a function to
CC expression product(s) of the sample nucleic acids. The entire process
CC lends itself to automation especially when implemented in a 96-well or
CC other multi-well format. The high throughput screening, using a number of
CC different in vitro assays, provides a means of efficiently obtaining
CC functional information in a relatively short period of time. The
CC member(s) of the recombinant adenoviral libraries that exhibit or induce
CC a desired phenotype in a host in vitro or in situ are identified to
CC reduce the libraries to a manageable number of recombinant adenoviral
CC vectors or clones which can be tested in vitro in an animal model.
CC Furthermore, the methods produce RCA-free adenoviral libraries. RCA
CC (replication competent adenovirus) contamination throughout the libraries
CC could become a major obstacle, especially if libraries are continuously
CC amplified for use in multiple screening programs. Additionally, a further
CC advantage is minimization of the number of steps involved in the process.
CC There is no requirement for cloning each individual adenovirus before use
CC in a high throughput screening program. Other systems include one or more
CC steps in E. coli to achieve homologous recombination for the various
CC adenoviral plasmids necessary for vector generation. The present
CC sequence is a PCR primer used in the construction of the adenoviral
CC vector library of the invention.
XX
XX Sequence 27 BP; 3 A; 3 C; 13 G; 8 T; 0 other;
SO
XX
XX Query Match 69.5%; Score 13.2; DB 24; Length 27;
XX Best Local Similarity 83.3%; Pred. No. 5e+03;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 2 GGTCTGCACGCGGATGCT 19
XX | |||| ||||| |||
XX Db 8 GTTCTGCACGCGGAGGT 25
XX
XX RESULT 14
XX AA097259/c
XX ID AA097259 standard; cDNA; 33 BP.
XX AC
XX AA097259;
XX
XX 28-DEC-1995 (first entry)
XX
XX ATF-2 5' bridging primer.
XX
XX Astrocyte-derived neurotrophic factor; ATF-1; neuron; GDNF;
XX primer; polymerase chain reaction; PCR; ss.
XX

```

```

OS Synthetic.
XX
XX Key Location/Qualifiers
FH misc_feature 1..17
FT
FT misc_feature /tag= a
FT /note= bases 1-17 corresp. to GDNF bases 95-111*
FT 18..33
FT misc_feature /tag= b
FT /note= bases 18-33 corresp. to GDNF bases 338-353*
XX
XX W09517203-A1.
XX
XX 29-JUN-1995.
XX
XX 22-DEC-1994; 94MO-US14771.
XX
XX 20-DEC-1994; 94US-0359480.
XX 22-DEC-1993; 93US-0172327.
XX 18-JUL-1994; 94US-0275709.
XX
XX (UYNE-) UNIV NEM JERSEY.
XX
XX Black IB, Dreyfuss CF, Schaar DG;
XX
XX WPI; 1995-240472/31.
XX
XX New astrocyte-derived neurotrophic factor proteins - related nucleic
PT acid, vectors and transformed cells, useful for stimulating neuronal
PT cell survival and growth
XX
XX Example 1; Page 38; 107pp; English.
XX
XX The GDNF sequences deleted in human ATF-1 and ATF-2 cDNA clones
CC (AA097241-42, respectively) were analyzed by PCR using the bridging
CC primers given in AA097258-59. ATF mRNAs were expressed in substantia
CC nigra, caudate and putamen brain regions.
XX
XX Sequence 33 BP; 6 A; 16 C; 7 G; 4 T; 0 other;
SO
XX
XX Query Match 69.5%; Score 13.2; DB 16; Length 33;
XX Best Local Similarity 83.3%; Pred. No. 5.1e+03;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1 GGGTCTGCACGCGGATGC 18
XX |||| |
XX Db 28 GGGTCTGCACGCGGAGG 11
XX
XX RESULT 15
XX AAT33615
XX ID AAT33615 standard; cDNA; 38 BP.
XX AC
XX AAT33615;
XX
XX 30-NOV-1996 (first entry)
XX
XX Murine VRF167 mRNA probe.
XX
XX VRF; vascular endothelial growth factor; VEGF; SOM175; neuron;
XX astroglial proliferation; probe; ss.
XX
XX Synthetic.
XX
XX W09627007-A1.
XX
XX 06-SEP-1996.
XX
XX 22-FEB-1996; 96MO-AU00094.
XX
XX 22-DEC-1995; 95AU-0007274.
XX 02-MAR-1995; 95AU-0001457.
XX 20-NOV-1995; 95AU-0006647.
XX

```

PA (AMRA-) AMRAD OPERATIONS PTY LTD.

PI Grimmond S, Hayward NK, Larsson C, Nordenskjöld M;

PI Weber G;

DR WP1; 1996-412774/41.

PT New growth factor related to vascular endothelial growth factor -  
PT useful for inducing astroglial proliferation and promoting neuronal  
PT survival

PS Example 6; Page 27; 113pp; English.

XX  
0120000

CC nucleotides found in the mRNA coding for alternatively spliced  
CC nucleotides found in the mRNA coding for alternatively spliced  
CC nucleotides found in the mRNA coding for alternatively spliced

CC and nervous system. In E17 embryos, and in young adult mice, CC expression was confined to the heart and brown fat tissue.

Sequence 38 BP; 6 A; 5 C; 18 G; 9 T; 0 other;

Query Match	Score	DB	Length
69.58	13.2	17	38

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGGTCTGCAGCGGATGG 18

Db 7 CCGGCTGGAGTGGATGC 24

Completed: November 28 2003 17:34:13

Job time : 177.575 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 16:42:34 ; Search time 1103.97 Seconds

(Without alignments)  
500.879 Million cell updates/sec

Title: US-09-719-737-9

Perfect score: 19

Sequence: 1 gggtcgcagcgagatggt 19

Scoring table:

IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 841850

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl: \*  
1: gb\_ba: \*  
2: gb\_hlg: \*  
3: gb\_in: \*  
4: gb\_om: \*  
5: gb\_ov: \*  
6: gb\_pat: \*  
7: gb\_ph: \*  
8: gb\_pl: \*  
9: gb\_pr: \*  
10: gb\_ro: \*  
11: gb\_sts: \*  
12: gb\_sy: \*  
13: gb\_un: \*  
14: gb\_vl: \*  
15: em\_ba: \*  
16: em\_fun: \*  
17: em\_hum: \*  
18: em\_in: \*  
19: em\_mu: \*  
20: em\_om: \*  
21: em\_or: \*  
22: em\_ov: \*  
23: em\_pat: \*  
24: em\_ph: \*  
25: em\_pl: \*  
26: em\_ro: \*  
27: em\_sts: \*  
28: em\_un: \*  
29: em\_vl: \*  
30: em\_hlg\_hum: \*  
31: em\_hlg\_inv: \*  
32: em\_hlg\_other: \*  
33: em\_hlg\_mus: \*  
34: em\_hlg\_pln: \*  
35: em\_hlg\_rod: \*  
36: em\_hlg\_mam: \*  
37: em\_hlg\_vrt: \*  
38: em\_sy: \*  
39: em\_hlg\_hum: \*  
40: em\_hlg\_mus: \*  
41: em\_hlg\_other: \*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	19	100.0	19	6	AX008655	AX008655 Sequence
2	19	100.0	19	6	AX008656	AX008656 Sequence
3	18	94.7	19	6	AX008657	AX008657 Sequence
4	18	94.7	19	6	AX008658	AX008658 Sequence
5	17	89.5	19	6	AX008662	AX008662 Sequence
6	16	84.2	19	6	AX008659	AX008659 Sequence
C 7	14.2	74.7	34	6	E50113	E50113 DNA fragment
C 8	13.2	69.5	43	6	A04394	A04394 Oligonucleo
9	13.2	69.5	43	6	A04408	A04408 Oligonucleo
10	13	68.4	19	6	AX008660	AX008660 Sequence
11	12.8	67.4	50	6	AX199584	AX199584 Sequence
C 12	12.6	66.3	32	6	AR199663	AR199663 Sequence
C 13	12.6	66.3	33	6	AX058080	AX058080 Sequence
C 14	12.6	66.3	33	6	AX067827	AX067827 Sequence
C 15	12.6	66.3	33	6	AX078782	AX078782 Sequence
C 16	12.6	66.3	38	6	AR006787	AR006787 Sequence
C 17	12.6	66.3	38	6	AR135395	AR135395 Sequence
C 18	12.6	66.3	38	6	AR171299	AR171299 Sequence
C 19	12.6	66.3	41	6	AR096931	AR096931 Sequence
C 20	12.6	66.3	43	6	AR152008	AR152008 Sequence
C 21	12.6	66.3	43	6	AR161408	AR161408 Sequence
C 22	12.6	66.3	44	6	AR033897	AR033897 Sequence
C 23	12.6	66.3	44	6	AR175030	AR175030 Sequence
C 24	12.6	66.3	44	6	AX032462	AX032462 Sequence
C 25	12.6	66.3	44	6	AX057388	AX057388 Sequence
C 26	12.6	66.3	44	6	AX067833	AX067833 Sequence
27	12.4	65.3	20	6	A45408	A45408 Sequence 78
28	12.4	65.3	20	6	AR061213	AR061213 Sequence
29	12.4	65.3	20	6	AR117659	AR117659 Sequence
30	12.4	65.3	21	6	AX096151	AX096151 Sequence
31	12.4	65.3	28	6	I11634	I11634 Sequence 19
32	12.4	65.3	35	9	H00D3E12M5	D17038 Human HepG2
33	12.2	64.2	21	6	AX004671	AX004671 Sequence
34	12.2	64.2	21	6	AX154148	AX154148 Sequence
C 35	12.2	64.2	21	6	AX327343	AX327343 Sequence
C 36	12.2	64.2	25	6	AX393937	AX393937 Sequence
C 37	12.2	64.2	26	6	AX399113	AX399113 Sequence
C 38	12.2	64.2	27	6	A07485	A07485 Nucleotide
C 39	12.2	64.2	31	6	AX249162	AX249162 Sequence
40	12.2	64.2	31	6	E64737	E64737 Method for
41	12.2	64.2	34	6	AR016403	AR016403 Sequence
42	12.2	64.2	34	6	AR019261	AR019261 Sequence
C 43	12.2	64.2	34	6	I49868	I49868 Sequence 54
C 44	12.2	64.2	44	1	ECORC06	K01112 E.coli 23S
45	12.2	64.2	48	6	A07502	A07502 Nucleotide

#### ALIGNMENTS

RESULT 1  
AX008655/C  
LOCUS AX008655  
DEFINITION Sequence 8 from Patent WO966037.  
ACCESSION AX008655  
VERSION AX008655.1 GI:9996179  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct.  
artificial construct.  
REFERENCE  
1 (bases 1 to 19)  
AUTHORS  
Renzi, P.  
TITLE  
Antisense oligonucleotides for treating or preventing atopic  
diseases and neoplastic cell proliferation  
JOURNAL  
Patent: WO 966037-A 8 23-DEC-1999;

RENTI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/db.xref="taxon:32630"  
/note="Sense oligonucleotide for IL-3, IL-5 and GM-CSF"  
BASE COUNT 4 a 10 c 3 g 2 t  
ORIGIN

Query Match 100.0%; Score 19; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGTCTGCAGCGCGATGCT 19  
DB 19 GGGTCTGCAGCGCGATGCT 1

RESULT 2  
AX008656  
LOCUS AX008656 19 bp DNA linear PAT 06-SEP-2000  
DEFINITION Sequence 9 from Patent WO9966037.  
ACCESSION AX008656  
VERSION AX008656.1 GI:9996180  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Renzi, P.  
TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
JOURNAL Patent: WO 9966037-A 9 23-DEC-1999;  
RENTI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/db.xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common subunit of IL-3, IL-5 and GM-CSF human receptor"  
BASE COUNT 2 a 3 c 10 g 4 t  
ORIGIN

Query Match 100.0%; Score 19; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGTCTGCAGCGCGATGCT 19  
DB 1 GGGTCTGCAGCGCGATGCT 19

RESULT 3  
AX008657  
LOCUS AX008657 19 bp DNA linear PAT 06-SEP-2000  
DEFINITION Sequence 10 from Patent WO9966037.  
ACCESSION AX008657  
VERSION AX008657.1 GI:9996181  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Renzi, P.  
TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
JOURNAL Patent: WO 9966037-A 10 23-DEC-1999;  
RENTI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/db.xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common

subunit of IL-3, IL-5 and GM-CSF human receptor"  
BASE COUNT 2 a 3 c 9 g 5 t  
ORIGIN

Query Match 94.7%; Score 18; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 4.1e+02;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 GGTCTGCAGCGCGATGCT 19  
DB 1 GGTCTGCAGCGCGATGCT 18

RESULT 4  
AX008658  
LOCUS AX008658 19 bp DNA linear PAT 06-SEP-2000  
DEFINITION Sequence 11 from Patent WO9966037.  
ACCESSION AX008658  
VERSION AX008658.1 GI:9996182  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Renzi, P.  
TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
JOURNAL Patent: WO 9966037-A 11 23-DEC-1999;  
RENTI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/db.xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common subunit of IL-3, IL-5 and GM-CSF human receptor"  
BASE COUNT 3 a 3 c 10 g 3 t  
ORIGIN

Query Match 94.7%; Score 18; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 4.1e+02;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGTCTGCAGCGCGATGCT 18  
DB 2 GGGTCTGCAGCGCGATGCT 19

RESULT 5  
AX008662  
LOCUS AX008662 19 bp DNA linear PAT 06-SEP-2000  
DEFINITION Sequence 15 from Patent WO9966037.  
ACCESSION AX008662  
VERSION AX008662.1 GI:9996186  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Renzi, P.  
TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
JOURNAL Patent: WO 9966037-A 15 23-DEC-1999;  
RENTI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/db.xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common subunit of IL-3, IL-5 and GM-CSF human receptor"  
BASE COUNT 2 a 3 c 8 g 6 t  
ORIGIN

Query Match 89.5%; Score 17; DB 6; Length 19;



Best Local Similarity 100.0%; Pred. No. 1.3e+03;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GGTCTGCAGCGGATGCT 19  
|||||  
Db 1 GGTCTGCAGCGGATGCT 17

RESULT 6  
AX008659 19 bp DNA linear PAT 06-SEP-2000  
LOCUS Sequence 12 from Patent WO966037.  
ACCESSION AX008659  
VERSION AX008659.1 GI:9996183  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Renzi, P.  
TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
JOURNAL Patent: WO 966037-A 12 23-DEC-1999;  
RENZI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
source 1..19  
location/Qualifiers  
/organism="synthetic construct"  
/db\_xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common subunit of IL-3, IL-5 and GM-CSF human receptor"

BASE COUNT 3 a 4 c 9 g 3 t  
ORIGIN

Query Match 84.2%; Score 16; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 4e+03;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGTCTGCAGCGGAT 16  
|||||  
Db 4 GGTCTGCAGCGGAT 19

RESULT 7  
E50113/c 34 bp DNA linear PAT 31-JAN-2002  
LOCUS E50113  
DEFINITION DNA fragment containing toluene monooxygenase gene, recombinant plasmid, transformed microorganism, process for decomposing halogenated aliphatic hydrocarbon and aromatic compound, and method for repairing environment by using the microorganism.  
ACCESSION E50113  
VERSION E50113.1 GI:18629391  
KEYWORDS JP 2000224994-A/2.  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 34)  
AUTHORS Yano, T., Nomoto, T. and Imanura, T.  
TITLE DNA fragment containing toluene monooxygenase gene, recombinant plasmid, transformed microorganism, process for decomposing halogenated aliphatic hydrocarbon and aromatic compound, and method for repairing environment by using the microorganism  
JOURNAL Patent: JP 2000224994-A 2 15-AUG-2000;  
CANON INC  
COMMENT  
OS Artificial Sequence  
PN JP 2000224994-A/2  
PD 15-AUG-2000  
PF 03-DEC-1999 JP 1999345421  
PR  
PT TETSUYA YANO, TAKESHI NOMOTO, TSUYOSHI IMAMURA  
PC C12N15/09, A62D3/00, B01D53/70, B09C1/10, C02F3/34, C12N1/00, PC C12N1/21,  
PC C12N9/04, C12N1/21, C12R1/19, C12N9/04, C12R1/19, C12N15/00, PC B01D53/34,

PC B09B3/00  
CC  
FT source  
FT Location/Qualifiers  
1..34  
/organism="Artificial Sequence".

FEATURES  
source 1..34  
location/Qualifiers  
/organism="synthetic construct"  
/db\_xref="taxon:32630"

BASE COUNT 8 a 14 c 7 g 5 t  
ORIGIN

Query Match 74.7%; Score 14.2; DB 6; Length 34;  
Best Local Similarity 84.2%; Pred. No. 2.9e+04;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGTCTGCAGCGGATGCT 19  
|||||  
Db 31 GGTCTGCAGCGGATGCT 13

RESULT 8  
A04394 43 bp DNA linear PAT 29-APR-1993  
LOCUS A04394/c  
DEFINITION Oligonucleotide US for porcine growth hormone.  
ACCESSION A04394  
VERSION A04394.1 GI:344897  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 43)  
AUTHORS  
TITLE Location/Qualifiers  
/organism="synthetic construct"  
/db\_xref="taxon:32630"

BASE COUNT 11 a 15 c 13 g 4 t  
ORIGIN

Query Match 69.5%; Score 13.2; DB 6; Length 43;  
Best Local Similarity 83.3%; Pred. No. 9e+04;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 GGTCTGCAGCGGATGCT 19  
|||||  
Db 18 GGTCTGCAGCGGATGCT 1

RESULT 9  
A04408 43 bp DNA linear PAT 29-APR-1993  
LOCUS A04408  
DEFINITION Oligonucleotide L5 for porcine growth hormone.  
ACCESSION A04408  
VERSION A04408.1 GI:344911  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 43)  
AUTHORS  
TITLE Location/Qualifiers  
/organism="synthetic construct"  
/db\_xref="taxon:32630"

BASE COUNT 10 a 10 c 15 g 8 t  
ORIGIN

Query Match 69.5%; Score 13.2; DB 6; Length 43;  
Best Local Similarity 83.3%; Pred. No. 9e+04;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 GGTCTGCAGCGGATGCT 19  
|||||  
Db 8 GGTCTGCAGCGGATGCT 25

RESULT 10  
LOCUS AX008660 19 bp DNA Linear PAT 06-SEP-2000  
DEFINITION Sequence 13 from Patent WO996037.  
ACCESSION AX008660  
VERSION AX008660.1 GI:9996184  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Renzl,P.  
TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
JOURNAL Patent: WO 996037-A 13 23-DEC-1999;  
REMI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
FEATURES  
SOURCE 1..19  
/db\_xref="taxon:32630"  
/note="Antisense oligonucleotide inhibiting the common subunit of IL-3, IL-5 and GM-CSF human receptor"  
BASE COUNT 2 a 4 c 7 g 6 t  
ORIGIN  
Query Match 68.4%; Score 13; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.2e+05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 7 GCAGCGGATGCT 19  
Db 1 GCAGCGGATGCT 13  
RESULT 11  
LOCUS AX199584 50 bp DNA Linear PAT 29-AUG-2001  
DEFINITION Sequence 514 from Patent WO0151670.  
ACCESSION AX199584  
VERSION AX199584.1 GI:15390017  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 50)  
AUTHORS Mammalla; Eutheria; Primates; Catarhhl; Homindae; Homo.  
TITLE Shinkets,R.A. and Leach,M.D.  
JOURNAL Nucleic acids containing single nucleotide polymorphisms and methods of use thereof  
Patent: WO 0151670-A 514 19-JUL-2001;  
Curagen Corporation (US)  
FEATURES  
SOURCE 1..50  
Location/Qualifiers  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
misc\_feature 25..26  
/note="Nucleotide deleted between bases 25 and 26  
Accession number c943951144"  
misc\_feature 26  
/note="2 of 2 allelic variants (513 is other entry)"  
BASE COUNT 11 a 17 c 12 g 10 t  
ORIGIN  
Query Match 67.4%; Score 12.8; DB 6; Length 50;  
Best Local Similarity 87.5%; Pred. No. 1.4e+05;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 GGGTCTGACGCGGAT 16  
Db 8 GGGTCTGACGCGGAT 23  
RESULT 12  
.

AR199663/C  
LOCUS AR199663 32 bp DNA Linear PAT 20-APR-2002  
DEFINITION Sequence 5 from patent US 6355479.  
ACCESSION AR199663  
VERSION AR199663.1 GI:20249737  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 32)  
AUTHORS Webb,S.R., Wingvist,O., Karlsson,L., Jackson,M.R. and Peterson,P.A.  
TITLE MHC class II antigen-presenting systems and methods for activating CD4+ T cells  
JOURNAL Patent: US 6355479-A 5 12-MAR-2002;  
FEATURES  
SOURCE 1..32  
Location/Qualifiers  
/organism="unknown"  
BASE COUNT 7 a 12 c 5 g 8 t  
ORIGIN  
Query Match 66.3%; Score 12.6; DB 6; Length 32;  
Best Local Similarity 78.9%; Pred. No. 1.8e+05;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1 GGGTCTGACGCGGATGCT 19  
Db 29 GGGTCTGACGCGGATGCT 11  
RESULT 13  
LOCUS AX058080 33 bp DNA Linear PAT 17-JAN-2001  
DEFINITION Sequence 9 from Patent WO0077188.  
ACCESSION AX058080  
VERSION AX058080.1 GI:12310660  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 33)  
AUTHORS Audonnet,J.C., Bublolt,M., Perez,J.M. and Charreyre,C.E.  
TITLE Dna pcv vaccine  
JOURNAL Patent: WO 0077188-A 9 21-DEC-2000;  
Merial (FR)  
FEATURES  
SOURCE 1..33  
Location/Qualifiers  
/organism="synthetic construct"  
/db\_xref="taxon:32630"  
/note="oligonucleotide"  
BASE COUNT 6 a 11 c 10 g 6 t  
ORIGIN  
Query Match 66.3%; Score 12.6; DB 6; Length 33;  
Best Local Similarity 78.9%; Pred. No. 1.8e+05;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1 GGGTCTGACGCGGATGCT 19  
Db 31 GGGTCTGACGCGGATGCT 13  
RESULT 14  
LOCUS AX067827 33 bp DNA Linear PAT 19-JAN-2001  
DEFINITION Sequence 64 from Patent WO0077043.  
ACCESSION AX067827  
VERSION AX067827.1 GI:12329705  
KEYWORDS  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 33)  
AUTHORS Fischer,L.J., Barzu-le Roux,S. and Audonnet,J.C.

**TITLE** Dna vaccines for pets and sport animals  
**JOURNAL** Patent: WO 0077043-A 64 21-DEC-2000;

MATERIAL (FR)

FEATURES	Location/Qualifiers
source	1. .33

33.

```
/organism="synthetic construct"
/db_xref="taxon:32630"
```

```
/db_xref="taxon:32630"
/note="oligonuclotide"
```

```

/note="oligonucl otide"
11 c 10 q 6 t

```

BASE COUNT	6 a	11 c	10 g	6 t
ORIGIN				

ORIGIN

Query Match	66.38;	Score 12.6;	DB 6;	Length 33;
Best [local] similarity	79.08;	Pred vs 1 dev		

2003 Local Similarity	10.56	PreU. NO. 1.08e+03							
Matches	15	Conservative	0	Mismatches	4	Indels	0	Gaps	0

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GGGTCTGCAGCCGGATGCT 19

**Dh**

31. **AGTTCCTACCAATCCT** 13

RESULT 15

AX078782/  
LOCUS

LOCUS	AX078782	33 bp	DNA	Linear	PAT 22-FEB-2001
DEFINITION	Sequence 30 from Patent WO0105074				

DEFINITION	Sequence 20 from patent WO0105934.
ACCESSION	AX078782

[illegible]

VERSION MAY 06/04.1 Q1:13130393  
KEYWORDS .

SOURCE	synthetic construct.
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1 (bases 1 to 33)  
AUTHORS Audonnet J C, Baudu

AUTHORS	TITLE
Audonnet, J.C., Baudu, P.G. and Brunet, S.C.	Feline calicivirus genes and vaccines

# Title Feline calicivirus genes and vaccines, in particular recombinant vaccines

Vaccines  
JOURNAL Patent: WO 0105934-A 20 25-JAN-2001;

MATERIAL (FR)

### FEATURES

Location/Qualifiers

source	1. .33
--------	--------

```
/organism="synthetic construct"  
/db_xref="taxon:32620"
```

```
/db_xref="taxon:32630"
/note="ojia nucleotide"
```

BASE COUNT		/note="oligonucleotide"
6 a	10 g	
11 c		

ORIGIN	11 C	10 g	6 f
ENCL COMM	0 a		

1

Query Match	Score	DB	Length
66.38	12.6	6	33

Best Local Similarity 78.98; Pred. No. 1.8e+05;  
Matches 15; Corresponding 0

Matches	15;	Conservative	0;	Mismatches	4;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

GGGTCTGCAGCGGATGCT 19

1 GGGTCTGACCGGGATGGT 19

Search completed: November 28, 2002, 18:20:38  
Job time : 1105.97 secs

Job time : 1105.97 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:10:34 : Search time 1372.59 Seconds

(without alignments)  
224.186 Million cell updates/sec

Title: US-09-719-737-18

Sequence: 1 ctggcgcacatgcagctctg 19

Scoring table: IDENTITY-NUC

Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 102860

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST: \*  
1: em\_estba: \*  
2: em\_esthum: \*  
3: em\_estlin: \*  
4: em\_estnu: \*  
5: em\_estov: \*  
6: em\_estpl: \*  
7: em\_estro: \*  
8: em\_hlc: \*  
9: gb\_est1: \*  
10: gb\_est2: \*  
11: gb\_hlc: \*  
12: gb\_est3: \*  
13: gb\_est4: \*  
14: gb\_est5: \*  
15: em\_estfun: \*  
16: em\_estcom: \*  
17: gb\_gss: \*  
18: em\_gss\_hum: \*  
19: em\_gss\_inv: \*  
20: em\_gss\_pln: \*  
21: em\_gss\_vrt: \*  
22: em\_gss\_fun: \*  
23: em\_gss\_mam: \*  
24: em\_gss\_mus: \*  
25: em\_gss\_other: \*  
26: em\_gss\_pro: \*  
27: em\_gss\_rod: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	12.4	65.3	38	17	AZ834919
2	12.2	64.2	29	17	TA59R050
3	12	63.2	31	12	BF181705
4	12	63.2	38	17	BH792093
5	12	63.2	49	17	AZ472469
6	11.8	62.1	35	13	BJ084423

C	7	11.8	62.1	36	17	AL762128
	8	11.8	62.1	37	17	AZ384612
	9	11.8	62.1	44	17	BH000259
C	10	11.8	62.1	45	17	AZ309922
	11	11.8	62.1	48	17	BH791856
	12	11.6	61.1	33	17	AZ391565
	13	11.6	61.1	35	12	BF793800
	14	11.6	61.1	40	17	AZ807388
	15	11.6	61.1	41	17	AZ774224
C	16	11.4	60.0	39	17	AZ829271
	17	11.4	60.0	41	17	AZ437628
	18	11.4	60.0	44	10	AV843723
	19	11.4	60.0	48	17	AZ602280
	20	11.2	58.9	31	9	AA181661
	21	11.2	58.9	31	13	BI154945
	22	11.2	58.9	33	13	BI103577
	23	11.2	58.9	34	9	AA109657
	24	11.2	58.9	49	9	AA691710
	25	11	57.9	25	17	AZ648037
	26	11	57.9	30	17	AZ949156
	27	11	57.9	32	10	AV834034
	28	11	57.9	32	10	AV956830
	29	11	57.9	32	17	AZ441593
	30	11	57.9	32	17	AZ600248
	31	11	57.9	32	17	AZ816444
	32	11	57.9	34	17	AZ482003
C	33	11	57.9	35	17	AZ581423
	34	11	57.9	35	17	AZ860292
	35	11	57.9	35	17	BH128269
C	36	11	57.9	43	9	A1496922
	37	11	57.9	43	17	AZ834960
	38	11	57.9	44	13	BJ033250
	39	11	57.9	44	17	AZ662473
C	40	11	57.9	45	17	AZ839967
	41	11	57.9	46	9	AA652871
	42	11	57.9	47	17	AZ481505
	43	11	57.9	49	9	A1744224
C	44	11	57.9	50	9	AU102583
	45	11	57.9	50	9	AU105201

## ALIGNMENTS

RESULT 1  
AZ834919/c 38 bp DNA linear GSS 20-FEB-2001  
LOCUS 2M0117D21R Mouse 10kb plasmid UGCM library Mus musculus genomic  
DEFINITION AZ834919  
ACCESSION AZ834919  
VERSION AZ834919.1 GI:13004827  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausen,A. and Wright,D., Weiss,R.  
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss.  
University of Utah Genome Center  
University of Utah  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT 84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00

Plate: 0117 row: D column: 21  
 Seq primer: CACACAGCAACACGCTATCACC  
 Class: plasmid ends  
 High quality sequence stop: 38.  
 Location/Qualifiers

## FEATURES

source

1..38  
 /organism="Mus musculus"  
 /strain="C57BL/6J"  
 /db\_xref="taxon:10090"  
 /clone="U062M0117D21"  
 /clone\_11b="Mouse 10kb plasmid U062M117D21"  
 /sex="Male"  
 /lab\_host="E. coli strain XL10-Gold, T1-resistant, F-"  
 /note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gll473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

## BASE COUNT

15 a 10 c 7 g 6 t

## ORIGIN

Query Match 65.3%; Score 12.4; DB 17; Length 38;  
 Best Local Similarity 92.9%; Pred. No. 4e+04;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2 TCGGCCATCAGTCG 15  
 ||||| ||||| |||||  
 Db 30 TCGCTCATCAGTCG 17

## RESULT 2

TA59B05Q

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

## COMMENT

1 (bases 1 to 29)  
 Hall, N., Bowman, S., Leonard, N.J., Doggett, J., Atkin, R.,  
 Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,  
 Melville, S.E., Rajandream, M.A. and Barrell, B.G.  
 Direct Submission  
 Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing  
 project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,  
 Cambridgeshire CB10 1SA. E-mail: barrell@sanger.ac.uk and  
 nh1@sanger.ac.uk  
 Constructed at the Institute for Genomic Research (TIGR),  
 Rockville, MD. Genomic DNA isolated from a cloned population of  
 Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared  
 to give a tight size distribution (4 kb). The v + i method used for the library construction is  
 described in detail in Smith, H. and Venter, J.C. (Making small  
 insert libraries for whole genome shotgun sequencing projects. In  
 Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.

Barrell, Oxford University Press, 1999).  
 Email: nh1@sanger.ac.uk  
 Details of T. brucei sequencing at the Sanger Centre are available  
 at http://www.sanger.ac.uk/Projects/T\_brucei/.

## FEATURES

source

1..29  
 /organism="Trypanosoma brucei"  
 /strain="TREU927"  
 /db\_xref="taxon:5691"  
 /clone="59B05"  
 /clone\_11b="Mouse 10kb plasmid U062M117D21"

## BASE COUNT

5 a 11 c 6 g 7 t

## ORIGIN

Query Match 64.2%; Score 12.2; DB 17; Length 29;  
 Best Local Similarity 82.4%; Pred. No. 4.3e+04;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1 CTGGCCATCAGTCG 17  
 ||||| ||||| |||||  
 Db 13 CTGGCTCATCAGTCG 29

## RESULT 3

BF181705

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BF181705 31 bp mRNA EST 31-OCT-2000  
 601805518F1 NCI\_GAP\_Mam5 Mus musculus cDNA clone IMAGE:4036180 5',  
 mRNA sequence.  
 BF181705  
 BF181705.1 GI:11059647  
 EST.  
 house mouse.  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 31)  
 NIH-MGC http://mgc.nci.nih.gov/  
 National Institutes of Health, Mammalian Gene Collection (MGC)  
 Unpublished (1999)  
 Contact: Robert Strausberg, Ph.D.  
 Email: cgapbs-remail.nih.gov  
 Tissue Procurement: Lothar Hennighausen Ph.D., Robin Humphreys  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LLAM9311 row: d column: 05  
 High quality sequence stop: 31.  
 Location/Qualifiers

## FEATURES

source

1..31  
 /organism="Mus musculus"  
 /strain="C57BL/6J"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:4036180"  
 /clone\_11b="NCI\_GAP\_Mam5"  
 /tissue\_type="tumor, gross tissue"  
 /dev\_stage="7 months"  
 /lab\_host="DH10B"  
 /note="Organ: mammary; Vector: pCMV-SPORT6; Site: 1; Salt:  
 site\_2: NotI; Cloned unidirectionally. Primer: Oligo dT.  
 Library constructed by Life Technologies. Investigators  
 providing samples: Lothar Hennighausen/Robin Humphreys,  
 NIH"

## BASE COUNT

5 a 10 c 10 g 6 t

## ORIGIN

Query Match 63.2%; Score 12; DB 12; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 5.5e+04;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CTGGCCATCAG 12  
 ||||| ||||| |||||

Db 3 CTGGCCATCAG 14

RESULT 4  
BH792093/c  
LOCUS  
DEFINITION

BH792093 38 bp DNA linear GSS 02-APR-2002  
SALK\_062674.45.30.x Arabidopsis thaliana TDNA insertion lines  
Arabidopsis thaliana genomic clone SALK\_062674.45.30.x DNA  
sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BH792093 GI:19888485  
GSS.  
thale cress.  
Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
Rosidae; eustosids II; Brassicales; Brassicaceae; Arabidops.  
1 (bases 1 to 38)  
Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadlinab  
, C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednits,L., Shinn,P.,  
, Zimmerman,J. and Ecker,J.R.  
A Sequence-indexed Library of Insertion Mutations in the  
Arabidopsis Genome  
Unpublished (2001)  
Contact: Joseph R. Ecker  
Salk Institute Genomic Analysis Laboratory (SIGAL)  
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
Tel: 858 453 4100 x1752  
Fax: 858 558 6379  
Email: ecker@salk.edu  
This is single pass sequence recovered from the left border of  
TDNA. This sequence lies within an annotated exon of At5g05390.  
Class: TDNA tagged.

FEATURES  
source  
Location/Qualifiers  
1..38  
/organism="Arabidopsis thaliana"  
/strain="Columbia 0"  
/db\_xref="taxon:3702"  
/clone="SALK\_062674.45.30.x"  
/clone\_lib="Arabidopsis thaliana TDNA insertion lines"  
/note="PCR was performed on Arabidopsis thaliana lines  
each of which contains one or more TDNA insertion  
elements. The resultant fragment for each line was  
directly sequenced to determine the genomic sequence at  
the site of insertion. Details of the protocols used can  
be found at [http://signal.salk.edu/tdna\\_protocols.html](http://signal.salk.edu/tdna_protocols.html)"

BASE COUNT 12 a 7 c 13 g 6 t

ORIGIN

Query Match 63.2%; Score 12; DB 17; Length 38;  
Best Local Similarity 100.0%; Pred. No. 6.2e+04;  
Matches 12: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTGGCCATCAG 12  
|||||  
Db 34 CTGGCCATCAG 23

RESULT 5  
A2472469  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

A2472469 49 bp DNA linear GSS 04-OCT-2000  
clone UUGC1M0287P09 R, DNA sequence.  
A2472469  
A2472469.1 GI:10630594  
GSS.  
house mouse.  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 49)  
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,

Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly  
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.  
and Wright,D., Weiss,R.  
Mouse whole genome scaffolding with paired end reads from 10kb  
Plasmid inserts  
Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center  
University of Utah  
Rm 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT  
84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0287 row: P column: 09  
Seq primer: CACACGACAAACACCATCACC  
Class: plasmid ends  
High quality sequence stop: 49.

FEATURES  
source  
Location/Qualifiers  
1..49  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUGC1M0287P09"  
/clone\_lib="Mouse 10kb plasmid UUGC1M library"  
/sex="Male"  
/lab\_host="E. coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: PWD42nv; Purified genomic DNA from M.  
musculus C57BL/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(<http://www.jax.org/resources/documents/dnares/>). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adaptor DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of PWD42 (9114732114|9b|AF129072.1), a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adaptor mouse DNA was annealed to  
adaptor vector DNA, and transformed into  
chemically-competent E. coli XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."

BASE COUNT 10 a 11 c 15 g 13 t

ORIGIN

Query Match 63.2%; Score 12; DB 17; Length 49;  
Best Local Similarity 100.0%; Pred. No. 7.1e+04;  
Matches 12: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GGGCCATCAGTG 14  
|||||  
Db 29 GGGCCATCAGTG 40

RESULT 6  
BJ084423/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BJ084423 35 bp mRNA linear EST 12-DEC-2001  
BJ084423 NIBB Mochil normalized Xenopus tailbud library  
laevis cDNA clone XL089C18 3', mRNA sequence.  
BJ084423  
BJ084423.1 GI:17579964  
EST.  
African clawed frog.  
Xenopus laevis  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Amphibia; Batrachia; Anura; Mesobatrachia; Pipridae; Pipridae;  
Xenopodinae; Xenopus.  
1 (bases 1 to 35)

FEATURES	Source	Accession	Score	DB	Length	Gap
AUTHORS	Kilayama, A., Teresaka, C., Mochi, M., Ueno, N., Shin-I, T. and Kohara Y.					
TITLE	Expressed genes in <i>X. laevis</i> embryo					
JOURNAL	Unpublished (2001)					
COMMENT	Contact: Tadashi Shin-I Center for Genetic Resource Information National Institute of Genetics 1111 Yata, Mishima, Shizuoka 411-8540, Japan Tel: 81-559-81-6856 Fax: 81-559-81-6855 Email: tsuhin@genes.nig.ac.jp. Location/Qualifiers					
FEATURES	Source	Accession	Score <td>DB <td>Length <td>Gap</td> </td></td>	DB <td>Length <td>Gap</td> </td>	Length <td>Gap</td>	Gap
1. .35	/organism="Xenopus laevis"					
/db_xref="taxon:8355"						
/clone="XL089c18"						
/clone_lib="NIBB Mochi normalized Xenopus tailbud library"						
/library_type="whole embryo"						
/dev_stage="stage 25"						
/note="Vector: pBSRN3; Site_1: NotI; Site_2: EcoRI; cDNAs were oligo-dT primed and directionally cloned. Staging according to Newkirk and Faber. Library is subtracted and was constructed by N. Garrett and A.M. Zorn, (Wellcome/CRC Institute)."						
BASE COUNT	9 a 6 c 9 g 10 t 1 others					
ORIGIN						
Query March	62.1%; Score 11.8; DB 13; Length 35;					
Best Local Similarity	86.7%; Pred. No. 7.3e+04;					
Matches 13; Conservative	0; Mismatches 2; Indels 0; Gaps 0;					
Qy 4	GGCCATCACTGCTCT 18					
db 29	GGCCATCAAGACTCT 15					
RESULT 7						
AL762128/c	36 bp DNA linear GSS 18-JUN-2002					
LOCUS	Arabidopsis thaliana T-DNA flanking sequence GK-021B05-013692,					
DEFINITION	genomic survey sequence.					
ACCESSION	AL762128					
VERSION	AL762128.1 GI:21506683					
KEYWORDS	GSS.					
SOURCE	thale cress.					
ORGANISM	Arabidopsis thaliana					
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;					
AUTHORS	Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;					
	Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.					
1	Strizhov, N., Li, Y., Rosso, M., Viehoever, P., Dekker, K., Suedler, H.					
	and Weisshaar, B.					
TITLE	A pipeline for automated high-throughput generation of ESTs					
	(flanking sequence tags) from Arabidopsis thaliana T-DNA					
	transformed lines					
	Unpublished					
2	Rosso, M., Strizhov, N., Li, Y., Reiss, B., Dekker, K. and Weisshaar, B.					
	A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)					
	for flanking sequence tag based reverse genetics					
	Unpublished					
	3 (bases 1 to 36)					
	Rosso, M., Li, Y., Strizhov, N. and Weisshaar, B.					
JOURNAL	Direct Submission					
REFERENCE	Submitted (17-JUN-2002) Weisshaar B., Max-Planck-Institut fuer					
AUTHORS	Zuechtungs-forschung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany					
TITLE	This sequence is recovered from the left border of the T-DNA. It					
	indicates an insertion within the locus defined by clone 1567. The					
	sequences are generated at the MPI for Plant Breeding Research in					
	the context of the GABI-Kat project. GABI-Kat is part of the German					
	Plant Genomics program designated 'GABI'. Information on line					
	availability can be found at:					
COMMENT						

http://www.mpiz-koeln.mpg.de/GABI-Kat/.

Location/Qualifiers

1. .36

/organism="Arabidopsis thaliana"

/strain="Columbia 0"

/db\_xref="taxon:3702"

/clone="GK-021B05-013692"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/note="PCR was performed on DNA from Arabidopsis thaliana plants (T1) which were transformed with the T-DNA from vector pAC106. The lines contain one or more T-DNA insertions. The DNA fragment(s) resulting from the PCR were directly sequenced to determine the genomic sequence flanking the insertion. Sequences displaying significant similarity to the A. thaliana nuclear genome sequence were processed for submission. T-DNA derived sequences were removed"

BASE COUNT 7 a 13 c 7 g 9 t

ORIGIN

Query Match 62.1%; Score 11.8; DB 17; Length 36;

Best Local Similarity 86.7%; Pred. NO. 7.5e+04;

Matches 13: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 TGGCCATCAGTGGCT 16

1111 111111111

Db 31 TGGGGATTCAGTGGCT 17

RESULT 8

AZ384612 37 bp DNA linear GSS 02-OCT-2000

LOCUS 1M0142008R Mouse 10kb plasmid UUCG1M library Mus musculus genomic

DEFINITION clone UUCG1M0142008 R, DNA sequence.

ACCESSION AZ384612

VERSION

KEYWORDS

SOURCE GSS.

ORGANISM house mouse.

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 37)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0142 row: 0 column: 08

Seq primer: CACACAGCAACAGCATGACC

Class: plasmid ends

High quality sequence stop: 37.

Location/Qualifiers

1. .37

/organism="Mus musculus"

/strain="C57BL/6J"

/db\_xref="taxon:10090"

/clone="UUCG1M0142008"

/clone\_lib="Mouse 10kb plasmid UUCG1M library"

/sex="Male"

/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PMD42inv. Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson



Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g1147321149b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT  
ORIGIN  
4 a 10 c 14 g 9 t

Query Match 62.1%; Score 11.8; DB 17; Length 37;  
Best Local Similarity 86.7%; Pred. No. 7.6e+04;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGCCATCAGTCG 15  
||||| ||| |||  
Db 12 CTGGCCCTCATTGC 26

RESULT 9  
BH000259 44 bp DNA linear GSS 27-APR-2001  
LOCUS 2M0288A03F Mouse 10kb plasmid UUGC2M library Mus musculus genomic  
DEFINITION clone UUGC2M0288A03 F, DNA sequence.  
ACCESSION BH000259  
VERSION BH000259.1 GI:13871485  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 44)  
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weiss,R.  
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss  
University of Utah Genome Center  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0288 Row: A Column: 03  
Seq primer: CGTGTAAACGACGCGCCAGT  
Class: plasmid ends  
High quality sequence stop: 44.  
Location/Qualifiers  
1..44  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUGC2M0288A03"  
/clone\_11b="Mouse 10kb plasmid UUGC2M library"  
/sex="Female"  
/lab\_host="E. coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: pMD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson

Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g1147321149b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT  
ORIGIN  
14 a 8 c 10 g 12 t

Query Match 62.1%; Score 11.8; DB 17; Length 44;  
Best Local Similarity 86.7%; Pred. No. 8.3e+04;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5 GCCATCAGTCCTCTG 19  
|| ||| ||| ||| |||  
Db 22 GCTATCAATGCTCTG 36

RESULT 10  
AZ309922/c 45 bp DNA linear GSS 29-SEP-2000  
LOCUS IM0017C23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic  
DEFINITION clone UUGC1M0017C23 F, DNA sequence.  
ACCESSION AZ309922  
VERSION AZ309922.1 GI:10351397  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 45)  
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weiss,R.  
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss  
University of Utah Genome Center  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0017 Row: C Column: 23  
Seq primer: CGTGTAAACGACGCGCCAGT  
Class: plasmid ends  
High quality sequence stop: 45.  
Location/Qualifiers  
1..45  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUGC1M0017C23"  
/clone\_11b="Mouse 10kb plasmid UUGC1M library"  
/sex="Male"  
/lab\_host="E. coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: pMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource  
(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 19 a 14 c 3 g 9 t

ORIGIN

Query Match 62.1%; Score 11.8; DB 17; Length 45;  
Best Local Similarity 86.7%; Pred. No. 8.4e+04;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 TGGCCATCAGTCT 16  
|||||  
Db 28 TGGCCATCAGTCTT 14

RESULT 11 48 bp DNA linear GSS 02-APR-2002  
BH791856 SALK\_061836.50.60.x Arabidopsis thaliana TDNA insertion lines  
LOCUS  
DEFINITION Arabidopsis thaliana genomic clone SALK\_061836.50.60.x, DNA  
sequence.

ACCESSION BH791856 GI:19886151  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

thale cress.  
Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicot;  
Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
1 (bases 1 to 48)  
Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadgilab,  
C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.,  
Zimmerman,J. and Ecker,J.R.

TITLE A Sequence-Indexed Library of Insertion Mutations in the  
Arabidopsis Genome  
JOURNAL  
COMMENT Unpublished (2001)  
Contact: Joseph R. Ecker  
The Salk Institute for Biological Studies  
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
Tel: 858 453 4100 x1752  
Fax: 858 558 6379  
Email: ecker@salk.edu

This is single pass sequence recovered from the left border of  
TDNA. This sequence lies within an annotated exon of A5g14310.  
Class: TDNA tagged.

FEATURES  
source

1. 48  
/organism="Arabidopsis thaliana"  
/strain="Columbia 0"  
/db\_xref="taxon:3702"  
/clone="SALK\_061836.50.60.x"  
/note="PCR was performed on Arabidopsis thaliana lines  
each of which contains one or more TDNA insertion  
elements. The resultant fragment for each line was  
directly sequenced to determine the genomic sequence at  
the site of insertion. Details of the protocols used can  
be found at [http://signal.salk.edu/tdna\\_protocols.html](http://signal.salk.edu/tdna_protocols.html)"

BASE COUNT 15 a 9 c 12 g 12 t

ORIGIN

Query Match 62.1%; Score 11.8; DB 17; Length 48;  
Best Local Similarity 86.7%; Pred. No. 8.7e+04;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 4 GGCATCAGTCTCT 18  
|||||  
Db 18 GGCATCAGTCTCT 4

RESULT 12 33 bp DNA linear GSS 03-OCT-2000  
A2391565  
LOCUS  
DEFINITION 1M0153F16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic  
clone UUGC1M0153F16 R, DNA sequence.

ACCESSION A2391565 GI:10506608  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

house mouse.  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 33)  
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,  
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,  
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.  
and Wright,D., Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb  
plasmid inserts  
Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center  
University of Utah  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT  
84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert length: 1000 Std Error: 0.00  
Plate: 0153 row: F column: 16  
Seq primer: CACACGAGAACGCTATCACC  
Class: Plasmid ends  
High quality sequence stop: 33.

FEATURES  
source

1. 33  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUGC1M0153F16"  
/clone\_lib="mouse 10kb plasmid UUGC1M library"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: pMD42nv. Purified genomic DNA from M.  
musculus C57BL/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(<http://www.jax.org/resources/documents/dnares/>). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adaptor DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of pMD42 (g11473211419b1AF129072.1), a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adaptor mouse DNA was annealed to  
adaptor vector DNA, and transformed into  
chemically-competent *E. coli* XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."

BASE COUNT 5 a 8 c 7 g 13 t  
ORIGIN  
Query Match 61.1%; Score 11.6; DB 17; Length 33;  
Best Local Similarity 77.8%; Pred. No. 8.8e+04;  
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 2 TGGGCGCATCAGTCTGTG 19  
|||||  
Db 12 TGGGACATCATCTCTTTG 29

RESULT 13  
LOCUS BF793800 35 bp mRNA linear EST 12-JAN-2001  
DEFINITION 602254477F1 NIH\_MGC\_84 Homo sapiens CDNA clone IMAGE:4346610 5',  
mRNA sequence.  
ACCESSION BF793800  
VERSION BF793800.1 GI:12098863  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 35)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgaabs-remail.nih.gov  
Tissue Procurement: ATCC  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LRAM9968 row: j column: 19  
High quality sequence stop: 35.  
Location/Qualifiers  
1..35  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_image="4346610"  
/clone\_lib="NIH\_MGC\_84"  
/tissue\_type="adrenal cortex carcinoma, cell line"  
/lab\_host="DH10B (phage-resistant)"  
/note="Organ: adrenal gland; Vector: PCMV-SPORT6; Site: 1;  
NotI; Site: 2; SalI; Cloned unidirectionally; oligo-dr  
primed. Average insert size 1.229 kb. Library enriched for  
full-length clones and constructed by Life Technologies.  
Note: this is a NIH-MGC Library."  
BASE COUNT 3 a 15 c 8 g 9 t  
ORIGIN

Query Match 61.1%; Score 11.6; DB 12; Length 35;  
Best Local Similarity 77.8%; Pred. No. 9.1e+04;  
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CTGGGCCATCAGTCTCT 18  
|||||  
Db 16 CTGGGCCACCATAGCCCT 33

RESULT 14  
LOCUS A2807388 40 bp DNA linear GSS 20-FEB-2001  
DEFINITION 2M0070010F Mouse 10kb plasmid UUCG1M library Mus musculus genomic  
clone UUCG2M0070010 F, DNA sequence.  
ACCESSION A2807388  
VERSION A2807388.1 GI:12971685  
KEYWORDS GSS.  
SOURCE house mouse.

ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 40)  
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamll,C.,  
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,  
M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausen,A.,  
and Wright,D., Weiss,R.  
Mouse whole genome scaffolding with paired end reads from 10kb  
plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss  
University of Utah Genome Center  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT  
84112 USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert length: 10000 Std Error: 0.00  
Plate: 0070 row: 0 column: 10  
Seq primer: CGTTGTAACGACGCCAGT  
Class: plasmid ends  
High quality sequence stop: 40.  
Location/Qualifiers  
1..40  
/organism="Mus musculus"  
/strain="C57Bl/6J"  
/db\_xref="taxon:10090"  
/clone\_image="2M0070010"  
/clone\_lib="Mouse 10kb plasmid UUCG1M library"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, Tl-resistant, F-"  
/note="Vector: PMD42nv; Purified genomic DNA from M.  
musculus C57Bl/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and r4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adapted DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of pMD42 (9114732114|9b|AF129072.1) a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adapted mouse DNA was annealed to  
adapted vector DNA, and transformed into  
chemically-competent E. coli XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."  
BASE COUNT 6 a 6 c 17 g 11 t  
ORIGIN

Query Match 61.1%; Score 11.6; DB 17; Length 40;  
Best Local Similarity 77.8%; Pred. No. 9.8e+04;  
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CTGGGCCATCAGTCTCT 18  
|||||  
Db 13 CTGGGCCATCAGTCTTTT 30

RESULT 15  
LOCUS A2774224 41 bp DNA linear GSS 16-FEB-2001  
DEFINITION 2M0003E19F Mouse 10kb plasmid UUCG1M library Mus musculus genomic  
clone UUCG2M0003E19 F, DNA sequence.  
ACCESSION A2774224  
VERSION A2774224.1 GI:12899427  
KEYWORDS GSS.  
SOURCE house mouse.

ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 41)  
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,  
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Relliy  
 ,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.  
 and Wright,D., Weiss,R.  
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb  
 plasmid inserts  
 JOURNAL Unpublished (2000)  
 COMMENT Contact: Robert B. Weiss  
 University of Utah Genome Center  
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
 84112, USA  
 Tel: 801 585 5606  
 Fax: 801 585 7177  
 Email: ddunn@genetics.utah.edu  
 Insert length: 10000 Std Error: 0.00  
 Plate: 0003 row: E column: 19  
 Seq primer: CATTGTAAACGACGCGCAGT  
 Class: Plasmid ends  
 High quality sequence stop: 41.  
 Location/Qualifiers  
 1..41  
 /organism="Mus musculus"  
 /strain="C57Bl/6J"  
 /db\_xref="taxon:10090"  
 /clone="UUCG2M0003E19"  
 /clone\_lib="Mouse 10kb plasmid UUCG1M library"  
 /sex="Male"  
 /lab\_host="E. coli strain XL10-Gold, T1-resistant, F-"  
 /note="Vector: pMD2uv; Purified genomic DNA from M.  
 musculus C57Bl/6J (male) was obtained from the Jackson  
 Laboratory Mouse DNA Resource  
 (http://www.jax.org/resources/documents/dnares/). The DNA  
 was hydrodynamically sheared by repeated passage through a  
 0.005 inch orifice at constant velocity. The sheared DNA  
 was blunt end-repaired with T4 DNA polymerase and T4  
 polynucleotide kinase. Adaptor oligonucleotides were  
 ligated to the blunt ends in high molar excess. The  
 adaptor DNA was purified and size-selected for a 9.5 to  
 10.5 kb range using preparative agarose gel  
 electrophoresis. Vector DNA was prepared from a derivative  
 of pMD2 (gll4732114|gb|AF129072.1), a copy-number  
 inducible derivative of plasmid R1. The vector was ligated  
 with adaptors complementary to the insert adaptors and  
 purified. The sheared, adaptor mouse DNA was annealed to  
 adaptor vector DNA, and transformed into  
 chemically-competent E. coli XL10-Gold (Stratagene) cells  
 and selected for ampicillin resistance."

BASE COUNT 6 a 9 c 11 g 15 t  
 ORIGIN

Query Match 61.1%; Score 11.6; DB 17; Length 41;  
 Best Local Similarity 77.8%; Pred. No. 9.9e+04;  
 Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 CTGGCCATCAGTCTCT 18  
 ||| ||||| |||||  
 DB 16 CTTCAGCATCAGTCTCT 33

Search completed: November 28, 2002, 19:30:47  
 Job time : 1375.59 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:15:39 : Search time 39.9655 Seconds

(without alignments)  
183.088 Million cell updates/sec

Title: US-09-719-737-18

Perfect score: 19

Sequence: 1 ctgggcacatcagtcctctg 19

Scoring table: IDENTITY\_NUC

Gapop 10.0, Gapext 1.0

Searched: 341543 seqs, 192557720 residues

Total number of hits satisfying chosen parameters: 177872

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :  
1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgn2\_6/ptodata/1/pubpna/PCV\_NEW\_PUB.seq:\*  
3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgn2\_6/ptodata/1/pubpna/PCVUS\_PUBCOMB.seq:\*  
7: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*  
10: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*  
11: /cgn2\_6/ptodata/1/pubpna/US10\_NEW\_PUB.seq:\*  
12: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*  
13: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*  
14: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	13	68.4	36	10	US-09-504-231A-1780
C 2	13	68.4	36	10	US-09-274-553D-1780
C 3	12.8	67.4	17	10	US-09-866-108-6582
C 4	12.8	67.4	17	10	US-09-866-108-6583
C 5	12.8	67.4	25	10	US-09-795-232-4
C 6	12.8	67.4	25	10	US-09-866-108-11474
C 7	12.8	67.4	25	10	US-09-866-108-11475
C 8	12.8	67.4	25	10	US-09-866-108-11476
C 9	12.8	67.4	25	10	US-09-866-108-11477
C 10	12.8	67.4	25	10	US-09-866-108-11478
C 11	12.8	67.4	25	10	US-09-866-108-11479
C 12	12.8	67.4	25	10	US-09-866-108-11480
C 13	12.8	67.4	25	10	US-09-866-108-11481
C 14	12.8	67.4	25	10	US-09-866-108-11482
C 15	12.8	67.4	25	10	US-09-866-108-11483
C 16	12.6	66.3	43	10	US-09-766-378A-2
C 17	12.6	66.3	44	10	US-09-848-164-40
C 18	12.4	65.3	17	9	US-09-872-462-249
C 19	12.4	65.3	17	9	US-09-872-462-250

20	12.4	65.3	17	9	US-09-872-462-251	Sequence 251, App
21	12.4	65.3	17	9	US-09-872-462-252	Sequence 252, App
C 22	12.4	65.3	20	10	US-09-820-339A-22	Sequence 22, Appl
C 23	12.4	65.3	25	9	US-09-872-462-460	Sequence 460, App
C 24	12.4	65.3	25	9	US-09-872-462-461	Sequence 461, App
C 25	12.4	65.3	25	9	US-09-872-462-462	Sequence 462, App
C 26	12.4	65.3	25	9	US-09-872-462-463	Sequence 463, App
C 27	12.4	65.3	25	9	US-09-872-462-464	Sequence 464, App
C 28	12.4	65.3	25	9	US-09-872-462-465	Sequence 465, App
C 29	12.4	65.3	25	9	US-09-872-462-466	Sequence 466, App
C 30	12.4	65.3	25	9	US-09-872-462-467	Sequence 467, App
C 31	12.4	65.3	20	10	US-09-898-541-24	Sequence 24, Appl
C 32	12.2	64.2	31	10	US-09-854-883-193	Sequence 193, App
C 33	12.2	64.2	31	10	US-09-801-274-1400	Sequence 1400, App
C 34	12	63.2	17	9	US-09-872-462-253	Sequence 253, App
C 35	12	63.2	17	9	US-09-872-462-254	Sequence 254, App
C 36	12	63.2	31	10	US-09-801-274-1721	Sequence 1721, App
C 37	12	63.2	39	10	US-09-894-633A-7	Sequence 7, Appl
C 38	11.8	62.1	17	10	US-09-866-108-6581	Sequence 6581, App
C 39	11.8	62.1	17	10	US-09-866-108-6584	Sequence 387, App
C 40	11.8	62.1	18	9	US-09-905-291A-387	Sequence 387, App
C 41	11.8	62.1	18	10	US-09-909-320-387	Sequence 387, App
C 42	11.8	62.1	18	10	US-09-909-0888-387	Sequence 387, App
C 43	11.8	62.1	25	10	US-09-866-108-11473	Sequence 11473, A
C 44	11.8	62.1	25	10	US-09-866-108-11484	Sequence 11484, A
C 45	11.6	61.1	30	9	US-09-898-234-9	Sequence 9, Appl

## ALIGNMENTS

RESULT 1  
US-09-504-231A-1780/C  
: Sequence 1780, Application US/09504231A  
: Patent No. US2002013456A1  
: GENERAL INFORMATION:  
: APPLICANT: Bialt, Lawrence  
: APPLICANT: McSwigen, James  
: APPLICANT: Roberts, Beth  
: APPLICANT: Pavco, Pamela  
: APPLICANT: Mecejak, Dennis  
: TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS REL  
: FILE REFERENCE: HEPATITIS C VIRUS INFECTION  
: CURRENT APPLICATION NUMBER: US/09/504,231A  
: PRIOR FILING DATE: 1999-02-15  
: PRIOR APPLICATION NUMBER: 09/274,553  
: PRIOR FILING DATE: 1999-03-23  
: PRIOR APPLICATION NUMBER: 09/257,608  
: PRIOR FILING DATE: 1999-02-24  
: PRIOR APPLICATION NUMBER: 60/100,842  
: PRIOR FILING DATE: 1998-09-18  
: PRIOR APPLICATION NUMBER: 60/083,217  
: NUMBER OF SEQ ID NOS: 3242  
: SOFTWARE: PatentIn version 3.0  
: SEQ ID NO 1780  
: LENGTH: 36  
: TYPE: RNA  
: ORGANISM: Artificial Sequence  
: FEATURE:  
: OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic Acid Mo  
US-09-504-231A-1780

Query Match 68.4%; Score 13; DB 10; Length 36;  
Best local similarity 100.0%; Pred. No. 7.1e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 13 CATCACTGCTCTG 1  
7 CATCACTGCTCTG 19



```
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6583
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6583

Query Match
Best Local Similarity 67.4%; Score 12.8; DB 10; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGGCCATCAGTGCT 16
DB 16 CTGGACCCCTCAGTGCT 1

RESULT 5
US-09-795-232-4/c
; Sequence 4, Application US/09795232
; Patent No. US20010012627A1
; GENERAL INFORMATION:
; APPLICANT: Anthony M. Brown
; APPLICANT: Conrad Gerald Chapman
; APPLICANT: Israel Simon Gloger
; APPLICANT: Joanne Rachel Evans
; APPLICANT: William Cairns
; APPLICANT: Hugh Jonathan Herdon
; TITLE OF INVENTION: NOVEL COMPOUNDS
; FILE REFERENCE: GP-30176-D1
; CURRENT APPLICATION NUMBER: US/09/795,232
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/182,728
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 9818890.7
; PRIOR FILING DATE: 1998-08-28
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 25
; TYPE: DNA
; ORGANISM: HOMO SAPIENS
US-09-795-232-4

Query Match
Best Local Similarity 67.4%; Score 12.8; DB 10; Length 25;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGGCCATCAGTGCT 16
DB 21 CTGGGCATCAGTGCT 6

RESULT 6
US-09-866-108-11474/c
; Sequence 11474, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 11474
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-11474

Query Match
Best Local Similarity 67.4%; Score 12.8; DB 10; Length 25;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGGCCATCAGTGCT 16
DB 25 CTGGACCCCTCAGTGCT 10

RESULT 7
US-09-866-108-11475/c
; Sequence 11475, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 11475
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-11475
```

```
Query Match 67.4%; Score 12.8; DB 10; Length 25;
Best Local Similarity 87.5%; Pred. No. 8.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1 CTGGCCATCAGTCT 16
    ||||| |||||
DB 24 CTGGACCTCAGTCT 9
```

```
RESULT 8
US-09-866-108-11476/c
; Sequence 11476, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 11476
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-11476
```

```
Query Match 67.4%; Score 12.8; DB 10; Length 25;
Best Local Similarity 87.5%; Pred. No. 8.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1 CTGGCCATCAGTCT 16
    ||||| |||||
DB 23 CTGGACCTCAGTCT 8
```

```
RESULT 9
US-09-866-108-11477/c
; Sequence 11477, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
```



SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 11477  
LENGTH: 25  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-11477

Query Match 67.4%; Score 12.8; DB 10; Length 25;  
Best Local Similarity 87.5%; Pred. No. 8.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGCCATCAGTCT 16  
|||||  
Db 22 CTGGACCTCAGTCT 7

RESULT 10  
US-09-866-108-11478/c  
Sequence 11478, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 11478  
LENGTH: 25  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-11478

Query Match 67.4%; Score 12.8; DB 10; Length 25;  
Best Local Similarity 87.5%; Pred. No. 8.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGCCATCAGTCT 16  
|||||  
Db 21 CTGGACCTCAGTCT 6

RESULT 11  
US-09-866-108-11479/c  
Sequence 11479, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,5  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 11479  
LENGTH: 25  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-11479

Query Match 67.4%; Score 12.8; DB 10; Length 25;  
Best Local Similarity 87.5%; Pred. No. 8.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGCCATCAGTCT 16  
|||||  
Db 20 CTGGACCTCAGTCT 5

RESULT 12  
US-09-866-108-11480/c  
Sequence 11480, Application US/09866108  
Patent No. US20020048800A1

```

: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yonggang
: APPLICANT: PENN, Sharon G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark
: TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
: FILE REFERENCE: AEOMICA-7
: CURRENT APPLICATION NUMBER: US/09/866,108
: PRIOR FILING DATE: 2001-05-25
: PRIOR APPLICATION NUMBER: US 60/207,456
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: GB 24263.6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00663
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00662
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00661
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00670
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: US 60/234,687
: PRIOR FILING DATE: 2000-09-21
: PRIOR APPLICATION NUMBER: US 60/266,860
: PRIOR FILING DATE: 2001-02-05
: NUMBER OF SEQ ID NOS: 15752
: SOFTWARE: Aeomica Sequence Listing Engine
: SEQ ID NO 11480
: LENGTH: 25
: TYPE: DNA
: ORGANISM: Homo sapiens
: US-09-866-108-11480

Query Match      67.4%: Score 12.8; DB 10; Length 25;
Best Local Similarity 87.5%: Pred. No. 8.5e+02;
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1 CTGGCCATCAGTGCT 16
      ||||| |||||
Db      19 CTGACCCCTCAGTGCT 4

RESULT 13
US-09-866-108-11481/c
: Sequence 11481, Application US/09866108
: Patent No. US20020048800A1
: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yonggang
: APPLICANT: PENN, Sharon G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark
: TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
: FILE REFERENCE: AEOMICA-7

```

```

: CURRENT APPLICATION NUMBER: US/09/866,108
: CURRENT FILING DATE: 2001-05-25
: PRIOR APPLICATION NUMBER: US 60/207,456
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: GB 24263.6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00663
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00662
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00661
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00670
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: US 60/234,687
: PRIOR FILING DATE: 2000-09-21
: PRIOR APPLICATION NUMBER: US 60/266,860
: PRIOR FILING DATE: 2001-02-05
: NUMBER OF SEQ ID NOS: 15752
: SOFTWARE: Aeomica Sequence Listing Engine
: SEQ ID NO 11481
: LENGTH: 25
: TYPE: DNA
: ORGANISM: Homo sapiens
: US-09-866-108-11481

Query Match      67.4%: Score 12.8; DB 10; Length 25;
Best Local Similarity 87.5%: Pred. No. 8.5e+02;
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1 CTGGCCATCAGTGCT 16
      ||||| |||||
Db      18 CTGACCCCTCAGTGCT 3

RESULT 14
US-09-866-108-11482/c
: Sequence 11482, Application US/09866108
: Patent No. US20020048800A1
: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yonggang
: APPLICANT: PENN, Sharon G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark
: TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
: FILE REFERENCE: AEOMICA-7
: CURRENT APPLICATION NUMBER: US/09/866,108
: CURRENT FILING DATE: 2001-05-25
: PRIOR APPLICATION NUMBER: US 60/207,456
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: GB 24263.6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30

```

```

: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00663
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00662
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00661
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00670
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: US 60/234,687
: PRIOR FILING DATE: 2000-09-21
: PRIOR APPLICATION NUMBER: US 60/266,860
: PRIOR FILING DATE: 2001-02-05
: NUMBER OF SEQ ID NOS: 15752
: SOFTWARE: Aecomica Sequence Listing Engine
: SEQ ID NO 11482
: LENGTH: 25
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-866-108-11482
```

```

Query Match      67.4%: Score 12.8; DB 10: Length 25;
Best Local Similarity 87.5%: Pred. No. 8.5e+02;
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1 CTGGCCATCAGTCT 16
      11111111111111111111
Db      17 CTGGACCCCTCAGTCT 2
```

```

RESULT 15
US-09-866-108-11483/C
: Sequence 11483, Application us/09866108
: Patent No. US20020048800A1
: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yonggang
: APPLICANT: PENN, Sharon G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark
: TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
: FILE REFERENCE: AEOMICA-7
: CURRENT APPLICATION NUMBER: US/09/866,108
: CURRENT FILING DATE: 2001-05-25.
: PRIOR APPLICATION NUMBER: US 60/207,456
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: GB 24263,6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
```

```

: PRIOR APPLICATION NUMBER: PCT/US01/00663
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00662
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00661
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00670
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: US 60/234,687
: PRIOR FILING DATE: 2000-09-21
: PRIOR APPLICATION NUMBER: US 60/266,860
: PRIOR FILING DATE: 2001-02-05
: NUMBER OF SEQ ID NOS: 15752
: SOFTWARE: Aecomica Sequence Listing Engine
: SEQ ID NO 11483
: LENGTH: 25
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-866-108-11483
```

```

Query Match      67.4%: Score 12.8; DB 10: Length 25;
Best Local Similarity 87.5%: Pred. No. 8.5e+02;
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1 CTGGCCATCAGTCT 16
      11111111111111111111
Db      16 CTGGACCCCTCAGTCT 1
```

```

Search completed: November 28, 2002, 19:35:04
Job time : 39.9655 secs
```



GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 17:12:29 ; Search time 38.3276 Seconds

(without alignments)  
152.028 Million cell updates/sec

Title: US-09-719-737-18

Sequence: 1 ctggggcattcagctgctg 19

Scoring table: IDENTITY\_NUC

GapPen 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 609818

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued\_Patents\_NA:\*

- 1: /cgn2\_6/ptodata/2/ina/5A.COMB.seq:\*
- 2: /cgn2\_6/ptodata/2/ina/5B.COMB.seq:\*
- 3: /cgn2\_6/ptodata/2/ina/6A.COMB.seq:\*
- 4: /cgn2\_6/ptodata/2/ina/6B.COMB.seq:\*
- 5: /cgn2\_6/ptodata/2/ina/PTCUTS.COMB.seq:\*
- 6: /cgn2\_6/ptodata/2/ina/Backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	15.8	83.2	45	2	US-08-687-355A-14
2	15.8	83.2	45	4	US-09-407-367-14
3	14.8	77.9	45	2	US-08-687-355A-13
4	14.8	77.9	45	4	US-09-407-367-13
5	14.4	75.8	20	1	US-08-742-023-15
6	14.4	75.8	20	3	US-08-968-503-15
7	13.2	65.5	33	3	US-09-233-506-11
8	13.2	65.5	33	4	US-08-584-040-4815
9	12.8	67.4	25	4	US-09-182-728A-4
10	12.8	67.4	25	4	US-09-795-232-4
11	12.6	66.3	43	4	US-08-960-190A-2
12	12.6	66.3	44	2	US-08-596-387B-40
13	12.6	66.3	44	4	US-09-067-615-40
14	12.6	66.3	44	5	PCR-0595-09816A-40
15	12.4	65.3	18	3	US-08-773-731A-12
16	12.4	65.3	30	4	US-09-230-199-24
17	12.4	65.3	31	1	US-08-390-850-222
18	12.4	65.3	31	1	US-08-390-850-223
19	12.4	65.3	31	1	US-08-390-850-224
20	12.4	65.3	31	1	US-08-435-634-222
21	12.4	65.3	31	1	US-08-435-634-223
22	12.4	65.3	31	1	US-08-435-634-224
23	12.4	65.3	31	1	US-08-859-998-167
24	12.4	65.3	31	4	US-09-225-928-167
25	12.4	65.3	40	4	US-09-485-737B-15
26	12.2	64.2	40	4	US-09-487-368A-193
27	12.2	64.2	36	4	US-09-101-126-13

C	28	12.2	64.2	45	2	US-08-944-982-1	Sequence 1, Appl
	29	12	63.2	20	4	US-09-429-322-61	Sequence 61, Appl
	30	12	63.2	21	3	US-09-009-913-19	Sequence 19, Appl
	31	12	63.2	27	4	US-08-584-040-1443	Sequence 1443, Ap
	32	12	63.2	27	4	US-08-584-040-3326	Sequence 3326, Ap
	33	12	63.2	27	4	US-08-584-040-5279	Sequence 5279, Ap
	34	12	63.2	36	1	US-08-291-932A-568	Sequence 568, App
	35	11.8	62.1	20	2	US-08-117-952-476	Sequence 476, App
	36	11.8	62.1	27	3	US-08-513-974B-121	Sequence 121, App
	37	11.8	62.1	36	4	US-08-484-686B-18	Sequence 18, Appl
	38	11.8	62.1	35	4	US-08-463-160B-18	Sequence 18, Appl
	39	11.8	62.1	45	1	US-08-171-389-257	Sequence 257, App
	40	11.8	62.1	45	1	US-08-167-939A-13	Sequence 13, Appl
	41	11.8	62.1	45	1	US-08-123-936-257	Sequence 257, App
	42	11.8	62.1	45	1	US-08-567-538-13	Sequence 13, Appl
	43	11.8	62.1	45	3	US-08-475-228A-257	Sequence 257, App
	44	11.8	62.1	45	2	US-08-482-080A-257	Sequence 257, App
	45	11.8	62.1	45	4	US-09-354-947-257	Sequence 257, App

## ALIGNMENTS

RESULT 1  
US-08-687-355A-14/C  
Sequence 14, Application US/08687355A  
Patent No. 5989834  
GENERAL INFORMATION:  
APPLICANT: Synaptic Pharmaceutical Corporation  
TITLE OF INVENTION: NUCLEIC ACID ENCODING NEUROPEPTIDE  
NUMBER OF INVENTIONS: 27  
TITLE OF SEQUENCES: Y/PEPTIDE Y (Y2) RECEPTORS AND USES THEREOF  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham LLP  
STREET: 1185 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: U.S.A.  
ZIP: 10036  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/687,355A  
FILING DATE: No. 5989834member 26, 1996  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28, 678  
REFERENCE/DOCKET NUMBER: 44742-A-PCT/JPM/MAT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-278-0400  
TELEFAX: 212-391-0525  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 45 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-08-687-355A-14  
Query Match 83.2%; Score 15.8; DB 2; Length 45;  
Best Local Similarity 89.5%; Pred. No. 16;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
DB 43 CTGGGCATCACTGCTG 19  
||||| ||||||| |||

RESULT 2  
US-09-407-367-14/C  
Sequence 14, Application US/09407367  
Patent No. 6420532  
GENERAL INFORMATION:  
APPLICANT: Christophe P.G. Gerald, et al.  
TITLE OF INVENTION: METHOD OF OBTAINING COMPOSITIONS COMPRISING Y2 SPECIFIC COMPO  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham LLP  
STREET: 1185 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: U.S.A.  
ZIP: 10036  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/407,367  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 44742-AA-PCT-US/JPM  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-278-0400  
TELEFAX: 212-391-0525  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 45 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-09-407-367-14

Query Match 83.2%; Score 15.8; DB 4; Length 45;  
Best Local Similarity 89.5%; Pred. No. 16;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGGCATCAGTCTCTG 19  
||||| ||||| ||||| |||||  
DB 43 CTGGGCATCAGTCTCTG 25

RESULT 3  
US-08-687-355A-13  
Sequence 13, Application US/08687355A  
Patent No. 5989834  
GENERAL INFORMATION:  
APPLICANT: Symplic Pharmaceutical Corporation  
TITLE OF INVENTION: NUCLEIC ACID ENCODING NEUROPEPTIDE  
TITLE OF INVENTION: Y/PEPTIDE YY (Y2) RECEPTORS AND USES THEREOF  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham LLP  
STREET: 1185 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: U.S.A.  
ZIP: 10036  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/687,355A  
FILING DATE: No. 5989834emder 26, 1996  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 44742-A-PCT-US/JPM/MAT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-278-0400  
TELEFAX: 212-391-0525  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 45 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-08-687-355A-13

Query Match 77.9%; Score 14.8; DB 2; Length 45;  
Best Local Similarity 88.9%; Pred. No. 53;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGGCATCAGTCTCT 18  
||||| ||||| ||||| |||||  
DB 28 CTGGGCATCAGTCTCT 45

RESULT 4  
US-09-407-367-13  
Sequence 13, Application US/09407367  
Patent No. 6420532  
GENERAL INFORMATION:  
APPLICANT: Christophe P.G. Gerald, et al.  
TITLE OF INVENTION: METHOD OF OBTAINING COMPOSITIONS COMPRISING Y2 SPECIFIC COM  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham LLP  
STREET: 1185 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: U.S.A.  
ZIP: 10036  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/407,367  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 44742-AA-PCT-US/JPM  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-278-0400  
TELEFAX: 212-391-0525  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 45 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-09-407-367-13

Query Match 77.9%; Score 14.8; DB 4; Length 45;  
Best Local Similarity 88.9%; Pred. No. 53;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGCCATCAGTCTCTG 18  
|||||  
Db 28 CTGGCCATCAGTCTCTG 45

RESULT 5  
US-08-742-023-15

; Sequence 15, Application US/08742023

; Patent No. 5800997

; GENERAL INFORMATION:

; APPLICANT: Beck, James J.

; TITLE OF INVENTION: Detection of Maize Fungal Pathogens

; NUMBER OF SEQUENCES: 41

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: CIBA-GEIGY Corporation

; STREET: 520 White Plains Road, P.O. Box 2005

; CITY: Tarrytown

; STATE: NY

; COUNTRY: USA

; ZIP: 10591

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentln Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/742,023

; FILING DATE:

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Meigs, J. Timothy

; REGISTRATION NUMBER: 38,241

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (919) 541-8587

; TELEFAX: (919) 541-8689

; INFORMATION FOR SEQ ID NO: 15:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: other nucleic acid

; DESCRIPTION: /desc = "primer JB586"

US-08-742-023-15

Query Match

Best Local Similarity 75.8%; Score 14.4; DB 1; Length 20;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 GGCAATCAGTCTCTG 19  
|||||

Db 2 GGCAATCAGTCTCTG 17

RESULT 6

US-08-968-505-15

; Sequence 15, Application US/08968505

; Patent No. 6071698

; GENERAL INFORMATION:

; APPLICANT: Beck, James J.

; TITLE OF INVENTION: Detection of Maize Fungal Pathogens

; NUMBER OF SEQUENCES: 41

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: CIBA-GEIGY Corporation

; STREET: 520 White Plains Road, P.O. Box 2005

; CITY: Tarrytown

STATE: NY  
COUNTRY: USA  
ZIP: 10591

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentln Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/968,505

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/742,023

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Meigs, J. Timothy

; REGISTRATION NUMBER: 38,241

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (919) 541-8587

; TELEFAX: (919) 541-8689

; INFORMATION FOR SEQ ID NO: 15:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: other nucleic acid

; DESCRIPTION: /desc = "primer JB586"

US-08-968-505-15

Query Match

Best Local Similarity 75.8%; Score 14.4; DB 3; Length 20;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 GGCAATCAGTCTCTG 19  
|||||

Db 2 GGCAATCAGTCTCTG 17

RESULT 7

US-09-233-506-11/c

; Sequence 11, Application US/09233506

; Patent No. 6136580

; GENERAL INFORMATION:

; APPLICANT: Fukuda, Minoru

; TITLE OF INVENTION: A Beta-1,6-N-Acetylglucosaminyltransferase That Forms

; FILE REFERENCE: P-LJ 3415

; CURRENT APPLICATION NUMBER: US/09/233,506

; CURRENT FILING DATE: 1999-01-19

; NUMBER OF SEQ ID NOS: 14

; SOFTWARE: Patentln Ver. 2.0

; SEQ ID NO 11

; LENGTH: 33

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-233-506-11

Query Match

Best Local Similarity 69.5%; Score 13.2; DB 3; Length 33;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CTGGCCATCAGTCTCT 18  
|||||

Db 24 CTGGCCATCAGTCTCT 7

RESULT 8

US-08-584-040-4815/c

; Sequence 4815, Application US/08584040

; Patent No. 6346398

GENERAL INFORMATION:  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwigen, James  
APPLICANT: Slinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
NUMBER OF SEQUENCES: 8502  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: Suite 4700  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 4815:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
FEATURE:  
OTHER INFORMATION: The letter "N" represents the stem II region  
US-08-584-040-4815  
Query Match 68.4%; Score 13; DB 4; Length 27;  
Best Local Similarity 100.0%; Pred. No. 4.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 7 CATGAGTCTGCTG 19  
DB 14 CATGAGTCTGCTG 2  
RESULT 9  
US-09-182-728A-4/C  
Sequence 4, Application US/09182728A  
GENERAL INFORMATION:  
APPLICANT: BROWN, ANTHONY  
APPLICANT: CHAPMAN, CONRAD GERALD  
APPLICANT: GLOGER, ISRAEL SIMON  
APPLICANT: EVANS, JOANNE RACHEL  
APPLICANT: CAIRNS, WILLIAM  
APPLICANT: HERDON, HUGH  
TITLE OF INVENTION: NOVEL COMPOUNDS  
FILE REFERENCE: GP-30176

CURRENT APPLICATION NUMBER: US/09/182,728A  
CURRENT FILING DATE: 1998-10-29  
PRIOR APPLICATION NUMBER: 9818890.7  
PRIOR FILING DATE: 1998-08-28  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 4  
LENGTH: 25  
TYPE: DNA  
ORGANISM: HOMO SAPIENS  
US-09-182-728A-4  
Query Match 67.4%; Score 12.8; DB 4; Length 25;  
Best Local Similarity 87.5%; Pred. No. 5.2e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 1 CTGGGCATCATGCTGCT 16  
DB 21 CTGGGCATCATGCTGCT 6  
RESULT 10  
US-09-795-232-4/C  
Sequence 4, Application US/09795232  
Patent No. 6426405  
GENERAL INFORMATION:  
APPLICANT: Anthony M. Brown  
APPLICANT: Conrad Gerald Chapman  
APPLICANT: Israel Simon Gloger  
APPLICANT: Joanne Rachel Evans  
APPLICANT: William Cairns  
APPLICANT: Hugh Jonathan Herdon  
TITLE OF INVENTION: NOVEL COMPOUNDS  
FILE REFERENCE: GP-30176-D1  
CURRENT APPLICATION NUMBER: US/09/795,232  
CURRENT FILING DATE: 2001-02-28  
PRIOR APPLICATION NUMBER: 09/182,728  
PRIOR FILING DATE: 1998-10-29  
PRIOR APPLICATION NUMBER: 9818890.7  
PRIOR FILING DATE: 1998-08-28  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 4  
LENGTH: 25  
TYPE: DNA  
ORGANISM: HOMO SAPIENS  
US-09-795-232-4  
Query Match 67.4%; Score 12.8; DB 4; Length 25;  
Best Local Similarity 87.5%; Pred. No. 5.2e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 1 CTGGGCATCATGCTGCT 16  
DB 21 CTGGGCATCATGCTGCT 6  
RESULT 11  
US-08-960-190A-2  
Sequence 2, Application US/08960190A  
GENERAL INFORMATION:  
APPLICANT: Rhode, Peter R.  
APPLICANT: Acevedo, Jorge  
APPLICANT: Burkhardt, Martin  
APPLICANT: Jiao, Jin-an  
APPLICANT: Wong, Hing C.  
TITLE OF INVENTION: SOLUBLE MHC COMPLEXES AND  
TITLE OF INVENTION: METHODS OF USE THEREOF  
NUMBER OF SEQUENCES: 38  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dike, Bronstein, Roberts & Cushman, LLP  
STREET: 130 Water Street



RESULT 13  
 US-09-067-615-40  
 : Sequence 40, Application US/09067615  
 : Patent No. 6309645  
 :  
 : GENERAL INFORMATION:  
 : APPLICANT: Rhode, Peter R.  
 : APPLICANT: Jiao, Jin-An  
 : APPLICANT: Burkhardt, Martin  
 : APPLICANT: Wong, Hing  
 : TITLE OF INVENTION: MHC COMPLEXES AND USES THEREOF  
 : NUMBER OF SEQUENCES: 124  
 : CORRESPONDENCE ADDRESS:  
 : ADDRESSEE: Dade International, Inc.  
 : STREET: 1717 Deerfield Road  
 : CITY: Deerfield  
 : STATE: Illinois  
 : COUNTRY: USA  
 : ZIP: 60015  
 :  
 : COMPUTER READABLE FORM:  
 : MEDIUM TYPE: Floppy disk  
 : COMPUTER: IBM PC compatible  
 : OPERATING SYSTEM: PC-DOS/MS-DOS  
 : SOFTWARE: Patentin Data: #1.0, Version #1.30  
 : CURRENT APPLICATION DATA:  
 : APPLICATION NUMBER: US/09/067,615  
 : FILING DATE:  
 : CLASSIFICATION:  
 : PRIOR APPLICATION DATA:  
 : APPLICATION NUMBER: 08/596,387  
 : FILING DATE:  
 : PRIOR APPLICATION DATA:  
 : APPLICATION NUMBER: US 08/382,454  
 : FILING DATE: 01-FEB-1995  
 : PRIOR APPLICATION DATA:  
 : APPLICATION NUMBER: US 08/283,302  
 : FILING DATE: 29-JUL-1994  
 : ATTORNEY/AGENT INFORMATION:  
 : NAME: Pearson, Louise S.  
 : REGISTRATION NUMBER: 32,169  
 : REFERENCE/DOCKET NUMBER: STR-4665-CIP2  
 : TELECOMMUNICATION INFORMATION:  
 : TELEPHONE: (708) 267-5300  
 : TELEFAX: (708) 267-5376  
 : INFORMATION FOR SEQ ID NO: 40:  
 : SEQUENCE CHARACTERISTICS:



GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 28, 2002, 15:32:44 ; Search time 176.241 Seconds

(without alignments)  
242.780 Million cell updates/sec

Title: US-09-719-737-18

Sequence: 1 ctggcgcatcagtcctctg 19

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2166140

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :  
1: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:\*  
2: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:\*  
3: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:\*  
4: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:\*  
5: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:\*  
6: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:\*  
7: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:\*  
8: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:\*  
9: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:\*  
10: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:\*  
11: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:\*  
12: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:\*  
13: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:\*  
14: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:\*  
15: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:\*  
16: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:\*  
17: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:\*  
18: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:\*  
19: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:\*  
20: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:\*  
21: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:\*  
22: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:\*  
23: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:\*  
24: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	19	21	AA257602
2	15.8	83.2	45	16	AA095044
3	14.8	77.9	45	16	AA095043
4	14.4	75.8	20	19	AA433277
5	14.2	74.7	20	20	AA937497
6	14.2	74.7	36	22	AAH41073
7	13.4	70.5	47	21	AA664407
8	13.2	69.5	33	22	AA662140
9	13.2	69.5	47	21	AA264660
					Human map-related

C	10	13	68.4	25	22	AAH38907	SNP specific SNPE
C	11	13	68.4	27	18	AAH72065	Mouse flk-1 VEGF r
C	12	13	68.4	27	21	AA262041	Hammerhead ribozyme
C	13	13	68.4	29	21	AA066558	Hammerhead ribozyme
C	14	13	68.4	29	21	AAA24583	Oestrogen receptor
C	15	12.8	67.4	17	24	ABN06590	Human GDMPL-1 17-m
C	16	12.8	67.4	17	24	ABN06591	Human GDMPL-1 17-m
C	17	12.8	67.4	25	24	ABN05538	Human SC polypeptid
C	18	12.8	67.4	25	24	ABN11482	Human GDMPL-1 25-m
C	19	12.8	67.4	25	24	ABN11483	Human GDMPL-1 25-m
C	20	12.8	67.4	25	24	ABN11484	Human GDMPL-1 25-m
C	21	12.8	67.4	25	24	ABN11485	Human GDMPL-1 25-m
C	22	12.8	67.4	25	24	ABN11486	Human GDMPL-1 25-m
C	23	12.8	67.4	25	24	ABN11487	Human GDMPL-1 25-m
C	24	12.8	67.4	25	24	ABN11488	Human GDMPL-1 25-m
C	25	12.8	67.4	25	24	ABN11489	Human GDMPL-1 25-m
C	26	12.8	67.4	25	24	ABN11490	Human GDMPL-1 25-m
C	27	12.8	67.4	25	24	ABN11491	Human GDMPL-1 25-m
C	28	12.8	67.4	39	21	AA26575	T cell antigen rec
C	29	12.8	67.4	50	22	AA26575	Human SNP oligonuc
C	30	12.6	66.3	19	22	AAH37830	SNP specific lower
C	31	12.6	66.3	30	22	AAH75322	Extended TOCA prim
C	32	12.6	66.3	43	20	AAH89047	PCR primer OPR132
C	33	12.6	66.3	44	17	AAH34718	PCR primer OPR132
C	34	12.6	66.3	44	18	AAH86972	Primer used in MHC
C	35	12.6	66.3	47	21	AA267507	Human map-related
C	36	12.6	66.3	48	19	AAV22976	PCR primer tau-dl-
C	37	12.6	66.3	48	20	AAV70655	Human SNP oligonuc
C	38	12.6	66.3	50	22	AAH27963	Human SNP oligonuc
C	39	12.6	66.3	50	22	AAH33841	Human SNP oligonuc
C	40	12.6	66.3	50	23	ABL00017	Human s11ent nonco
C	41	12.4	65.3	17	24	ABN97702	Human NEDD-1 scan
C	42	12.4	65.3	17	24	ABN97703	Human NEDD-1 scan
C	43	12.4	65.3	17	24	ABN97704	Human NEDD-1 scan
C	44	12.4	65.3	17	24	ABN97705	Human NEDD-1 scan
C	45	12.4	65.3	18	14	AA050297	Human NEDD-1 scan
							PCR primer for pre

#### ALIGNMENTS

RESULT 1  
ID AA257602 standard; DNA; 19 BP.  
XX  
AC AA257602:  
XX  
DT 28-MAR-2000 (first entry)  
XX  
DE Antisense oligonucleotide CCR3AS to inhibit CCR3 receptor expression.  
XX  
XX Antisense oligonucleotide: CCR3 receptor; Chemokine receptor; aschma;  
KW allergy; cancer; receptor expression inhibitor; hypereosinophilia;  
KW inflammation; ss.  
XX  
OS Homo sapiens.  
XX  
XX MO9966037-A2  
XX  
XX PD 28-MAR-1999.  
XX  
XX PF 17-JUN-1999; 99MO-CA00572.  
XX  
XX PR 17-JUN-1998; 98CA-2235420.  
XX  
PA (REEX-) RECH EXPERTISES & DEV MEDICAUX PARENZ IN.  
XX  
XX Renzi P;  
XX  
XX WPI; 2000-097743/08.  
XX  
XX Antisense oligonucleotides directed to CCR3, interleukin or granulocyte  
PT macrophage colony stimulating factor receptors, used for treating or

PT preventing asthma, allergies, hypersosinophilia, inflammation or cancer  
 PT  
 XX  
 PS Claim 5; Page 32; 72pp; English.

CC This is an antisense oligonucleotide directed against the CCR3 receptor.  
 CC The antisense oligonucleotide inhibits CCR3 receptor expression. The CCR3  
 CC receptor is important in the recruitment of eosinophils into the sites of  
 CC allergic or asthmatic inflammation. The chemokines Eotaxin, MCP-4 and  
 CC RANTES mediate most of their effects through the CCR3 receptor. The  
 CC invention relates to antisense oligonucleotides directed against a  
 CC nucleic acid sequence encoding either a CCR3 receptor, a common subunit  
 CC of interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, or a common  
 CC subunit of IL-3, IL-5 and GM-CSF receptors. The antisense  
 CC oligonucleotides can be used in the treatment or prevention of asthma,  
 CC allergy, hypersosinophilia, general inflammation or cancer.

XX Sequence 19 BP; 2 A; 6 C; 6 G; 5 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 2.7;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CTGGGCCATCAGTCTCTG 19  
 DB 1 CTGGGCCATCAGTCTCTG 19

RESULT 2  
 AA095044/C  
 ID AA095044 standard; DNA: 45 BP.

XX AA095044;

XX 06-MAR-1996 (first entry)

XX Human hippocampal neuropeptide Y2 receptor (-) strand DNA probe TM4.

XX Hippocampus; brain; neuropeptide; peptide; hypertension; pain;

XX gastrointestinal disorder; diagnosis; sleeping disorder; epilepsy;

XX memory loss; diarrhoea; nasal congestion; DNA probe;

XX oligonucleotide; ss.

XX Synthetic.

XX WO9521245-A1.

XX 10-AUG-1995.

XX 03-FEB-1995; 95WO-US01469.

XX 03-FEB-1994; 94US-0192288.

XX (SYNA-) SYNAPTIC PHARM CORP.

XX Branchek T, Gerald C, Walker MW, Weinschank R;

XX WPI; 1995-283765/37.

XX Human and rat Y2 receptor DNA and protein - useful in diagnosis and

XX treatment of e.g. cognitive and gastrointestinal disorder(s),

XX hypertension and pain

XX Disclosure; Page 50; 193pp; English.

XX This oligonucleotide probe corresponding to nucleotides 531-600 of

XX human neuropeptide Y2 receptor cDNA and to a transmembrane region

XX of the amino acid sequence of the receptor, was used to obtain the

XX rat homologue of the human Y2 receptor.

XX Sequence 45 BP; 10 A; 13 C; 17 G; 5 T; 0 other;

XX Query Match 83.2%; Score 15.8; DB 16; Length 45;

Best Local Similarity 89.5%; Pred. No. 1.3e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 CTGGGCCATCAGTCTCTG 19  
 DB 43 CTGGGCCATCAGTCCCTG 25

RESULT 3  
 AA095043  
 ID AA095043 standard; DNA: 45 BP.

XX AA095043;

XX 06-MAR-1996 (first entry)

XX Human hippocampal neuropeptide Y2 receptor (+) strand DNA probe TM4.

XX Hippocampus; brain; neuropeptide; peptide; hypertension; pain;

XX gastrointestinal disorder; diagnosis; sleeping disorder; epilepsy;

XX memory loss; diarrhoea; nasal congestion; DNA probe;

XX oligonucleotide; ss.

XX Synthetic.

XX WO9521245-A1.

XX 10-AUG-1995.

XX 03-FEB-1995; 95WO-US01469.

XX 03-FEB-1994; 94US-0192288.

XX (SYNA-) SYNAPTIC PHARM CORP.

XX Branchek T, Gerald C, Walker MW, Weinschank R;

XX WPI; 1995-283765/37.

XX Human and rat Y2 receptor DNA and protein - useful in diagnosis and

XX treatment of e.g. cognitive and gastrointestinal disorder(s),

XX hypertension and pain

XX Disclosure; Page 50; 193pp; English.

XX This oligonucleotide probe corresponding to nucleotides 531-600 of

XX human neuropeptide Y2 receptor cDNA and to a transmembrane region

XX of the amino acid sequence of the receptor, was used to obtain the

XX rat homologue of the human Y2 receptor.

XX Sequence 45 BP; 7 A; 12 C; 12 G; 14 T; 0 other;

XX Query Match 77.9%; Score 14.8; DB 16; Length 45;

XX Best Local Similarity 88.9%; Pred. No. 4.2e+02;

XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX 1 CTGGGCCATCAGTCTCTG 18

XX 28 CTGGGCCATCAGTCCCTG 45

RESULT 4  
 AA095043  
 ID AA095043 standard; DNA: 20 BP.

XX AA095043;

XX 26-OCT-1998 (first entry)

XX primer JBS86 for amplification-based detection of fungal ITS regions.

XX Internal transcribed spacer; ITS; detection; maize; fungal-pathogen;

XX PCR primer; ss.

```

XX OS Synthetic.
XX OS Helminthosporium turcicum.
XX PN EP859061-A2.
XX PD 19-AUG-1998.
XX PF 03-NOV-1997; 97EP-0810779.
XX PR 01-NOV-1996; 96US-0742023.
XX PA (NOVS ) NOVARTIS AG.
XX PI Beck JJ;
XX DR WPI; 1998-429687/37.
XX PT New internal transcribed spacer sequences of maize fungal pathogens
XX PT and primers and primer pairs - used to detect pathogens e.g.
XX PT Helminthosporium carbonum, Cercospora zea-maydis and Kabatiella
XX PT zea
XX PS Claim 4; Page 11; 49pp; English.
XX CC PCR primers AAV43277-303 are used to in amplification-based detection of
XX CC maize fungal internal transcribed spacer (ITS) regions. They are used
XX CC to identify Helminthosporium turcicum, H. maydis, H. carbonum,
XX CC Kabatiella zea and Cercospora zea-maydis. The method comprises
XX CC isolating DNA from a plant leaf infected with a pathogen, subjecting the
XX CC DNA to PCR amplification using at least one primer derived from the ITS
XX CC sequence.
XX SO Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 other;

Query Match          75.8%; Score 14.4; DB 19; Length 20;
Best Local Similarity 93.8%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 GGGCATCAGTCCTCTG 19
   ||| ||||| ||||| |||
Db 2 GGCATATCAGTCCTCTG 17

RESULT 5
AAx97497
ID AAX97497 standard; DNA: 20 BP.
XX AC AAX97497;
XX DT 13-SEP-1999 (first entry)
XX DE Primer used to amplify Chlamydia pneumoniae polynucleotides.
XX KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
XX KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;
XX KW vaccine; neutralising epitope; PCR primer; ss.
XX OS Synthetic.
XX OS Chlamydia pneumoniae.
XX PN WO9927105-A2.
XX PD 03-JUN-1999.
XX PF 20-NOV-1998; 98MO-1B01890.
XX PR 04-NOV-1998; 98US-0107078.
XX PR 21-NOV-1997; 97FR-0014673.
XX PA (GEST ) GENSET.
XX PI Griffiths R;

```

```

XX DR WPI; 1999-357842/30.
XX XX Genome sequence of Chlamydia pneumoniae
XX PT Page 1909; Disclosure; 1912pp; English.
XX PS
XX CC AAX91991-X97517 represent PCR primers used to amplify open reading
XX CC frames and other nucleic acid sequences from the genome of
XX CC Chlamydia pneumoniae (see AAX91990). C. pneumoniae causes respiratory
XX CC disease such as pneumonia and bronchitis and is thought to be a
XX CC contributing factor in heart disease, sarcoidosis, sinusitis, purulent
XX CC otitis media, erythema nodosum or pharyngitis. The polypeptides encoded
XX CC by the open reading frames of the C. pneumoniae genome (see AAY34584-
XX CC AAY35879) can be used in immunogenic compositions as vaccines. Vectors
XX CC containing C. pneumoniae nucleotides sequences can also be used as
XX CC immunogenic compositions, especially where the vector directs the
XX CC expression of a neutralising epitope of C. pneumoniae.
XX SO Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 other;

Query Match          74.7%; Score 14.2; DB 20; Length 20;
Best Local Similarity 84.2%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CTGGGCCATCAGTCCTCTG 19
   |||| |||| ||| ||| |||
Db 1 CTGGACCATTAAGTACTCTG 19

RESULT 6
AAH41073/C
ID AAH41073 standard; DNA: 36 BP.
XX AC AAH41073;
XX DT 03-SEP-2001 (first entry)
XX DE PCR primer specific for ecdysone C-terminus insertion site DNA SEQ ID 29.
XX KW Steroid hormone; thyroid hormone; receptor; DNA binding; PCR primer;
XX KW chimeric protein; expression modulation; ecdysone receptor; ss.
XX OS Unidentified.
XX PN WO200136447-A2.
XX PD 25-MAY-2001.
XX PF 17-OCT-2000; 2000MO-US41224.
XX PR 20-OCT-1999; 99US-0421971.
XX PA (SALK ) SALK INST BIOLOGICAL STUDIES.
XX PI Gage FH, Suhr ST, Gil EB, Senut MC;
XX DR WPI; 2001-355608/37.
XX PT Novel chimeric protein useful for modulating exogenous gene expression
XX PT in subjects, comprises two functional protein units, each containing
XX PT dimerization domain of steroid/thyroid hormone nuclear receptor
XX PT superfamily -
XX PS
XX CC Example 1; Page 39; 60pp; English.
XX CC The present invention relates to a chimeric protein which consists of at
XX CC least two functional protein units where each protein unit comprises the
XX CC dimerisation domain of a member of the steroid/thyroid hormone nuclear
XX CC receptor superfamily. The protein units are linked by a linker peptide,
XX CC and the two protein units form a functional entity. The invention
XX CC includes a method for modulating the expression of an exogenous gene in
XX CC an organism or cell containing the chimeric protein. The cell or organism

```

CC also contains a DNA construct comprising the exogenous gene under the  
 CC control of a response element with which the chimeric protein interacts.  
 CC The response element controls the expression of the exogenous gene. The  
 CC method also involves administering to the subject or cell an effective  
 CC amount of an exogenous ligand for at least one functional unit of the  
 CC chimeric protein. The chimeric protein is useful for modulating the  
 CC expression of an exogenous gene in a subject organism. The present  
 CC sequence represents a PCR primer specific for DNA encoding the C-terminus  
 CC insertion site of the ecdysone receptor. The PCR product is used in an  
 CC example illustrating the construction of a chimeric protein of the  
 CC invention.

CC Sequence 36 BP: 6 A; 9 C; 12 G; 9 T; 0 other;

Query Match 74.7%; Score 14.2; DB 22: Length 36;  
 Best Local Similarity 84.2%; Pred. No. 8.1e+02;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 CTGGCCATCAGTCTCTG 19  
 ||||| ||| ||| |||

Db 27 CTGGCCACAGGCGCTG 9

RESULT 7  
 AAZ66407/c  
 ID AAZ66407 standard; DNA; 47 BP.

AC AAZ66407;

DT 10-SEP-2001 (first entry)

DE Human map-related diallelic marker SEQ ID NO:754.

XX Human genome: diallelic marker: high density disequilibrium map;  
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;  
 KW haplotyping; hybridisation; identification; characterisation;  
 KW diagnosis; single nucleotide polymorphism; SNP; ds.

OS Homo sapiens.

XX key Location/Qualifiers  
 FT variation replace(24,C)  
 FT \*tag= a

PN W0954500-A2. /standard\_name= "single nucleotide polymorphism"

XX 28-OCT-1999.

XX 21-APR-1999; 99W0-1B00822.

XX 21-APR-1998; 98US-0082614.

XX 23-NOV-1998; 98US-0109732.

XX (GEST ) GENSET.

XX Cohen D, Blumenfeld M, Chumakov I;

XX WPI; 2000-013267/01.

PT Novel diallelic markers used to construct a high density disequilibrium  
 map of the human genome -

XX Claim 1: Page 391; 2745pp; English.

XX AAZ6654 to AAZ69578 represent human diallelic markers from the present  
 CC invention, which contain a polymorphic base at position 24 of their  
 CC nucleotide sequences. AAZ69579 to AAZ7440 represent amplification  
 CC primers for the diallelic markers. The diallelic markers of the  
 CC invention have a variety of uses: they can be used for high density  
 CC mapping of the human genome, and in complex association studies and  
 CC haplotyping studies which are useful in determining the genetic basis  
 CC for disease states. Compositions and methods of the invention can also

CC be useful for the identification of the targets for the development of  
 CC pharmaceutical agents and diagnostic methods, as well as the  
 CC characterisation of the differential efficacious responses to and side  
 CC effects from pharmaceutical agents acting on a disease as well as other  
 CC treatment.  
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297  
 CC and 3367, are not actually given a sequence in the Sequence Listing  
 CC from the present invention.

XX Sequence 47 BP: 12 A; 17 C; 8 G; 10 T; 0 other;

Query Match 70.5%; Score 13.4; DB 21: Length 47;  
 Best Local Similarity 93.3%; Pred. No. 2.2e+03;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 GGGCCATCAGTCTCTC 17  
 ||| ||||| |||||

Db 34 GGGCCATCAGTCTCTC 20

RESULT 8  
 AAC62140/c  
 ID AAC62140 standard; DNA; 33 BP.

AC AAC62140;

DT 06-MAR-2001 (first entry)

DE PCR primer for beta-1-6-N-acetylglucosaminyltransferase DNA fragment.  
 XX Human: beta-1-6-N-acetylglucosaminyltransferase; C2GNT-M; inflammation;  
 KW membrane protein; branched sialyl lex; L-selectin; immune reaction;  
 KW inflammation; tissue rejection; tumour metastasis; PCR primer; ss.

XX Mus musculus.

XX US6136580-A.

XX 24-OCT-2000.

XX 19-JAN-1999; 99US-0233506.

XX 19-JAN-1999; 99US-0233506.

XX (BURN-) BURHAM INST.

XX Fukuda M, Yeh J;

XX WPI; 2001-040238/05.

XX New C2GNT-M polypeptides having core 2, core 4 and I branching  
 PT beta-1-6-N-acetylglucosaminyltransferase activities for preparing  
 PT reagents useful for diagnosing, preventing or treating inflammation or  
 PT tumour metastasis -

XX Example 5: Column 21; 25pp; English.

XX PCR primers AAC62140-41 were used to amplify a DNA fragment encoding a  
 CC beta-1-6-N-acetylglucosaminyltransferase polypeptide, with core2, core4  
 CC and I branching activities. It is designated C2GNT-M. C2GNT-M is a  
 CC membrane protein that is predominantly expressed in colon, small  
 CC intestine, trachea, stomach and thyroid, as well as in certain cancer  
 CC cell lines. C2GNT-M polypeptides may be used to prepare molecules having  
 CC highly branched sialyl lex and L-selectins, which may be subsequently  
 CC used to modulate immune reactions, e.g. inflammation and tissue  
 CC rejection, and to prevent or inhibit tumour metastasis.

XX Sequence 33 BP: 8 A; 8 C; 10 G; 7 T; 0 other;

Query Match 69.5%; Score 13.2; DB 22: Length 33;  
 Best Local Similarity 83.3%; Pred. No. 2.6e+03;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CTGGCCATCATGCTCT 18  
|||||  
DB 24 CTGACCATCTCTCTCT 7

RESULT 9  
AAZ66460  
ID AAZ66460 standard: DNA: 47 BP.

AC AAZ66460:

DT 10-SEP-2001 (first entry)

DE Human map-related diallelic marker SEQ ID NO:807.

XX Human genome; diallelic marker; high density disequilibrium map;  
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;  
KM haplotyping; hybridisation; identification; characterisation;  
KW diagnosis; single nucleotide polymorphism; SNP; ds.  
XX

OS Homo sapiens.

XX Key Location/Qualifiers  
FH variation replace(24,C)  
FT /\*tag="a

FT /standard\_name="single nucleotide polymorphism"

PN WO954500-A2.

PD 28-OCT-1999.

PF 21-APR-1999; 99WO-1B00822.

PR 21-APR-1998; 98US-0082614.

PR 23-NOV-1998; 98US-0109732.

XX (GEST ) GENSET.

XX PA Cohen D, Blumenfeld M, Chumakov I;

XX PI WPI: 2000-013267/01.

XX Novel diallelic markers used to construct a high density disequilibrium  
PT map of the human genome -  
XX  
XX  
PS Claim 1: Page 402: 2745pp: English.

CC AAZ65654 to AAZ69578 represent human diallelic markers from the present  
CC invention, which contain a polymorphic base at position 24 of their  
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification  
CC primers for the diallelic markers. The diallelic markers of the  
CC invention have a variety of uses: they can be used for high density  
CC mapping of the human genome, and in complex association studies and  
CC haplotyping studies which are useful in determining the genetic basis  
CC for disease states. Compositions and methods of the invention can also  
CC be useful for the identification of the targets for the development of  
CC pharmaceutical agents and diagnostic methods, as well as the  
CC characterisation of the differential efficacious responses to and side  
CC effects from pharmaceutical agents acting on a disease as well as other  
CC treatment.  
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297  
CC and 3367, were not actually given a sequence in the Sequence Listing  
CC from the present invention.  
XX

SO Sequence 47 BP; 10 A; 12 C; 15 G; 10 T; 0 other;

Query Match 69.5%; Score 13.2; DB 21: Length 47;

Best Local Similarity 83.3%; Pred. NO. 2.7e+03;

Matches 15: Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGGGCGATCATGCTCTG 19  
|||||

DB 15 TGGGCGCTTGAGAGCTCTG 32

RESULT 10  
AAH38907/C  
ID AAH38907 standard: DNA: 25 BP.

AC AAH38907:

DT 14-AUG-2001 (first entry)

DE SNP specific SNPE primer SEQ ID 1703.

XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;  
KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;  
KM Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;  
KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;  
KM acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;  
KW inflammation; forensic investigation; paternity analysis; primer; ss.  
XX

OS Homo sapiens.

PN WO200129262-A2.

PD 26-APR-2001.

PF 13-OCT-2000; 2000WO-US28436.

PR 15-OCT-1999; 99US-0160096.

XX (ORCH-) ORCHID BIOSCIENCES INC.

XX PI Picoult-Newburg L, Pohl M;

XX DR WPI: 2001-290930/30.

XX New genotyping oligonucleotide, useful for detecting the presence,  
PT absence or identity of single polynucleotide polymorphism in a nucleic  
PT acid sample -  
XX

PS Claim 1: Page 58; 83pp: English.

CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide  
CC primer extensions (SNPE) primers, and the sequences of regions flanking  
CC sites of single nucleotide polymorphisms SNPs. The present invention  
CC includes kits for determining the presence or absence of a SNP, using the  
CC oligonucleotides of the invention. The PCR primers are used to amplify a  
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.  
CC The oligonucleotides are useful for genotyping a nucleic acid sample by  
CC performing a single-nucleotide primer extension reaction. The  
CC oligonucleotides are useful for determining the presence, absence or  
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to  
CC assess by association analysis the genotype of an individual or group of  
CC individuals, having a pathological phenotypic trait suspected of being  
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.  
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular  
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,  
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic  
CC traits also include symptoms of and susceptibility to multifactorial  
CC disease of which a component is or may be genetic such as autoimmune  
CC diseases, including, rheumatoid arthritis, multiple sclerosis,  
CC inflammation, cancer, nervous system diseases and infection by pathogenic  
CC microorganism. The method is also useful in forensic investigations and  
CC paternity analysis. The present sequence represents a single nucleotide  
CC primer extension (SNPE) primer specific for a human SNP containing DNA  
CC sequence.  
XX

SO Sequence 25 BP; 4 A; 4 C; 10 G; 6 T; 1 other;

Query Match 68.4%; Score 13; DB 22: Length 25;

Best Local Similarity 86.7%; Pred. NO. 3.2e+03;

Matches 13: Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 5 GCGATCATGCTCTG 19

```

DB      19 GCCCTCAGAGCTCTG 5
      ||| ||| ||| ||| ||| |||
RESULT 11
AAZ72065/C
ID      AAZ72065 standard; RNA; 27 BP.
XX
XX
AC      AAZ72065;
XX
XX      28-JUL-1999 (first entry)
DE
XX      Mouse flk-1 VEGF receptor hammerhead ribozyme #309.
DE
XX      Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
XX      flk-1; KDR; hammerhead ribozyme; halpin ribozyme; cleavage;
XX      tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX      fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX      foetal liver kinase 1; ss.
XX
OS      Synthetic.
OS      Mus sp.
XX
XX      WO9715662-A2.
XX
XX      01-MAY-1997.
XX
XX      25-OCT-1996; 96WO-US17480.
XX
XX      11-JAN-1996; 96US-0584040.
XX      26-OCT-1995; 95US-0005974.
XX
XX      (CHIR ) CHIRON CORP.
XX      (RIBO-) RIBOZYME PHARM INC.
XX
XX      Escobedo J, McSwigen J, Pavco P, Stinchcomb D;
XX      WPI: 1997-259017/23.
XX
XX      Nucleic acid molecule modulating VEGF receptor(s) gene expression or
XX      mRNA stability - useful for treating e.g. tumour angiogenesis,
XX      psoriasis, rheumatoid arthritis, etc., in a human patient
XX
XX      Claim 9: Page 132; 218pp: English.
XX
XX      The present invention describes nucleic acid molecules which modulate
XX      the synthesis, expression and/or stability of a mRNA encoding 1 or more
XX      receptors of vascular endothelial growth factor (VEGF). A patient
XX      (preferably human) having a condition associated with the level of the
XX      fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX      receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX      angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
XX      be treated by administering the nucleic acid molecule or the expression
XX      vector to the patient. AAX67275 to AAX75752 represent specific examples
XX      of nucleic acid molecules from the present invention.
XX
XX      Sequence 27 BP; 10 A; 5 C; 7 G; 4 U; 1 other;
XX
XX      Query Match      68.4%; Score 13; DB 18; Length 27;
XX      Best Local Similarity 100.0%; Pred. No. 3.2e+03;
XX      Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      7 CATCAGTGCCTG 19
XX      ||| ||| ||| ||| ||| |||
XX      14 CATCAGTGCCTG 2
XX
RESULT 12
AAZ62041/C
ID      AAZ62041 standard; RNA; 27 BP.
XX
XX
AC      AAZ62041;
XX
XX

```

```

DT      28-MAR-2000 (first entry)
XX
XX      Hammerhead ribozyme HCV-2704 cleaves HCV RNA at nt. Position 2704.
DE
XX
XX      Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
XX      cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
XX      autoimmune disease; ss.
XX
XX      Synthetic.
XX
XX      Location/Qualifiers
XX      Key
XX      misc_difference 16
XX      /tag= a
XX      /note= "hammerhead ribozyme stem-loop II (as defined
XX      by Hertel et al., NAR 20:3252 (1992))."
XX
XX      WO9955847-A2.
XX
XX      04-NOV-1999.
XX
XX      26-APR-1999; 99WO-US09027.
XX
XX      27-APR-1998; 98US-0083217.
XX      18-SEP-1998; 98US-0100842.
XX      25-FEB-1999; 99US-0257608.
XX      23-MAR-1999; 99US-0274553.
XX
XX      (RIBO-) RIBOZYME PHARM INC.
XX
XX      Blatt L, McSwigen JA, Roberts E, Pavco PA, Macejak D;
XX      WPI: 2000-062023/05.
XX
XX      Novel ribozymes for the treatment of diseases and conditions related to
XX      hepatitis C infection
XX
XX      Claim 8: Page 55; 123pp: English.
XX
XX      The present sequence represents an enzymatic nucleic acid, especially
XX      a hammerhead ribozyme, which cleaves the Hepatitis C virus (HCV) RNA
XX      sequence at the base position indicated in the descriptor line.
XX      The HCV sequence was screened for optimal ribozyme target sites using
XX      a computer folding algorithm and regions of the mRNA which did not form
XX      secondary folding structures and contained potential ribozyme cleavage
XX      sites were identified. Ribozymes were synthesised to target these sites
XX      and their activities optimised by either varying the length of the
XX      binding arms or by modification to prevent degradation by nucleases.
XX      The ribozymes of the invention inhibit gene expression and/or viral
XX      replication, and are used to treat diseases associated with Hepatitis C
XX      virus (HCV) infection, e.g. cirrhosis, liver failure and hepatocellular
XX      carcinoma. The ribozymes may be used in combination with interferon to
XX      treat HCV infection, other infectious diseases, autoimmune diseases, and
XX      cancer.
XX
XX      Sequence 27 BP; 8 A; 7 C; 8 G; 3 U; 1 other;
XX
XX      Query Match      68.4%; Score 13; DB 21; Length 27;
XX      Best Local Similarity 100.0%; Pred. No. 3.2e+03;
XX      Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      7 CATCAGTGCCTG 19
XX      ||| ||| ||| ||| ||| |||
XX      13 CATCAGTGCCTG 1
XX
RESULT 13
AAF06658/C
ID      AAF06658 standard; RNA; 29 BP.
XX
XX
AC      AAF06658;
XX
XX      16-FEB-2001 (first entry)
XX
XX

```



Query Match	Best Local Similarity	Score 13;	DB 21;	Length 29;
Matches 13; Conservative 0; <td>Mismatches 0; <td>Indels 0; <td>Gaps 0; <td></td> </td></td></td>	Mismatches 0; <td>Indels 0; <td>Gaps 0; <td></td> </td></td>	Indels 0; <td>Gaps 0; <td></td> </td>	Gaps 0; <td></td>	
14 CATCAGTGCCTCG 2				
19-JUL-2000 (first entry)				
Oestrogen receptor hammerhead ribozyme sequence SFO ID NO:1081.				
Hammerhead ribozyme; c-ras; k-ras; bcl-2; ribozyme; cleavage; hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide; gene expression modification; cancer; phosphorothioate; endonuclease; anticancer; breast cancer; endometrium cancer; ss.				
Homo sapiens.				
W09954459-A2.				
28-OCT-1999.				
19-APR-1999;				
20-APR-1998;				
23-JUN-1998;				
11-APR-2000; 2000WO-US09721.				
12-APR-1999;				
(RIBO-) RIBOZYME PHARM INC.				
Blatt L, Zwick M, Pavco P, McSwiggen J;				
WPI: 2000-647423/62.				
Enzymatic and antisense nucleic acid inhibition of repressor genes, useful for producing e.g. granulocyte colony stimulating factor protein, interferon alpha and erythropoietin				
Claim 59; Page 135; 164pp; English.				
The present invention relates to enzymatic and antisense nucleic acid molecules that act as inhibitors of the expression of repressor genes encoding the TR2 orphan receptor, EAR3/COUP-TF-1, the GATA transcription factor gene, IRF-2 and/or the C/EBP Displacement protein (CDP). Inhibition of the repressors removes prevents inhibition (and consequently increases expression of) genes involved in the production of erythropoietin, granulocyte colony stimulating factor protein and interferon alpha.				
Sequence 29 BP; 9 A; 7 C; 10 G; 2 U; 1 other;				
68.4%; Score 13; DB 21; Length 29;				
100.0%; Pred. No. 3.2e+03;				
14 CATCAGTGCCTCG 2				
19-JUL-2000 (first entry)				
Oestrogen receptor hammerhead ribozyme sequence SFO ID NO:1081.				
Hammerhead ribozyme; c-ras; k-ras; bcl-2; ribozyme; cleavage; hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide; gene expression modification; cancer; phosphorothioate; endonuclease; anticancer; breast cancer; endometrium cancer; ss.				
Homo sapiens.				
W09954459-A2.				
28-OCT-1999.				
19-APR-1999;				
20-APR-1998;				
23-JUN-1998;				
11-APR-2000; 2000WO-US09721.				
12-APR-1999;				
(RIBO-) RIBOZYME PHARM INC.				
Blatt L, Zwick M, Pavco P, McSwiggen J;				
WPI: 2000-647423/62.				
Enzymatic and antisense nucleic acid inhibition of repressor genes, useful for producing e.g. granulocyte colony stimulating factor protein, interferon alpha and erythropoietin				
Claim 59; Page 135; 164pp; English.				
The present invention relates to enzymatic and antisense nucleic acid molecules that act as inhibitors of the expression of repressor genes encoding the TR2 orphan receptor, EAR3/COUP-TF-1, the GATA transcription factor gene, IRF-2 and/or the C/EBP Displacement protein (CDP). Inhibition of the repressors removes prevents inhibition (and consequently increases expression of) genes involved in the production of erythropoietin, granulocyte colony stimulating factor protein and interferon alpha.				
Sequence 29 BP; 9 A; 7 C; 10 G; 2 U; 1 other;				
68.4%; Score 13; DB 21; Length 29;				
100.0%; Pred. No. 3.2e+03;				
14 CATCAGTGCCTCG 2				
19-JUL-2000 (first entry)				
Oestrogen receptor hammerhead ribozyme sequence SFO ID NO:1081.				
Hammerhead ribozyme; c-ras; k-ras; bcl-2; ribozyme; cleavage; hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide; gene expression modification; cancer; phosphorothioate; endonuclease; anticancer; breast cancer; endometrium cancer; ss.				
Homo sapiens.				
W09954459-A2.				
28-OCT-1999.				
19-APR-1999;				
20-APR-1998;				
23-JUN-1998;				
11-APR-2000; 2000WO-US09721.				
12-APR-1999;				
(RIBO-) RIBOZYME PHARM INC.				
Blatt L, Zwick M, Pavco P, McSwiggen J;				
WPI: 2000-647423/62.				
Enzymatic and antisense nucleic acid inhibition of repressor genes, useful for producing e.g. granulocyte colony stimulating factor protein, interferon alpha and erythropoietin				
Claim 59; Page 135; 164pp; English.				
The present invention relates to enzymatic and antisense nucleic acid molecules that act as inhibitors of the expression of repressor genes encoding the TR2 orphan receptor, EAR3/COUP-TF-1, the GATA transcription factor gene, IRF-2 and/or the C/EBP Displacement protein (CDP). Inhibition of the repressors removes prevents inhibition (and consequently increases expression of) genes involved in the production of erythropoietin, granulocyte colony stimulating factor protein and interferon alpha.				
Sequence 29 BP; 9 A; 7 C; 10 G; 2 U; 1 other;				
68.4%; Score 13; DB 21; Length 29;				
100.0%; Pred. No. 3.2e+03;				
14 CATCAGTGCCTCG 2				
19-JUL-2000 (first entry)				
Oestrogen receptor hammerhead ribozyme sequence SFO ID NO:1081.				
Hammerhead ribozyme; c-ras; k-ras; bcl-2; ribozyme; cleavage; hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide; gene expression modification; cancer; phosphorothioate; endonuclease; anticancer; breast cancer; endometrium cancer; ss.				
Homo sapiens.				
W09954459-A2.				
28-OCT-1999.				
19-APR-1999;				
20-APR-1998;				
23-JUN-1998;				

PA	(RIBO)-RIBOZYME PHARM INC.
XX	
PI	Thompson JD, Beigelman L, McSwiggen JA, Karpelsky A, Bellon L,
PI	Reynolds M, Zwick M, Jarvis T, Wolff T, Haeblerl P;
PI	Matulich-Adamcic J;
XX	
DR	WPI; 2000-013248/01.
XX	
PT	New nucleic acids that interact, and optionally cleave, target
PT	sequences, used to treat cancer -
XX	
PS	Claim 51; Page 91: 148pp; English.
XX	
CC	The present invention describes nucleic acids (A) that interact stably
CC	with a target sequence and contain at least one phosphorodithiolate
CC	link, having endonuclease activity. (A), and more generally any
CC	catalytic nucleic acid (A') that modulates expression of the oestrogen
CC	receptor gene, are used to treat cancer (particularly of breast or
CC	endometrium), in vivo or by transforming cells ex vivo and implanting
CC	treated cells, or for other conditions associated with levels of
CC	oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
CC	can also be used to correlate inhibition of gene expression with
CC	alterations in phenotype, particularly for identification of therapeutic
CC	targets, and as research reagents (for RNA, in the same way that
CC	restriction endonucleases are used with DNA). The combination of
CC	modifications in (A) improves resistance to nucleases, binding affinity
CC	and/or activity. AAA23503 to AAA2747 represent oestrogen receptor
CC	hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent
CC	corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
CC	receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
CC	their corresponding target sequences. AAA26219 to AAA26271 represent
CC	other ribozyme sequences and antisense oligonucleotides used in the
CC	exemplification of the present invention.
XX	
SQ	Sequence 29 BP; 12 A; 5 C; 7 G; 4 U; 1 other;
	Query Match 68.4%; Score 13; DB 21; Length 29;
	Best Local Similarity 100.0%; Pred. No. 3.2e+03;
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	7 CATCAGTCTCTG 19 
Dd	14 CATCAGTCTCTG 2
	RESULT 15
ID	ABN06590/C
ID	ABN06590 standard; DNA; 17 BP.
XX	
AC	ABN06590;
XX	
DT	29-MAY-2002 (first entry)
XX	
DE	Human GDMF-P 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6582.
XX	
KW	Human: genome-derived myosin-like protein 1; GDMF-P; hGDMF-P; heart; muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease; skeletal muscle disorder; amplicon; screening; ss.
XX	
OS	Homo sapiens.
XX	
PX	WO200192524-A2.
PD	
XX	06-DEC-2001.
PF	
XX	25-MAY-2001; 2001WO-USI6981.
PR	
XX	26-MAY-2000; 2000US-207456P.
PR	21-SEP-2000; 2000US-234687P.
PR	27-SEP-2000; 2000US-236359P.
PR	04-OCT-2000; 2000GB-0024263.
PR	30-JAN-2001; 2001WO-US00661.
PR	30-JAN-2001; 2001WO-US00662.

PR 30-JAN-2001: 2001WO-US00663.  
PR 30-JAN-2001: 2001WO-US00664.  
PR 30-JAN-2001: 2001WO-US00665.  
PR 30-JAN-2001: 2001WO-US00666.  
PR 30-JAN-2001: 2001WO-US00667.  
PR 30-JAN-2001: 2001WO-US00668.  
PR 30-JAN-2001: 2001WO-US00669.  
PR 30-JAN-2001: 2001WO-US00670.  
PR 05-FEB-2001: 2001US-266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPL: 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1  
PT proteins, or as specific biomolecule capture probes for  
PT surface-enhanced laser desorption/ionization, comprises human  
PT myosin-like protein hGDMLP-1 -  
XX  
XX  
PS Disclosure; SEQ ID 6582; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of  
CC hGDMLP-1 can be used in gene therapy and vaccine production. The  
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise  
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification  
CC substrates, to provide initial substrates for the recombinant engineering  
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and  
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may  
CC be used as immunogens to raise antibodies that specifically recognise  
CC hGDMLP-1 proteins, as standards in assays used to determine the  
CC concentration and/or amount specifically of hGDMLP proteins, as specific  
CC biomolecule capture probes for surface-enhanced laser desorption  
CC ionisation, as therapeutic supplement in patients having specific  
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement  
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for  
CC diagnosing a disorder associated with the expression of hGDMLP-1, in  
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to  
CC chromosome 22. The present sequence represents an oligomer used in the  
CC screening of the hGDMLP-1 sequence in the exemplification of the present  
CC invention.  
CC N.B. The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at fcp.wipo.int/pub/published\_pct\_sequence.  
XX  
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 other;  
Query Match 67.4%; Score 12.8; DB 24; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+03;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
0Y 1 CTGGGCATCATGCTCT 16  
11111111111111111111  
Db 17 CTGCACCCCTCATGCTCT 2

Search completed: November 28, 2002, 17:24:12  
Job time: 176.575 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OK nucleic - nucleic search, using sw model

Run on: November 28, 2002, 16:42:34 ; Search time 1103.97 Seconds

(Without alignments)  
500.879 Million cell updates/sec

Title: US-09-719-737-18

Perfect score: 19

Sequence: 1 ctggcgcacgcagctctctg 19

Scoring table: IDENTITY\_NUC

Gapop 10.0, Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 841850

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database:

GenBdb1:\*

1: gb\_ba:\*

2: gb\_bhg:\*

3: gb\_in:\*

4: gb\_om:\*

5: gb\_ov:\*

6: gb\_pat:\*

7: gb\_ph:\*

8: gb\_pl:\*

9: gb\_pr:\*

10: gb\_ro:\*

11: gb\_sts:\*

12: gb\_sy:\*

13: gb\_un:\*

14: gb\_vl:\*

15: em\_ba:\*

16: em\_fun:\*

17: em\_hum:\*

18: em\_in:\*

19: em\_mu:\*

20: em\_om:\*

21: em\_or:\*

22: em\_ov:\*

23: em\_pat:\*

24: em\_ph:\*

25: em\_pl:\*

26: em\_ro:\*

27: em\_sts:\*

28: em\_un:\*

29: em\_vl:\*

30: em\_htg\_hum:\*

31: em\_htg\_inv:\*

32: em\_htg\_other:\*

33: em\_htg\_mus:\*

34: em\_htg\_pla:\*

35: em\_htg\_rtd:\*

36: em\_htg\_man:\*

37: em\_htg\_vrt:\*

38: em\_sy:\*

39: em\_htgo\_hum:\*

40: em\_htgo\_mus:\*

41: em\_htgo\_other:\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	19	6	AX008665
2	19	100.0	19	6	AX008666
3	15.8	83.2	45	6	AR088050
4	14.8	77.9	45	6	AR088049
5	14.4	75.8	20	6	AR036920
6	14.4	75.8	20	6	AR036920
7	13.2	69.5	33	6	AR097255
8	13.2	69.5	40	6	AR136084
9	13.2	69.5	44	6	105997
10	13	68.4	25	6	AX116580
11	13	68.4	27	6	AR189327
12	12.8	67.4	25	6	AR154271
13	12.8	67.4	25	6	E38405
14	12.6	66.3	19	6	AX115503
15	12.6	66.3	43	6	AR152008
16	12.6	66.3	44	6	AR033897
17	12.6	66.3	44	6	AR175030
18	12.6	66.3	44	6	AX032462
19	12.6	66.3	48	6	E15948
20	12.6	66.3	50	6	AX164813
21	12.4	65.3	18	6	A76055
22	12.4	65.3	21	6	AX095087
23	12.4	65.3	31	6	AR090047
24	12.4	65.3	31	6	AR197082
25	12.4	65.3	31	6	137209
26	12.4	65.3	31	6	137210
27	12.4	65.3	31	6	137211
28	12.4	65.3	31	6	194059
29	12.4	65.3	31	6	194060
30	12.4	65.3	31	6	194061
31	12.4	65.3	40	6	A99027
32	12.4	65.3	40	6	AR195344
33	12.4	65.3	45	6	HSBRT1160
34	12.2	64.2	20	6	AX187998
35	12.2	64.2	21	6	A25404
36	12.2	64.2	21	6	A25412
37	12.2	64.2	31	6	AX249321
38	12.2	64.2	35	6	E36412
39	12.2	64.2	36	6	E16104
40	12.2	64.2	40	6	AX092544
41	12.2	64.2	45	6	AR032344
42	12.2	64.2	50	6	AX157400
43	12	63.2	20	6	AR130810
44	12	63.2	21	6	AR103495
45	12	63.2	21	6	AX096839

#### ALIGNMENTS

RESULT 1

AX008665

LOCUS AX008665

DEFINITION Sequence 18 (from Patent WO966037)

ACCESSION AX008665

VERSION AX008665.1 GI:9996189

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

19 bp DNA

Linear PAT 06-SEP-2000

synthetic construct.

artificial sequences.

1 (bases 1 to 19)

Renzi, P.

Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Patent: WO 966037-A 18 23-DEC-1999,

FEATURES RENZI PAOLO (CA): RECH EXPERTISES ET DEV MEDICAU (CA)  
 location/Qualifiers  
 source 1. 19  
 /db\_xref="taxon:32630"  
 /note="Antisense oligonucleotide inhibiting the CCR3 human receptor"

BASE COUNT 2 a 6 c 6 g 5 t

ORIGIN

Query Match 100.0%; Score 19; DB 6; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 7.8;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CTGGCCATCAGTCTCTG 19  
 |||||

Db 1 CTGGCCATCAGTCTCTG 19

RESULT 2  
 LOCUS AX008666 19 bp DNA linear PAT 06-SEP-2000  
 DEFINITION Sequence 19 from patent WO966037.  
 ACCESSION AX008666  
 VERSION AX008666.1 GI:9996190  
 KEYWORDS  
 SOURCE synthetic construct.  
 ORGANISM synthetic construct.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Renzi, P.  
 TITLE Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation  
 JOURNAL Patent: WO 966037-A 19 23-DEC-1999;  
 RENZI PAOLO (CA); RECH EXPERTISES ET DEV MEDICAU (CA)  
 FEATURES  
 source location/Qualifiers  
 1. 19  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"  
 /note="Sense oligonucleotide for the CCR3 human receptor"

BASE COUNT 5 a 6 c 6 g 2 t

ORIGIN

Query Match 100.0%; Score 19; DB 6; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 7.8;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CTGGCCATCAGTCTCTG 19  
 |||||

Db 19 CTGGCCATCAGTCTCTG 1

RESULT 3  
 LOCUS AR088050 45 bp DNA linear PAT 07-SEP-2000  
 DEFINITION Sequence 14 from patent US 5989834.  
 ACCESSION AR088050  
 VERSION AR088050.1 GI:10014813  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 45)  
 AUTHORS Gerald, C., Walker, M.W., Branche, T. and Weinschenk, R.L.  
 TITLE Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding  
 JOURNAL Patent: US 5989834-A 14 23-NOV-1999;  
 FEATURES  
 source location/Qualifiers  
 1. 45  
 /organism="unknown"

BASE COUNT 10 a 13 c 17 g 5 t

ORIGIN

Query Match 83.2%; Score 15.8; DB 6; Length 45;  
 Best Local Similarity 89.5%; Pred. No. 5.7e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 CTGGCCATCAGTCTCTG 19  
 |||||

Db 43 CTGGCCATCAGTCTCTG 25

RESULT 4  
 LOCUS AR088049 45 bp DNA linear PAT 07-SEP-2000  
 DEFINITION Sequence 13 from patent US 5989834.  
 ACCESSION AR088049  
 VERSION AR088049.1 GI:10014812  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 45)  
 AUTHORS Gerald, C., Walker, M.W., Branche, T. and Weinschenk, R.L.  
 TITLE Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding  
 JOURNAL Patent: US 5989834-A 13 23-NOV-1999;  
 FEATURES  
 source location/Qualifiers  
 1. 45  
 /organism="unknown"

BASE COUNT 7 a 12 c 12 g 14 t

ORIGIN

Query Match 77.9%; Score 14.8; DB 6; Length 45;  
 Best Local Similarity 88.9%; Pred. No. 2.1e+03;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 CTGGCCATCAGTCTCT 18  
 |||||

Db 28 CTGGCCATCAGTCTCT 45

RESULT 5  
 LOCUS AR036920 20 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 15 from patent US 5800997.  
 ACCESSION AR036920  
 VERSION AR036920.1 GI:5954776  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Beck, J. Joseph.  
 TITLE Detection of maize fungal pathogens using the polymerase chain reaction  
 JOURNAL Patent: US 5800997-A 15 01-SEP-1998;  
 FEATURES  
 source location/Qualifiers  
 1. 20  
 /organism="unknown"

BASE COUNT 3 a 5 c 6 g 6 t

ORIGIN

Query Match 75.8%; Score 14.4; DB 6; Length 20;  
 Best Local Similarity 93.8%; Pred. No. 3.6e+03;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4 GGCATCAGTCTCTG 19  
 |||

Db 2 GGCATCAGTCTCTG 17

RESULT 6  
 LOCUS AR097255 20 bp DNA linear PAT 14-FEB-2001  
 DEFINITION Sequence 15 from patent US 6071698.

ACCESSION	AR097255
VERSION	AR097255.1
KEYWORDS	GI:12805985
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 20)
TITLE	Beck,J.Joseph.
JOURNAL	DNA extraction buffer and method of use thereof
FEATURES	Patent: US 6071698-A 15 06-JUN-2000;
source	Location/Qualifiers
	1..20
BASE COUNT	/organism="unknown"
ORIGIN	3 a 5 c 6 g 6 t
Query Match	75.8%; Score 14.4; DB 6; Length 20;
Best Local Similarity	93.8%; Pred.No.3.6e+03;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY	4 GGCCATCACTGCTCG 19
Db	2 GGCCATCACTGCTCG 17
RESULT 7	
LOCUS	ARI36084 33 bp DNA linear PAT 16-JUN-2001
DEFINITION	Sequence 11 from patent US 6136580.
ACCESSION	ARI36084
VERSION	ARI36084.1
KEYWORDS	GI:14476756
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 33)
TITLE	Fukuda,M. and Yeh,J.-C.
JOURNAL	.beta.-1,6-N-acetylglucosaminyltransferase that forms core 2, core
FEATURES	4 and 1 branches
source	Patent: US 6136580-A 11 24-OCT-2000;
	Location/Qualifiers
	1..33
BASE COUNT	/organism="unknown"
ORIGIN	8 a 8 c 10 g 7 t
Query Match	69.5%; Score 13.2; DB 6; Length 33;
Best Local Similarity	83.3%; Pred.No.1.8e+04;
Matches	15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY	1 CTGGGCATCACTGCTCT 18
Db	24 CTGGACCATCTCTGCTCT 7
RESULT 8	
LOCUS	I05997 40 bp DNA linear PAT 02-DEC-1994
DEFINITION	Sequence 14 from Patent EP 0275856.
ACCESSION	I05997
VERSION	I05997.1
KEYWORDS	GI:590816
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 40)
TITLE	Bollen,A.J., Chyseen,D., Jacobs,P., Pierard,L. and Collen,D.J.
JOURNAL	New plasmidogen activators
FEATURES	Patent: EP 0275856-A1 14 27-JUL-1988;
source	Location/Qualifiers
	1..40
BASE COUNT	/organism="unknown"
	9 a 9 c 12 g 9 t 1 others

[illegible]

LOCUS	AR189327	27 bp	DNA	linear	PAT 20-APR-2002
DEFINITION	Sequence 4B15 from patent US 6346398.				
ACCESSION	AR189327				
VERSION	AR189327.1	GI:20235292			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 27)				
AUTHORS	Payco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.				
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor				
JOURNAL	Patent: US 6346398-A 4B15 12-FEB-2002;				
FEATURES	Location/Qualifiers				
source	1..27				
BASE COUNT	10 a 5 c 7 g 4 t			1 others	
ORIGIN	/organism="unknown"				
Query Match	68.4%;	Score 13;	DB 6;	Length 27;	
Best Local Similarity	100.0%;	Pred. No. 2.3e+04;			
Matches 13:	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
QY	7 CATCAGTGTCTTG 19				
Db	14 CATCAGTGTCTTG 2				
RESULT 12					
LOCUS	AR154271	25 bp	DNA	linear	PAT 08-AUG-2001
DEFINITION	Sequence 4 from patent US 6238893.				
ACCESSION	AR154271				
VERSION	AR154271.1	GI:15122324			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 25)				
AUTHORS	Brown,A.M., Chapman,C.,Gerald., Glover,I.,Simon., Evans,J.,Kachel., Calins,W. and Herdon,H.,Jonathan.				
TITLE	Neurotransmitter transporter SC6				
JOURNAL	Patent: US 6238893-A 4 29-MAY-2001;				
FEATURES	Location/Qualifiers				
source	1..25				
BASE COUNT	5 a 8 c 7 g 5 t				
ORIGIN	/organism="unknown"				
Query Match	67.4%;	Score 12.8;	DB 6;	Length 25;	
Best Local Similarity	87.5%;	Pred. No. 3e+04;			
Matches 14:	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;	
QY	1 CTGGCGCATCAGTCT 16				
Db	21 CTGGCGCATCAGTCT 6				
RESULT 13					
LOCUS	E38405	25 bp	DNA	linear	PAT 31-JAN-2002
DEFINITION	SC6 polypeptide and SC6 polynucleotide.				
ACCESSION	E38405				
VERSION	E38405.1	GI:18624976			
KEYWORDS	JP 2000069981-A/3.				
SOURCE	synthetic construct.				
ORGANISM	synthetic construct				
REFERENCE	1 (bases 1 to 25)				
AUTHORS	Brown,A.M., Chapman,K.J., Grogg,I.S., Evans,J.R., Kern,W. and Haddon,H.				
TITLE	SC6 polypeptide and SC6 polynucleotide				
JOURNAL	Patent: JP 2000069981-A 3 07-MAR-2000;				

COMMENT	SMITHKLINE BEECHAM CORP PUBLIC LTD CO
OS	Artificial Sequence
PN	JP 2000069981-A/3
PD	07-MAR-2000
PF	12-FEB-1999 JP 1999035070
PI	28-AUG-1998 GB 9818890:7
PR	ANTHONY M BROWN, KONRAD JERROLD CHAPMAN, ISRAEL SIMON GROGA, PI
PC	JOAN REICHEL, EVANS, WILLIAM KERN, HYU HADON
PC	C12N15/09, A61K31/00, A61K31/00, A61K31/00, A61K31/00, A61K31/00,
PC	A61K39/00,
PC	A61K45/00, A61K48/00, C07K14/47, C07K14/705, C07K16/28, C12N5/10,
PC	C12P21/02,
PC	C1201/68, G01N33/53, G01N33/566, G01N33/577//C12P21/08, C12N15/00,
CC	C12N5/00
FT	key
FT	source
FT	1.25
FEATURES	Location/Qualifiers
source	Location/Qualifiers
BASE COUNT	5 a 8 c 7 g 5 t
ORIGIN	
Query Match	67.4%; Score 12.8; DB 6; Length 25;
Best Local Similarity	87.5%; Pred. No. 3e+04;
Matches 14: Conservative	0; Mismatches 2; Indels 0; Gaps 0;
OY	1 CTGGGCATCACTGCT 16
DB	21 CTGGGCATCACTGCT 6
RESULT 14	
LOCUS	AX115503 19 bp DNA Linear PAT 11-MAY-2001
DEFINITION	Sequence 626 from Patent WO0129262.
ACCESSION	AX115503
VERSION	AX115503.1 GI:14032445
KEYWORDS	
SOURCE	synthetic construct.
ORGANISM	artificial construct.
REFERENCE	artificial sequences.
AUTHORS	1 (bases 1 to 19)
TITLE	Picoault-Newburg, L. and Pohl, M.
JOURNAL	Genotyping reagents, kits and methods of use thereof
FEATURES	Patent: WO 0129262-A 626 26-APR-2001;
source	Orchid Biosciences, Inc. (US)
ORIGIN	Location/Qualifiers
BASE COUNT	1.19
ORIGIN	4 a 7 c 4 g 4 t
Query Match	66.3%; Score 12.6; DB 6; Length 19;
Best Local Similarity	78.9%; Pred. No. 3.9e+04;
Matches 15: Conservative	0; Mismatches 4; Indels 0; Gaps 0;
OY	1 CTGGGCATCACTGCTG 19
DB	1 CAGAGCCATCACTGCTCG 19
RESULT 15	
LOCUS	ARI52008 43 bp DNA Linear PAT 08-AUG-2001
DEFINITION	Sequence 2 from patent US 6232445.
ACCESSION	ARI52008
VERSION	ARI52008.1 GI:15118058
KEYWORDS	

SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 43)  
 AUTHORS Rhode, P. R., Acevedo, J., Burkhardt, M., Jiao, J.-a. and Wong, H. C.  
 TITLE Soluble MHC complexes and methods of use thereof  
 JOURNAL Patent: US 6232445-A 2 15-MAY-2001;  
 FEATURES Location/Qualifiers  
 source 1..43  
 /Organism="unknown"  
 BASE COUNT 7 a 21 c 9 g 6 t  
 ORIGIN  
 Query Match 66.3%; Score 12.6; DB 6; Length 43;  
 Best Local Similarity 78.9%; Pred. No. 4e+04;  
 Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CTGGGCCATCAGTGCCTCTG 19  
 | ||||| || |||||  
 Db 13 CCGGGCCACCACATGGCTCTG 31

Search completed: November 28, 2002, 18:20:40  
 Job time : 1105.97 secs

